---
document_datetime: 2023-09-21 21:00:08
document_pages: 120
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/jardiance-h-c-002677-ii-0060-epar-assessment-report-variation_en.pdf
document_name: jardiance-h-c-002677-ii-0060-epar-assessment-report-variation_en.pdf
version: success
processing_time: 123.8847774
conversion_datetime: 2025-12-18 23:11:05.310177
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

27 January 2022 EMA/102340/2022 Committee for Medicinal Products for Human Use (CHMP)

## CHMP extension of indication variation assessment report

Invented name: Jardiance

International non-proprietary name: empagliflozin

Procedure No. EMEA/H/C/002677/II/0060

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 8                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................8 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................9                                                 |
| 2. Scientific discussion................................................................................                   | 9                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................9 |
| 2.1.1. Problem statement                                                                                                   | ............................................................................................9             |
| 2.1.2. About the product ...........................................................................................       | 11                                                                                                        |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice......                                     | 11                                                                                                        |
| 2.1.4. General comments on compliance with GLP, GCP                                                                        | ................................................ 12                                                       |
| 2.2. Non-clinical aspects............................................................................................      | 12                                                                                                        |
| 2.2.1. Introduction....................................................................................................    | 12                                                                                                        |
| 2.2.2. Pharmacology.................................................................................................       | 13                                                                                                        |
| 2.2.3. Pharmacokinetics                                                                                                    | ............................................................................................ 19           |
| 2.2.4. Toxicology......................................................................................................    | 19                                                                                                        |
| 2.2.5. Ecotoxicity/environmental risk assessment.........................................................                  | 19                                                                                                        |
| 2.2.6. Discussion on non-clinical aspects .....................................................................            | 21                                                                                                        |
| 2.2.7. Conclusion on the non-clinical aspects ...............................................................              | 22                                                                                                        |
| 2.3. Clinical aspects ..................................................................................................   | 22                                                                                                        |
| 2.3.1. Introduction....................................................................................................    | 22                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 23           |
| 2.3.3. Pharmacodynamics..........................................................................................          | 25                                                                                                        |
| 2.3.4. Discussion on clinical pharmacology...................................................................              | 26                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 26     |
| 2.4.1. Dose response study(ies) .................................................................................          | 26                                                                                                        |
| 2.4.2. Main study(ies) ...............................................................................................     | 26                                                                                                        |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 75                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................           | 79                                                                                                        |
| 2.5. Clinical safety ....................................................................................................  | 80                                                                                                        |
| Patient exposure.......................................................................................................    | 81                                                                                                        |
| Vital sign, physical findings and other observation related to safety ................................                     | 97                                                                                                        |
| Safety in special populations                                                                                              | ...................................................................................... 98                 |
| Safety related to drug-drug interactions and other interactions ....................................                       | 103                                                                                                       |
| Discontinuation due to adverse events ......................................................................               | 104                                                                                                       |
| Post marketing experience.......................................................................................           | 105                                                                                                       |
| 2.5.1. Discussion on clinical safety............................................................................           | 106                                                                                                       |
| 2.5.2. Conclusions on clinical safety..........................................................................            | 107                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                          | ................................................................................................... 108   |
| 2.6. Risk management plan                                                                                                  | ..................................................................................... 108                 |
| 2.6.1. Overall conclusion on the RMP ........................................................................              | 109                                                                                                       |
| 2.7. Update of the Product information......................................................................               | 109                                                                                                       |
| 2.7.1. User consultation ..........................................................................................        | 109                                                                                                       |
| 3. Benefit-Risk Balance...........................................................................                         | 110                                                                                                       |
| 3.1. Therapeutic Context                                                                                                   | ......................................................................................... 110             |

<div style=\"page-break-after: always\"></div>

3.1.1. Disease or condition ...................................................................................... 110

3.1.2. Available therapies and unmet medical need  ..................................................... 110

3.1.3. Main clinical studies  ....................................................................................... 111

3.2. Favourable effects  ............................................................................................ 112

3.3. Uncertainties and limitations about favourable effects  ........................................... 113

3.4. Unfavourable effects  ......................................................................................... 114

3.5. Uncertainties and limitations about unfavourable effects ....................................... 116

3.6. Effects Table  .................................................................................................... 117

3.7. Benefit-risk assessment and discussion  ............................................................... 118

3.7.1. Importance of favourable and unfavourable effects  ............................................ 118

3.7.2. Balance of benefits and risks .......................................................................... 119

3.8. Conclusions  ..................................................................................................... 119

4. Recommendations  ............................................................................... 120

<div style=\"page-break-after: always\"></div>

## List of abbreviations

6MWT

6-minute walk test

ACEi

Angiotensin converting enzyme inhibitor

ADR

Adverse drug reaction

AE

Adverse event

AELD

Adverse event leading to treatment discontinuation

AESI

Adverse event of special interest

AF

Atrial fibrillation or atrial flutter

ALT

Alanine aminotransferase

ANCOVA

Analysis of covariance

ARB

Angiotensin receptor blocker

ARNi

Angiotensin receptor neprilysin inhibitor

AST

Aspartate aminotransferase

BI

Boehringer Ingelheim

BIcMQ

BI-customised MedDRA query (used where SMQ is not available)

BMI

Body mass index

CEC

Clinical event committee

CHQ-SAS

Chronic heart failure questionnaire self-administered standardised format

CI

Confidence interval

CKD-EPI

Chronic kidney disease epidemiology collaboration equation

CMH

Cochran-Mantel-Haenszel

CMR

Cardiac magnetic resonance

CO

Clinical overview

CPET

Cardiopulmonary exercise test

CRF

Case report form

CRT (-D/P)

Cardiac resynchronisation therapy (-defibrillator/pacemaker)

CTD

Common Technical Document

CTP

Clinical trial protocol

CTR

Clinical trial report

CV

Cardiovascular

DBP

Diastolic blood pressure

DILI

Drug-induced liver injury

DMC

Data monitoring committee

<div style=\"page-break-after: always\"></div>

| ECG               | Electrocardiogram                                                                                                                                                                    |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| EF                | Ejection fraction                                                                                                                                                                    |
| eGFR              | Estimated glomerular filtration rate                                                                                                                                                 |
| eGFR (CKD-EPI) cr | Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement                                              |
| eGFR (MDRD)       | Glomerular filtration rate estimated by the modification of diet in renal disease formula                                                                                            |
| EMPA-VISION       | A mechanistic trial of empagliflozin on cardiac physiology and metabolism in patients with chronic heart failure; trial 1245.148                                                     |
| EMPERIAL          | Trials of empagliflozin on exercise ability and heart failure symptoms in patients with chronic heart failure; EMPERIAL-preserved: trial 1245.167; EMPERIAL- reduced: trial 1245.168 |
| EMPEROR           | Outcome trials of empagliflozin in patients with chronic heart failure; EMPEROR- reduced: trial 1245.121; EMPEROR-preserved: trial 1245.110                                          |
| ERA               | Environmental risk assessment                                                                                                                                                        |
| FU                | Follow up                                                                                                                                                                            |
| GCP               | Good clinical practice                                                                                                                                                               |
| gMean             | Geometric mean                                                                                                                                                                       |
| HF                | Heart failure                                                                                                                                                                        |
| HFD               | High fat diet                                                                                                                                                                        |
| HFmEF             | Heart failure with mid-range ejection fraction                                                                                                                                       |
| HFpEF             | Heart failure with preserved ejection fraction                                                                                                                                       |
| HFrEF             | Heart failure with reduced ejection fraction                                                                                                                                         |
| HHF               | Hospitalisation for heart failure                                                                                                                                                    |
| HL                | Hodges-Lehmann                                                                                                                                                                       |
| ICD               | Implantable cardioverter defibrillator                                                                                                                                               |
| ICH               | International conference on harmonisation                                                                                                                                            |
| IQR               | Interquartile range                                                                                                                                                                  |
| ISS               | Integrated summary of safety                                                                                                                                                         |
| ITT               | Intent to treat                                                                                                                                                                      |
| KCCQ              | Kansas City cardiomyopathy questionnaire                                                                                                                                             |
| LLA               | Lower limb amputation                                                                                                                                                                |
| LLN               | Lower limit of normal                                                                                                                                                                |
| LVEF              | Left ventricular ejection fraction                                                                                                                                                   |
| MDA               | Malondialdehyde                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| MDRD      | Modification of diet in renal disease                                                                                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------|
| MedDRA    | Medical dictionary for regulatory activities                                                                          |
| MI        | Myocardial infarction                                                                                                 |
| MMRM      | Mixed model repeated measure                                                                                          |
| MRA       | Mineralocorticoid receptor antagonist                                                                                 |
| NT-proBNP | N-terminal pro-brain natriuretic peptide                                                                              |
| NYHA      | New York heart association                                                                                            |
| OC-AD     | Observed case including data after treatment discontinuation                                                          |
| PBRER     | Periodic benefit-risk evaluation report                                                                               |
| PD        | Pharmacodynamic(s)                                                                                                    |
| PEC       | Predicted environmental concentration                                                                                 |
| PGI-C     | Patient global impression of change                                                                                   |
| PGI-S     | Patient global impression of severity                                                                                 |
| PK        | Pharmacokinetic(s)                                                                                                    |
| PRO       | Patient-reported outcome                                                                                              |
| PT        | Preferred term                                                                                                        |
| pt-yrs    | Patient-years                                                                                                         |
| qd        | Once daily                                                                                                            |
| RS        | Randomised set                                                                                                        |
| SAE       | Serious adverse event                                                                                                 |
| SAF-HF1   | Safety analysis grouping for trials in patients with heart failure (1245.110, 1245.121, 1245.148, 1245.167, 1245.168) |
| SBP       | Systolic blood pressure                                                                                               |
| SCE       | Summary of clinical efficacy                                                                                          |
| SCS       | Summary of clinical safety                                                                                            |
| SCR       | Screened set                                                                                                          |
| SD        | Standard deviation                                                                                                    |
| SEM       | Standard error of measurement                                                                                         |
| SGLT      | Sodium-dependent glucose co-transporter                                                                               |
| SMQ       | Standardised MedDRA query                                                                                             |
| SOC       | System organ class                                                                                                    |
| SOP       | Standard operating procedures                                                                                         |
| T1DM      | Type 1 diabetes mellitus                                                                                              |
| T2DM      | Type 2 diabetes mellitus                                                                                              |

<div style=\"page-break-after: always\"></div>

| TIA   | Transient ischaemic attack       |
|-------|----------------------------------|
| TS    | Treated set                      |
| TSAP  | Trial statistical analysis plans |
| TSS   | Total symptom score              |
| ULN   | Upper limit of normal            |
| UTI   | Urinary tract infection          |
| WCI   | Worst-case imputation            |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Boehringer Ingelheim International GmbH submitted to the European Medicines Agency on 26 August 2021 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to add the treatment of patients with Heart Failure with preserved ejection fraction based on the results from the clinical study 1245.110 EMPEROR-preserved.

As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC and sections 1 and 4 of the PIL are updated accordingly.

Further, the MAH applied for an additional year of market protection. The updated RMP v 16.0 has also been submitted.

In addition, the statement 'sodium free' was re-located from section 2 of the SmPC to section 4.4. to comply with EMA'S QRD guidance and minor linguistic changes to the national translations are included in this submission

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Not applicable

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur:                                          | Johann Lodewijk Hillege   | Co-Rapporteur: N/A   |
|------------------------------------------------------|---------------------------|----------------------|
| Timetable                                            |                           | Actual dates         |
| Submission date                                      |                           | 26 August 2021       |
| Start of procedure:                                  |                           | 18 September 2021    |
| CHMP Rapporteur Assessment Report                    |                           | 15 November 2021     |
| PRAC Rapporteur Assessment Report                    |                           | 19 November 2021     |
| PRAC Outcome                                         |                           | 2 December 2021      |
| CHMP members                                         | comments                  | 6 December 2021      |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report |                           | 9 December 2021      |
| Request for supplementary information (RSI)          |                           | 16 December 2021     |
| PRAC Rapporteur Assessment Report                    |                           | 12 January 2022      |
| CHMP Rapporteur Assessment Report                    |                           | 12 January 2022      |
| Updated CHMP Rapporteur Assessment Report            |                           | 20 January 2022      |
| Opinion                                              |                           | 27 January 2022      |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Chronic heart failure (HF) is a progressive syndrome characterised by the inability of the heart to provide adequate blood supply to meet the metabolic demand of different tissues, or the heart can only provide adequate blood supply at the expense of elevated left ventricular filling pressure. HF occurs due to failure of the heart to pump adequately (systolic dysfunction) and/or impaired relaxation (diastolic dysfunction).

## State the claimed the therapeutic indication

The claimed indication that is under assessment reads as follows (in bold the proposed extension of the indication):

## Heart failure

Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure independent of left ventricular with reduced ejection fraction.

In the first assessment round, the CHMP concluded that the wording of the indication should be adjusted.

<div style=\"page-break-after: always\"></div>

As the indication for the treatment of heart failure is for all types of heart failure, the wording ' for the treatment of symptomatic chronic heart failure' was considered more appropriate. In the response, the Applicant has adjusted the wording of the indication in accordance with the comments.

The approved indication reads as follows (in strikethrough the proposed extension of the indication):

## Heart failure

Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

## Epidemiology and risk factors

Worldwide, heart failure has a prevalence of 1% to 2% and affects over 64 million people as of 2017. In the US alone the prevalence is 6.2 million, and this number has been projected to grow to over 8 million by 2030. HF is associated with premature mortality and frequent hospitalisations. HF contributes to 1 in 9 deaths, and the estimated 5-year survival is about 50% at the time of diagnosis. In addition, HF is the leading cause of hospitalisation in patients above 65 years of age. In the US, more than 1 million patients annually are hospitalised with a primary diagnosis of HF.

## Clinical presentation, diagnosis

Symptoms of HF include dyspnoea (shortness of breath), oedema (build-up of fluid in the body tissues), persistent coughing and wheezing (due to build-up of fluid in the lungs), tiredness or fatigue, reduced appetite  or  nausea,  confusion,  disorientation,  and  increased  heart  rate.  The  most  commonly  used classification system, the New York Heart Association (NYHA) Functional Classification, places patients in one of four categories based on how much they are limited during physical activity. The classes range from I, i.e. no limitation of physical activity, to IV, i.e. unable to carry on any physical activity without discomfort.

Patients with HF are categorised according to left ventricular ejection fraction (LVEF); patients with LVEF ≤40% are considered to have HFrEF, and those with LVEF &gt;50% are considered to have HFpEF. LVEF of &gt;40% to &lt;50% is considered as HFpEF in many clinical trials and registries, although more recently, the term HF with 'mid-range' EF (HFmEF) was introduced to categorise this group separately. The relative prevalence of HFpEF among HF patients is approximately 50% and appears to be increasing.

HFrEF and HFpEF differ in several aspects, including underlying aetiologies, demographics, co-morbidities, and responses to treatment. For example, patients with HFpEF tend to be older, more often women, and more likely to have a history of hypertension and atrial fibrillation than patients with HFrEF. In addition, although  HFpEF  and  HFrEF  have  similarly  profound  impacts  on  patient  quality  of  life  and  prognosis, historically, therapies shown to improve prognosis in patients with HFrEF do not seem to be effective in patients with HFpEF.

In addition to a substantial risk of mortality and hospitalisation, HF is shown to have a major impact on all aspects of quality of life, and particularly on patients' mobility and usual activities. Poor quality of life scores independently predicts higher mortality and hospitalisation. Despite guideline-directed medical therapy, the quality of life in patients with HF remains greatly impaired.

## Management

Heart failure with a reduced ejection fraction can be treated with drugs that attenuate the overactivation of endogenous neurohormonal systems. However, the therapeutic options for patients with heart failure and a preserved ejection fraction are limited.

<div style=\"page-break-after: always\"></div>

Recommendations for the treatment of HFrEF include the use of angiotensin-converting enzyme inhibitors (ACEi),  angiotensin  receptor  blockers  (ARB),  angiotensin  receptor-neprilysin  inhibitors  (ARNi),  betablockers, mineralocorticoid receptor antagonists (MRA), and the use of implantable devices like ICD and CRT, all of which have been shown to reduce mortality in patients with HFrEF.

For patients with HFpEF, no therapy has been proven to be superior to control based on the pre-specified primary endpoint in any prior pivotal clinical outcome study in patients with HFpEF. According to the current guidelines, the management of HFpEF involves controlling congestive symptoms, usually with diuretics, and treating co-morbidities. A lack of therapeutic options that can reduce the risk of mortality and hospitalisation in these patients represents an unmet medical need.

## 2.1.2. About the product

Empagliflozin (Jardiance) is an orally administered, potent and selective inhibitor of the human sodiumglucose cotransporter-2 (SGLT 2) developed by Boehringer Ingelheim (BI). By inhibition of SGLT 2 in the kidneys, empagliflozin reduces the reabsorption of glucose by the kidneys leading to increased urinary glucose excretion and, consequently, to a lowering of blood glucose. Empagliflozin is approved for the treatment of type 2 diabetes mellitus (T2DM) worldwide as an adjunct therapy to diet and exercise to improve glycaemic control in adults with type 2 diabetes. In the United States and several other countries, it is also approved to reduce the risk of cardiovascular (CV) death in patients with T2DM and established CV disease. The results of the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in  Type  2  Diabetes  Mellitus  Patients)  showed  significant  improvement  in  the  primary  composite cardiovascular outcome (MACE-3) and significant reductions in cardiovascular death, hospitalization for heart failure (HHF) as well as death from any cause as compared to standard of care. These beneficial cardiovascular effects were found to be largely independent of the glucose-lowering effect of empagliflozin. On 17 Jun 2021, empagliflozin was approved in the EU for the treatment of heart failure with reduced ejection fraction based on the EMPEROR-Reduced study (1245.121) results.

Empagliflozin exerts its effect by preventing sodium and glucose reabsorption. While natriuresis will be compensated within days of drug administration through changes in tubulo-glomerular feedback, glucosuria will last for as long as the medication is used. This leads to long-lasting hemodynamic changes associated with modest osmotic diuresis, blood pressure-lowering effect, improvement in arterial stiffness, reduction in  oxidative  stress,  and  decrease  in  rate  pressure  product,  an  indirect  measure  of  myocardial  oxygen demands, with no increase in HR and no effect on sympathetic nerve activity. Therefore, the non-glycosuric physiological  and  hemodynamic  adaptations  under  empagliflozin  may  benefit  patients  with  HF  with  or without diabetes.

Based on the results of trial 1245.25 (EMPA-REG OUTCOME) in patients with T2DM and established CV disease,  BI  initiated  a  phase  III  program  for  empagliflozin  10  mg  once  daily  in  chronic  heart  failure regardless of diabetes status.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

## The development programme

BI initiated a Phase III program for empagliflozin 10 mg once daily in chronic heart failure regardless of diabetes status. There are two CV outcome trials ('EMPEROR'), two functional capacity trials ('EMPERIAL'), and a mechanistic Phase III trial ('EMPA-VISION') in patients with HFrEF (reduced ejection fraction) and HFpEF (preserved ejection fraction). All 5 trials are placebo-controlled, randomised (empagliflozin 10 mg

<div style=\"page-break-after: always\"></div>

to placebo 1:1), double-blind, and parallel-group by design.

The EMPEROR trials are pivotal outcome trials that investigate the long-term effect of empagliflozin in reducing the risk of hospitalisation for HF and of cardiovascular death in patients with heart failure. The EMPERIAL trials are additional trials that investigated the short-term (12 weeks) effect of empagliflozin on functional capacity, signs and symptoms of heart failure, and quality of life. The EMPA-VISION trial is a supporting trial  investigating  the  short-term  (12  weeks)  effect  of  empagliflozin  on  mechanistic  cardiac physiology and metabolism. All 5 trials have been completed and the clinical trial reports are available.

The EMPEROR-Reduced and the EMPERIAL trials have been previously submitted. The EMPEROR-Preserved trial results are described in this document. In addition, a meta-analysis of both EMPEROR trials for efficacy endpoints was prespecified.

## Compliance with CHMP guidance

The most relevant CHMP guideline is 'Clinical investigation of medicinal products in the treatment of chronic heart failure' (CPMP/EWP/235/95, Rev.2). The compliance with this guideline is addressed in the discussion of the design of the trial.

## Scientific advice

The Applicant requested scientific advice for both the EMPEROR-preserved and EMPEROR-reduced trial in procedure in 2016, Procedure No.: EMEA/H/SA/2969/2/2016/II.

## 2.1.4. General comments on compliance with GLP, GCP

## GLP

Not applicable

## GCP

According to the Applicant, the trials are carried out in compliance with the CTP, in accordance with the principles of the Declaration of Helsinki, in accordance with the ICH GCP, and in accordance with applicable regulatory requirements and BI's standard operating procedures.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

Empagliflozin is approved in many countries globally as an adjunct therapy to diet and exercise to improve glycaemic control in adults with type 2 diabetes, and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus  Patients),  empagliflozin  significantly  improved  the  primary  composite  cardiovascular  outcome (MACE-3: composite of death from cardiovascular causes, nonfatal myocardial infarction (excluding silent myocardial infarction), or nonfatal stroke) and significantly reduced cardiovascular death, hospitalization for heart failure (HHF) as well as death from any cause as compared to standard of care. In the EMPERORReduced trial, empagliflozin significantly improved cardiovascular and renal outcomes in patients with heart

<div style=\"page-break-after: always\"></div>

failure  with  reduced  ejection  fraction,  independent  of  baseline  diabetes  status.  Interestingly,  these beneficial cardiovascular effects were found to be largely independent of the glucose-lowering effect of empagliflozin.

The beneficial cardiovascular effects of empagliflozin in clinical studies may result - at least in part - from an  influence  on  neurohumoral  pathways,  such  as  RAAS  inhibition  via  tubulo-glomerular  feedback mechanisms and from a reduction of cardiac pre- and afterload by natriuretic and osmotic effects. Further, an increased haematocrit, decrease in blood pressure and cardiac sympathetic nerve activity have been observed with empagliflozin and may contribute to the effects on the cardiovascular system.

Effects  of  empagliflozin  on  pathophysiological  processes  in  the  cardiovascular  system  were  studied  in various pharmacological experimental settings, in particular in models of heart failure induced by different stimuli. Furthermore, effects of empagliflozin were studied in vitro in cardiac tissue of patients with HFpEF, respectively, as well as in tissues taken from mice.

In vivo studies were performed in different species like mice, rats and pigs in order to reproduce aspects of the beneficial results of the clinical studies and to better understand the mode of action of empagliflozin on the cardiovascular system. Importantly, studies were done in normoglycemic animals and in animals with pre-existing diabetes.

This  document  is  an  Addendum  to  the  Nonclinical  Overview  [U12-3933-01]  submitted  with  the  initial Marketing Authorization Application (MAA). Since the initial MAA, three nonclinical study reports with the corresponding Addendum to Nonclinical Overview were submitted to provide:

- results of a nonclinical study looking at the effect of empagliflozin on blood ketone level at refeeding after a fasting period and comparison between refeeding with glucose or fat [n00253114-01]

- results of an in vitro study investigating the inhibition of UGT2B7, UGT1A3, UGT1A8, and UGT1A9 by empagliflozin [n00234868-01]

- results from a nonclinical juvenile toxicity study in the rat [n00231757-01].

Empagliflozin is a SGLT2 inhibitor that reduces the reabsorption of glucose by the kidney resulting in the increased  urinary  glucose  excretion  and  subsequent  lowering  of  the  blood  glucose.  Empagliflozin  also showed beneficial cardiovascular effects in the clinical trials with patients with heart failure, which appear to be independent of its glycaemic control action. Empagliflozin is currently approved for the treatment of patients with heart failure with reduced ejection fraction (HFrEF). The current application concerns the extension of the indication to the patients with heart failure with preserved ejection fraction (HFpEF). The applicant  has  submitted  an  addendum  (dated  29  July  2021)  to  the  previously  provided  non-clinical overview,  including  the  pre-clinical  studies  conducted  to  investigate  the  cardiovascular  effects  of empagliflozin in vitro in vivo , to provide the rationale for the envisaged extension . As the clinical effects were shown to be independent of the well-documented glucose-lowering effects of empagliflozin, the preclinical studies were performed in normoglycaemic animals as well as in animals with pre-existing diabetes mellitus.  The  addendum  was  prepared  by  Dr.  Michael  Paul  Pieper  and  consists  of  17  pages  with  23 references. The CV of Dr. Pieper has been provided.

## 2.2.2. Pharmacology

## Primary pharmacodynamic studies

Empagliflozin is a potent and selective inhibitor of the human sodium-glucose cotransporter-2 (SGLT 2). By inhibition of SGLT 2 in the proximal tubules empagliflozin reduces the reabsorption of glucose by the kidneys

<div style=\"page-break-after: always\"></div>

leading to increased urinary glucose excretion and, in consequence, to a lowering of blood glucose under hyperglycaemic as well as normoglycemic conditions.

The results of the EMPA-REG OUTCOME trial as well as the EMPEROR-Reduced trial clearly demonstrated the beneficial effects of empagliflozin on the cardiovascular system.

In this section, pre-clinical studies are compiled that investigated the cardiovascular effects of empagliflozin in vitro and in vivo in various species and different experimental settings. As the clinical effects were shown to be independent of the well-documented glucose-lowering effects of empagliflozin, the pre-clinical studies were performed in normoglycemic animals as well as in animals with pre-existing diabetes mellitus.

## Effects of empagliflozin in vitro / ex vivo

Potential direct effects of 500 nmol/L empagliflozin on myocardial tissue were investigated in LV myocardial biopsies obtained from patients with HFpEF and compared to samples from non-failing hearts [P20-04305]. Inflammation  markers  including  ICAM-1,  VCAM-1,  TNF-a,  and  IL-6  were  higher  in  human  HFpEF myocardium than controls. Empagliflozin significantly reduced the inflammatory markers assessed both by ELISA and immunoblots. Empagliflozin lowered the pathophysiologically increased cardiomyocyte Ca 2+ independent passive force (Fpassive), a measure for cardiomyocyte stiffness, in cardiomyocytes from patients with  HFpEF in  vitro .  GSH  administration  resulted  in  a  further  additional  effect  on  Fpassive.  In  contrast, empagliflozin did not induce additional effects on Fpassive on top of GSH indicating an antioxidative effect of empagliflozin in cardiomyocytes.

Experiments were performed in murine papillary muscles from diabetic BKS.Cg-Dock7m +/+ Leprdb/J mice showing a typical diabetic cardiomyopathy phenotype [P18-09844]. Empagliflozin significantly reduced the excessive diastolic tension by ∼ 19.1 % in these isolated organs in vitro . This effect was reversible upon wash-out.

Thus, empagliflozin caused direct effects on the myocardium of patients with HFpEF and similar effects in mice  with  diabetic  cardiomyopathy  by  improving  diastolic  stiffness  that  may  translate  in  an  improved diastolic  function.  Furthermore,  empagliflozin  reduced  myocardial  inflammation  and  oxidative  stress  in cardiomyocytes from patients with HFpEF compared to tissue from non-failing hearts.

Effects of empagliflozin on endothelial dysfunction and cardiac remodelling were tested in obese Zucker diabetic fatty/spontaneously hypertensive heart failure F1 hybrid (ZSF1)-HFpEF rats, experimentally used as a model of metabolic syndrome. Rats develop a dysfunction in endothelium-dependent relaxations and cardiac remodelling. Lean rats were used as controls [P20-01824]. Rats were treated with empagliflozin via a diet admixture at a daily dose of 30 mg/kg for 6 weeks. Ex vivo ,  empagliflozin  restored  the normal endothelium-dependent relaxations and blunted endothelium-dependent contractile responses to acetylcholine.  Further,  empagliflozin  reduced  the  increased  heart  weight  as  well  as  the  increased  left ventricle volume in ZSF1 rats. Interestingly, SGLT2 protein expression was detected in vascular endothelial cells under stress conditions in this model.

## Effects of empagliflozin in animals with diabetes:

Effects  of  empagliflozin  on  diabetic  cardiovascular  injury  was  tested  in  male  db/db  mice  and  male nondiabetic and lean db/m mice as control [P14-15469]. Mice were fed a standard diet containing 0.03% empagliflozin for 10 weeks. Empagliflozin significantly ameliorated cardiac interstitial fibrosis, peri-coronary arterial  fibrosis,  coronary  arterial  thickening,  cardiac  interstitial  macrophage  infiltration,  and  cardiac superoxide levels in db/db mice. Further, empagliflozin significantly ameliorated the impairment of vascular endothelial function compared with control db/db mice.

In summary, empagliflozin ameliorated cardiac fibrosis, inflammation, coronary arterial remodelling, and vascular dysfunction in db/db diabetic mice.

<div style=\"page-break-after: always\"></div>

Effects of empagliflozin on cardiovascular function was tested in db/db mice on a high fat diet as a model of severe type 2 diabetes [P20-03987]. Mice were fed a high fat western-type diet (high fat diet (HFD), 39 kJ% fat, 41 kJ% carbohydrates and 20 kJ% protein) with or without 150 mg/kg empagliflozin. Empagliflozin induced glycosuria and reduced blood glucose levels. The increased expression of hepatic inflammatory cytokines  in  db/db  mice  was  significantly  reduced  by  empagliflozin  treatment.  Empagliflozin  reduced mortality in db/db mice: while 54 % of db/db mice on HFD died after 4.5 weeks, all heterogeneous wild type mice as well as all empagliflozin-treated db/db mice on HFD were alive. Hemodynamic investigations revealed that empagliflozin significantly improved cardiac relaxation as an indicator of diastolic function while numerically affecting systolic left ventricular function. Heart rate was unaffected by empagliflozin. No change in ketone bodies or branched-chain amino acids were observed in this study.

In summary, empagliflozin improved diastolic cardiac function and reduced mortality in db/db mice on a high fat diet.

Effects of empagliflozin on myocardial oxidative stress and fibrosis were tested in the genetic type 2 diabetic KK-Ay mouse model [P19-01258]. Levels of blood glucose levels as well as HbA1c levels in mice were significantly decreased by empagliflozin after 8 weeks of treatment. After 8 weeks of HFD, the LV mass/body weight ratio in mice with diabetes mellitus (DM) was significantly lower than that in control and diabetic mice treated with empagliflozin (DM+EM). Empagliflozin treatment largely restored the ejection fraction (EF), the fractional shortening (FS), the fractional area change (FAC), and the ratio between early (E)-tolate (A) diastolic mitral inflow (E/A ratio) in DM mice, which were similar to those in the control group. LV mass  was  decreased  in  all  of  the  diabetic  groups  compared  with  the  control  group.  However,  the  LV mass/body  weight  ratio  in  DM  mice  was  significantly  lower  than  that  in  control  and  DM  +  EM  mice. Empagliflozin inhibited the reduction of left ventricular internal dimension in diastole (LVIDd) and decreased interventricular  septum  thickness  in  diastole  (IVSd)  as  compared  to  the  control  group.  There  were, however, no significant differences in the values of left ventricular internal dimension in systole (LVIDs) and interventricular septum thickness in systole (IVSs) among the three groups. In the DM group, lipid hydroperoxide concentration and malondialdehyde (MDA) level were significantly higher than in control and DM + EM groups treated with empagliflozin. Furthermore, decreased levels of the antioxidant enzymes SOD and GSHPx were restored by empagliflozin. Thus, empagliflozin almost completely inhibited the increase in MDA that is considered a biomarker of oxidative stress.

DM mice showed a massive accumulation of extracellular matrix and myocardial fibrosis demonstrated by histology using Masson's trichrome staining as well as immunohistochemistry. Empagliflozin inhibited the increase in TGF-ß1-, collagen type I-, collagen type III- and connective tissue fraction- positive areas as compared to DM mice significantly.

Thus, empagliflozin inhibited LV dysfunction and remodelling and inhibited myocardial fibrosis and oxidative stress in the type 2 diabetic KK-Ay mice model.

Echocardiography in obese diabetic rats (ZDF) revealed a mild diastolic dysfunction (HFpEF) in comparison to their lean controls [P18-09844]. A prolonged isovolumetric relaxation time (IVRT), reduced E/A ratio and mild cardiac hypertrophy (increased wall thickness) was observed in the diseased rats. Empagliflozin after intravenous injection of 0,25 mg/kg significantly shortened IVRT (to 27.0±3.6 ms) and increased E/A ratio (to 1.6±0.4), indicating an improved diastolic function. The systolic contractile function as measured by ejection fraction was not altered. Further, the microvascular inflammation was reduced by empagliflozin in ZDF rats [P20-04305]. Empagliflozin reduced markers for oxidative stress, namely H2O2, 3-nitrotyrosine, and lipid peroxide and restored the antioxidant GSH to control levels. The NO-sGC-cGMP-PKG pathway was restored as well.

In summary, empagliflozin improved functional parameters of heart failure, induced anti-inflammatory as well as anti-oxidative effects and restored the NO bioavailability in vivo .

<div style=\"page-break-after: always\"></div>

Cardiac energy deficiency is characterized by a decreased cardiac phosphocreatinine-to-ATP ratio (PCr/ATP) and has been proposed to play a major role in the development of heart failure. Male diabetic C57BL/Ks db/db mice received a single oral dose of empagliflozin (30 mg/kg) after 4 hours of fasting [P18-09761]. After further 2 hours of fasting plasma glucose and ketone levels (ß-hydroxybutyrate) were measured. Thereafter in vivo cardiac PCr/ATP and function were measured using 31P magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI), respectively. Empagliflozin lowered plasma glucose and increased plasma ketone levels compared to placebo-treated mice. Cardiac PCr/ATP ratio was 45% higher in empagliflozin-treated mice compared to placebo. Empagliflozin reduced this ratio to a value measured in nondiabetic db/+ mice in a separate study. The cardiac PCr/ATP ratio correlated with plasma ketone but not with plasma glucose levels. Empagliflozin-treated mice showed a lower end-diastolic and stroke volume compared with placebo, whereas ejection fraction and end-systolic volume were not significantly affected.

In summary, the increase in plasma ketone levels by a single oral dose of empagliflozin is associated with an improvement of cardiac energetics and cardiac function in fasting diabetic db/db mice, suggesting a role for ketones in the energy supply in cardiometabolic health.

## Effects of empagliflozin in animals without diabetes:

As clinical studies indicate that empagliflozin exerts beneficial cardiovascular effects independently of the glucose-lowering  effects,  pre-clinical  pharmacological  studies  in  HF  models  were  performed  in  animals without diabetes mellitus.

There are multiple ways to induce heart failure in pre-clinical experimental settings, e.g. HF secondary to myocardial infarction (MI) induced by ischemia-reperfusion or ligation/occlusion of coronary arteries, HF induced by transverse aortic constriction (TAC) and by injections of the anti-cancer compound doxorubicin all of them demonstrating aspects of the human heart failure pathophysiology.

Doxorubicin is a marketed drug for the treatment of different types of cancer. A serious, well-known side effect of doxorubicin is dilated cardiomyopathy, leading to congestive heart failure. Thus, Doxorubicin is experimentally used to induce cardiomyopathy in different animal models. Doxorubicin-induced cardiotoxicity  is  characterized  by  left  ventricular  dysfunction  and  cardiac  hypertrophy,  which  lead  to congestive HF. In vivo experiments were performed after a single administration of doxorubicin as well as after repeated administration for 12 days [P19-10933]. In both settings, mice were randomized into 4 groups,  each:  Control  group,  empagliflozin-treated  group,  control  group  +  doxorubicin,  empagliflozintreated group + doxorubicin. For compound administration, mice were fed a normal chow diet containing 300 mg/kg empagliflozin. Empagliflozin reduced doxorubicin-induced myocardial fibrosis in mouse hearts as histologically demonstrated by Masson's trichrome staining in both acute and chronic settings.  Mouse hearts showed hypertrophic changes after 12 days of doxorubicin treatment. Empagliflozin significantly improved ejection fraction, reduced fractional shortening, left ventricular diastolic and systolic dimension and significantly reduced LV mass compared with the sham-treated doxorubicin group. Serum levels of ketone bodies, namely ß-hydroxybutyrate (ßOHB), were significantly elevated in empagliflozin-treated mice with or without single doxorubicin injection.

In order to investigate the effects of ketones (ßOHB), H9C2 cardiac myocytes were treated with ßOHB at concentrations of 100 μM, 1 mM, 10 mM and 30 mM in  vitro and exposed  to  5  μM  doxorubicin.  The doxorubicin increased ROS production in H9C2 cells was significantly decreased by pretreatment with ßOHB for 2 hours. Further, ßOHB restored the doxorubicin-induced decrease of tetramethylrhodamine methyl ester  (TMRM).  This  result  suggests  that  ßOHB  protects  cardiomyocytes  from  doxorubicin-induced mitochondrial dysfunction. Finally, ßOHB significantly increased intracellular levels of ATP in H9C2 cardiac myocytes.

<div style=\"page-break-after: always\"></div>

Effects of ßOHB were thereafter tested in vivo in single-dose doxorubicin-induced cardiomyopathy in mice. ßOHB preserved myofibril structure and reduced cardiac fibrosis in the left ventricles of mice exposed to doxorubicin.

In summary, empagliflozin attenuated doxorubicin-induced cardiomyopathy in mice. Doxorubicin-induced cardiac hypertrophy and myocardial fibrosis was reduced in empagliflozin diet-fed mice in the acute and chronic setting. Empagliflozin increased serum levels of ketone bodies. Ketone bodies were shown to induce cardioprotective effects. Thus, this study provides evidence that increased levels of ketone bodies may mediate these beneficial effects of empagliflozin.

Effects of empagliflozin on left ventricular dysfunction were tested in non-diabetic male Sprague-Dawley rats with myocardial infarction (MI) induced by permanent coronary artery ligation. Control rats underwent sham surgery [P19-03653]. Rats received a chow containing empagliflozin resulting in an average intake of 30 mg/kg/day or a control chow. Treatment started either 2 days before (early) or 2 weeks after surgery (late). Rats were stratified according to left ventricular ejection fraction (LVEF) 2 weeks post-surgery to ensure similar baseline cardiac function between the groups. The average infarct size in the left ventricle was 33 % and did not differ between the MI groups. MI induced a significant dilatation of the left ventricle and a reduction in LVEF. LVEF was significantly higher in both empagliflozin early and empagliflozin late group  as  compared  to  the  respective  sham-treated  MI  groups.  Thus,  empagliflozin  prevented  the progressive deterioration of cardiac function after MI. After MI, a marked cardiac hypertrophy was observed with a 10 % increase in ventricular mass and an 81 % increase in cardiomyocyte cross-sectional area. Empagliflozin attenuated the increase in LV mass both after early and late treatment and diminished the cardiomyocyte cross-sectional area compared to the sham-treated MI group.

The  three-fold  increase  in  myocardial  fibrosis  in  the  non-infarcted  left  ventricle  was  also  markedly attenuated  by  empagliflozin  treatment.  Empagliflozin-induced  reductions  in  fibrosis  were  paralleled  by similar reductions in the expression of the fibrosis markers collagen 1 and pro-collagen.

Empagliflozin  restored  mitochondrial  DNA  (mtDNA)  damage,  increased  mtDNA/nuclear  DNA  ratio  and restored PGC1αα expression, a critical mediator of mitochondrial biogenesis, indicating an attenuation of mitochondrial dysfunction. Cardiac ATP levels were significantly reduced in the MI-vehicle group and were significantly restored in the MI-EMPA-early group, and there was a trend towards increased ATP levels in the MI-EMPA-late group.

While the glucose and fatty acid oxidation is disrupted in the failing heart, ketone bodies are increasingly utilized as a fuel source. Empagliflozin increased circulating ketone levels and urinary ketone excretion in sham  and  MI  groups.  In  parallel,  ketone  utilization  was  increased  by  empagliflozin  as  measured  by expression of proteins involved in myocardial ketolysis: Ketone body transporter (MCT1), ketogenic enzyme ββ -hydroxy butyrate dehydrogenase (BDH1) and succinyl-CoA:3-ketoacid CoA transferase (SCOT).

In  summary,  empagliflozin  improved  cardiac  function  and  remodelling  in  non-diabetic  rats  with  LV dysfunction after MI. This effect was associated with substantial improvements in cardiac energy production measured as increased ATP levels.

Heart failure was induced in nondiabetic, female Yorkshire pigs by 2-h balloon occlusion of the proximal left anterior descending (LAD) artery followed by reperfusion [P19-03216]. Myocardial damage was confirmed by  3-dimensional  (3D)  echocardiography  and  cardiac  magnetic  resonance  (CMR).  Animals  were  then randomized to receive either 10 mg empagliflozin daily orally or placebo for 2 months. After this treatment period,  3D  echo  and  CMR  were  repeated.  Simultaneous  blood  samplings  from  coronary  arteries  and coronary sinus were performed to assess myocardial metabolite consumption and to calculate myocardial oxygen consumption and myocardial work efficiency. Tissue samples were collected for the assessment of myocardial energetics and molecular markers of cardiac metabolism.

<div style=\"page-break-after: always\"></div>

Animals in the treatment group showed marked glycosuria demonstrating effective SGLT 2 inhibition in the kidneys  of  non-diabetic  pigs.  Empagliflozin  ameliorated  adverse  cardiac  remodelling  and  HF.  In  detail, empagliflozin reduced LV end-systolic and end-diastolic volumes detected with CMR and 3D echocardiography. Further, mean LV mass measured by both CMR and direct weight immediately after necropsy  and  the  3D-sphericity  index  were  significantly  lower  in  the  empagliflozin-treated  animals compared to the control group. Two months post-MI, control animals showed a myocardial metabolic switch characterized by marked reduction in FFA and enhanced glucose consumption compared to the non-MI group. Glucose was mainly metabolized through anaerobic metabolism, as confirmed by increased net myocardial lactate production. Empagliflozin modified the cardiac energy metabolism by switching away from  glucose  towards  ketone  bodies  and  free  fatty  acids  as  a  source  of  energy.  Empagliflozin-treated animals  exhibited  higher  myocardial  ATP  (adenosine  triphosphate)  content.  In  summary,  empagliflozin improved LV systolic and diastolic function and ameliorated adverse LV remodelling. This effect is likely to be - at least in part - mediated by switching the energy metabolism towards ketone bodies and free fatty acids, thus improving cardiac energy supply in pigs with heart failure secondary to myocardial infarction.

Empagliflozin is a SGLT2 (sodium-glucose transport protein 2) inhibitor that reduces the reabsorption of glucose by the kidney resulting in increased urinary glucose excretion and subsequent lowering of the blood glucose. Empagliflozin also showed beneficial cardiovascular effects in patients with heart failure, which appear to be independent of its glycaemic control action. The pharmacological mechanism of this effect is, however, not completely elucidated. In order to justify the proposed extension of the indication to the patients with heart failure with preserved ejection fraction (HFpEF) the applicant has provided an addendum to the previously provided nonclinical overview, consisting of public literature data that investigated the effects  of  empagliflozin  on  the  cardiac  function in myocardial  samples of HFpEF patients, as well as in various pharmacological models of heart failure in different species (mice, rats and pigs). The investigations included both normoglycemic animals and animals with pre-existing diabetes.

SGLT2 inhibitors reduce blood glucose concentrations by inhibiting the main glucose transporter on the luminal surface of the proximal tubule in the kidneys, thus increasing urinary glucose excretion. The process works  as  a  co-transport  of  glucose  molecules  and  sodium  ions  (ratio  1:1),  resulting  in  an  increased concentration of sodium in the distal tubule and at the macula densa. Regulatory processes at the macula densa may influence neurohormonal pathways, such as RAAS inhibition, which together with a reduction of cardiac pre- and afterload by natriuretic and osmotic effects, may at least partially explain the beneficial cardiovascular effects of empagliflozin observed in clinical studies.

The provided literature overview demonstrated that in cardiomyocytes from the LV myocardial samples obtained from patients with HFpEF empagliflozin was shown to reduce the inflammation markers (ICAM-1, VCAM-1, TNFα and IL -6) compared to the samples from non-failing hearts and attenuated pathological oxidative  parameters  (H2O2,  3-nitrotyrosine,  GSH,  lipid  peroxide)  in  the  cardiomyocytal  cytosol  and mitochondria's. The observed effects were explained as being possibly related to the reduced inflammation and oxidative stress due to the improved eNOS phosphorylation and NO bioavailability in the myocardium, as empagliflozin was demonstrated to increase the NO levels, sGC activ ity, sGMP concentration and PKGIα activity.  Empagliflozin  was  also  shown  to  reduce  cardiomyocyte  stiffness,  measured  as  cardiomyocyte Ca2+-independent passive force (Fpassive), in cardiomyocytes from patients with HFpEF and in the treated in vivo murine ZDF obese rats, used as a model of HFpEF. In db/db mice on a high fat diet used as a type 2  diabetes  mellitus  model,  empagliflozin  improved  left  ventricular  function  and  reduced  mortality. Empagliflozin also improved functional parameters like ejection fraction, fractional shortening and the ratio between early (E)-to-late (A) diastolic mitral inflow (E/A ratio) in the genetic T2DM KK-Ay mouse model. In non-diabetic animals empagliflozin improved cardiac function in models of heart failure in ischemia/reperfusion-induced myocardial infarction in pigs, in doxorubicin-induced heart failure in mice and in coronary artery ligation-induced heart failure in rats. Further, empagliflozin increased the plasma levels

<div style=\"page-break-after: always\"></div>

of ketone bodies, namely ß-hydroxybutyrate, which have been suggested to play a role as an alternative fuel for failing hearts with less oxygen consumption compared to glucose oxidation.

In summary, beneficial cardiovascular effects of empagliflozin have been demonstrated in vitro in cardiac tissue of patients with HFpEF, as well as in a number of animal heart disease models, both in normoglycemic and in diabetic animals. However, the exact molecular mechanism of the beneficial effects of empagliflozin in these in vitro/ex vivo models remains unclear. It could be related to increasing tubuloglomerular feedback and reducing intraglomerular pressure lowering both pre- and postload of the heart, and downregulating of sympathetic activity. Other contributing mechanisms, such as reduced inflammation and oxidative stress and the increased plasma levels of ketone bodies, can also not be excluded.

## 2.2.3. Pharmacokinetics

No new information has been provided.

## 2.2.4. Toxicology

No new information has been provided.

## 2.2.5. Ecotoxicity/environmental risk assessment

An Environmental Risk Assessment (ERA) for empagliflozin was submitted with the initial MAA and an updated ERA after the completion of an additional study. The risk assessment resulted in the conclusion that no significant impact on the environment is expected.

In the current ERA, the estimation of the predicted environmental concentration (PEC) of empagliflozin in the various environmental compartments is based on the default market penetration factor (Fpen = 0.01), as  provided  in  the  EMA  guideline,  and  the  highest  maximum  daily  dose  of  25  mg.  The  recommended maximum daily dose of the newly proposed indication (heart failure in patients with preserved ejection fraction, HFpEF) will only be 10 mg.

The  default  Fpen  is  based  on  a  very  conservative  worst-case  estimation,  meaning  that  1%  of  all  EU inhabitants are treated 365 d/a with the recommended maximum daily dose. The market penetration factor was not refined though, e.g. by using the much smaller actual amount of substance placed on the market.

Therefore, the effects on the environment by adding the new intended heart failure indication (HFpEF) with a much smaller patient group are considered negligible and well covered by the used Fpen.

In previously submitted procedures, a full ERA of empagliflozin was submitted, including the determination of physical-chemical properties, Phase I and, due to the exceeded PECsw threshold limit (of 0.125), also the Phase II environmental fate studies. The conclusion of this ERA was that empagliflozin is neither PBT nor vPvB, and no unacceptable adverse effects for the surface water, groundwater, STP (sewage treatment plant) and sediment are expected from the prescribed use of empagliflozin. According to the MAH, the ERA submitted  with  the  initial  MAA  remains  valid  for  the  current  type  II  variation  covering  the  additional proposed indication. It is agreed with the MAH that, considering the lower maximum recommended dose, the PEC/PNEC ratios for the surface water, groundwater and STP will not increase more than twice and will therefore  still  be  below  the  threshold  level  for  Tier  B  (ratios  for  the  single  indication  were  0.00052, ≤0.0000125 and ≤0.000003125). Still, the MAH was requested to submit an updated ERA table with the new PECsurfacewater value. The summary ERA table submitted with the initial MAA was updated with the new PECsurfacewater values. The MAH was also requested to amend the ERA table by deleting the data on

<div style=\"page-break-after: always\"></div>

readily biodegradability and adding information data on persistence derived in the water/sediment study. Additionally, the MAH was requested to include data on toxicity to sediment dwelling organisms.

The summary ERA table which was included in the original authorization of Jardiance was updated by the MAH as requested (see table below).

<div style=\"page-break-after: always\"></div>

## Summary of main study results

| Substance (INN/Invented Name): Empagliflozin CAS-number (if available): 864070-44-0   | Substance (INN/Invented Name): Empagliflozin CAS-number (if available): 864070-44-0   | Substance (INN/Invented Name): Empagliflozin CAS-number (if available): 864070-44-0                                                                                                                                                                         | Substance (INN/Invented Name): Empagliflozin CAS-number (if available): 864070-44-0                                                                                                                                                                         | Substance (INN/Invented Name): Empagliflozin CAS-number (if available): 864070-44-0                                                                                                                                                                         | Substance (INN/Invented Name): Empagliflozin CAS-number (if available): 864070-44-0   |
|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| PBT screening                                                                         |                                                                                       | Result                                                                                                                                                                                                                                                      | Result                                                                                                                                                                                                                                                      | Result                                                                                                                                                                                                                                                      | Conclusion                                                                            |
| Bioaccumulation potential - log K ow                                                  | OECD107                                                                               | Log K ow = 1.73                                                                                                                                                                                                                                             | Log K ow = 1.73                                                                                                                                                                                                                                             | Log K ow = 1.73                                                                                                                                                                                                                                             | Not potentially PBT, nor vPvB                                                         |
| PBT-assessment                                                                        |                                                                                       |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |                                                                                       |
| Parameter                                                                             | Result relevant for conclusion                                                        |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             | Conclusion                                                                            |
| Bioaccumulation                                                                       | log K ow                                                                              | Log K ow = 1.73                                                                                                                                                                                                                                             | Log K ow = 1.73                                                                                                                                                                                                                                             | Log K ow = 1.73                                                                                                                                                                                                                                             | not B                                                                                 |
| Persistence                                                                           | DT50 or ready biodegradability                                                        | Parent: DT 50, 12°C water : 2.6/ 2.3 d DT 50, 12°C sediment : 5.5/4.1d Transformation products: TP M3 (stereoisomer of empagliflozin) DT 50, 12°C sediment = 189.8/140.9 d TP M12 : DT 50, 12°C water = 79.8 d TP M3 : very persistent in sediment, TP M12: | Parent: DT 50, 12°C water : 2.6/ 2.3 d DT 50, 12°C sediment : 5.5/4.1d Transformation products: TP M3 (stereoisomer of empagliflozin) DT 50, 12°C sediment = 189.8/140.9 d TP M12 : DT 50, 12°C water = 79.8 d TP M3 : very persistent in sediment, TP M12: | Parent: DT 50, 12°C water : 2.6/ 2.3 d DT 50, 12°C sediment : 5.5/4.1d Transformation products: TP M3 (stereoisomer of empagliflozin) DT 50, 12°C sediment = 189.8/140.9 d TP M12 : DT 50, 12°C water = 79.8 d TP M3 : very persistent in sediment, TP M12: | vP (for transformation products M3 in sediment, TP M12 in water)                      |
| Toxicity                                                                              | NOEC or CMR                                                                           | very persistent in water 2.4 mg/L                                                                                                                                                                                                                           | very persistent in water 2.4 mg/L                                                                                                                                                                                                                           | very persistent in water 2.4 mg/L                                                                                                                                                                                                                           | not T                                                                                 |
| PBT-statement Phase I                                                                 | The compound is considered                                                            | not PBT and not vPvB                                                                                                                                                                                                                                        | not PBT and not vPvB                                                                                                                                                                                                                                        | not PBT and not vPvB                                                                                                                                                                                                                                        |                                                                                       |
| Calculation                                                                           | Value                                                                                 | Unit                                                                                                                                                                                                                                                        | Unit                                                                                                                                                                                                                                                        | Unit                                                                                                                                                                                                                                                        | Conclusion                                                                            |
| PEC surfacewater (all indications), default or refined (e.g. prevalence, literature)  | 0.225                                                                                 | µg/L                                                                                                                                                                                                                                                        | µg/L                                                                                                                                                                                                                                                        | µg/L                                                                                                                                                                                                                                                        | > 0.01 threshold                                                                      |
| Other concerns (e.g. chemical class)                                                  |                                                                                       |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             | No                                                                                    |
| Phase II Physical-chemical properties and fate                                        | Phase II Physical-chemical properties and fate                                        | Phase II Physical-chemical properties and fate                                                                                                                                                                                                              | Phase II Physical-chemical properties and fate                                                                                                                                                                                                              | Phase II Physical-chemical properties and fate                                                                                                                                                                                                              | Phase II Physical-chemical properties and fate                                        |
| Study type                                                                            | Test protocol                                                                         | Results                                                                                                                                                                                                                                                     | Results                                                                                                                                                                                                                                                     | Results                                                                                                                                                                                                                                                     | Remarks                                                                               |
| Adsorption-Desorption                                                                 | OECD 106                                                                              | K oc = 51.5 L/kg                                                                                                                                                                                                                                            | K oc = 51.5 L/kg                                                                                                                                                                                                                                            | K oc = 51.5 L/kg                                                                                                                                                                                                                                            | Mean of 49 and 54 L/kg for WWTP sludge.                                               |
| Ready Biodegradability Test                                                           | OECD 301                                                                              | Not readily biodegradable                                                                                                                                                                                                                                   | Not readily biodegradable                                                                                                                                                                                                                                   | Not readily biodegradable                                                                                                                                                                                                                                   |                                                                                       |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems                      | OECD 308                                                                              | DT 50, water = 1.2/1.1 d (r/p) DT 50, sediment = 2.6/1.9 d (r/p) DT 50, whole system = 1.3/1.3 d (r/p)                                                                                                                                                      | DT 50, water = 1.2/1.1 d (r/p) DT 50, sediment = 2.6/1.9 d (r/p) DT 50, whole system = 1.3/1.3 d (r/p)                                                                                                                                                      | DT 50, water = 1.2/1.1 d (r/p) DT 50, sediment = 2.6/1.9 d (r/p) DT 50, whole system = 1.3/1.3 d (r/p)                                                                                                                                                      | r = river, p = pond, Significant shifting to sediment observed                        |
| Phase IIa Effect studies                                                              | Phase IIa Effect studies                                                              | Phase IIa Effect studies                                                                                                                                                                                                                                    | Phase IIa Effect studies                                                                                                                                                                                                                                    | Phase IIa Effect studies                                                                                                                                                                                                                                    | Phase IIa Effect studies                                                              |
| Study type                                                                            | Test protocol                                                                         | Endpoin t                                                                                                                                                                                                                                                   | valu e                                                                                                                                                                                                                                                      | Unit                                                                                                                                                                                                                                                        | Remarks                                                                               |
| Algae, Growth Inhibition Test / Pseudokirchneriella subcaptitat                       | OECD 201                                                                              | NOEC                                                                                                                                                                                                                                                        | ≥ 100                                                                                                                                                                                                                                                       | mg/L                                                                                                                                                                                                                                                        |                                                                                       |
| Daphnia sp . Reproduction Test                                                        | OECD 211                                                                              | NOEC                                                                                                                                                                                                                                                        | ≥ 100                                                                                                                                                                                                                                                       | mg/L                                                                                                                                                                                                                                                        |                                                                                       |
| Fish, Early Life Stage Toxicity Test / Danio rerio                                    | OECD 210                                                                              | NOEC                                                                                                                                                                                                                                                        | 2.4                                                                                                                                                                                                                                                         | mg/L                                                                                                                                                                                                                                                        |                                                                                       |
| Activated Sludge, Respiration Inhibition Test                                         | OECD 209                                                                              | NOEC                                                                                                                                                                                                                                                        | ≥ 100                                                                                                                                                                                                                                                       | mg/L                                                                                                                                                                                                                                                        |                                                                                       |
| Phase IIb studies                                                                     |                                                                                       |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |                                                                                       |
| Sediment dwelling organism Chironomus riparius                                        | OECD 218                                                                              | NOEC                                                                                                                                                                                                                                                        | 1010                                                                                                                                                                                                                                                        | mg/kg                                                                                                                                                                                                                                                       | normalized to 10% Corg                                                                |

## 2.2.6. Discussion on non-clinical aspects

The current application concerns an extension of the indication of Jardiance to patients with heart failure with preserved ejection fraction (HFpEF). The active substance empagliflozin is a SGLT2 (sodium glucose transport  protein  2)  inhibitor  that  reduces  the  reabsorption  of  glucose  by  the  kidney  resulting  in  the

<div style=\"page-break-after: always\"></div>

increased  urinary  glucose  excretion  and  subsequent  lowering  of  the  blood  glucose.  Empagliflozin  also showed beneficial cardiovascular effects in patients with heart failure, which appear to be independent of its  glycaemic control action. The pharmacological mechanism of this effect is, however, not completely elucidated. The applicant has provided an addendum to the previously submitted non-clinical overview based on public literature data that demonstrated beneficial cardiovascular effects of empagliflozin in vitro in  cardiac  tissue  of  patients  with  HFpEF  and  in  a  number  of  animal  heart  disease  models,  both  in normoglycemic  and  in  diabetic  animals.  It  has  been  concluded  that  these  effects  could  be  related  to increasing  tubuloglomerular  feedback  and  reducing  intraglomerular  pressure,  lowering  both  pre-  and postload of the heart, and downregulating of sympathetic activity. Other contributing mechanisms, such as reduced inflammation and oxidative stress and the increased plasma levels of ketone bodies, can also not be excluded.

It is agreed with the MAH that the ERA conclusions based on the previous ERA of empagliflozin remain unchanged. The DT50-values for the total system, sediment and water normalised to 12 °C for empagliflozin and the relevant transformation products M3, M1 and M12 are included in the updated ERA as well as the proposed molecular structures of M3 and M1. It is also mentioned in the ERA that M3 is proposed to be a stereoisomer of the active substance empagliflozin and thus might be pharmacologically active. The MAH was however asked to submit an updated ERA table with the new PECsurfacewater value, deletion of the data  on  readily  biodegradability  and  addition  of  information  data  on  persistence  derived  in  the water/sediment study and data on toxicity to sediment dwelling organisms.

## 2.2.7. Conclusion on the non-clinical aspects

Although several factors have been mentioned that may contribute to the positive actions of empagliflozin on  heart  function,  the  precise  molecular  mechanisms  of  these  effects  are  not  clear.  Several  possible mechanisms may play a role, such as a reduced sodium reabsorption in the proximal tubules, resulting in reduced intraglomerular pressure and lowered cardiac pre- and afterload; increased level of ketone bodies, improving cardiac energy supply by increasing cardiac uptake and oxidization of β -hydroxybutyrate. It is currently not clear which of the numerous potential mechanisms of action are of clinical relevance or which one would be the dominant one. The provided information is endorsed.

Based on the updated data submitted in this application, the new/extended indication does not lead to a significant increase in environmental exposure further to the use of empagliflozin.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH (Table 1).

<div style=\"page-break-after: always\"></div>

Table 1. Tabular overview of clinical studies

| Trial no.                                                     | Phase                                                         | No. randomised                                                | Patient population                                            | Treatment duration                                            | First patient screened                                        | Last patient completed CTR                                    | Last patient completed CTR                                    |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               |
| 1245.121                                                      | III                                                           | 3730                                                          | HFrEF (LVEF ≤40%)                                             | Event- driven                                                 | Apr 2017                                                      | May 2020                                                      | [c28576542]                                                   |
| 1245.110                                                      | III                                                           | 5988                                                          | HFpEF (LVEF >40%)                                             | Event- driven                                                 | Mar 2017                                                      | Apr 2021                                                      | [c31803238]                                                   |
| Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     |
| 1245.168                                                      | III                                                           | 312                                                           | HFrEF                                                         | 12 weeks                                                      | Mar 2018                                                      | Oct 2019                                                      | [c26554767]                                                   |
| 1245.167                                                      | III                                                           | 315                                                           | HFpEF                                                         | 12 weeks                                                      | Apr 2018                                                      | Oct 2019                                                      | [c26554599]                                                   |
| Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') |
| 1245.148                                                      | III                                                           | 72                                                            | HFrEF/HFpEF separate cohorts                                  | 12 weeks                                                      | Mar 2018                                                      | May 2020                                                      | [c31537568]                                                   |

## 2.3.2. Pharmacokinetics

No new information has been provided with regard to basal pharmacokinetics. This is all described in previous applications.

Additionally, pharmacokinetic data from trial 1245.110 was compared with the data from trial 1245.121. As a measure of systemic drug exposure to empagliflozin, steady-state trough PK samples were taken in the EMPEROR-preserved trial in a subset of patients (overall number of patients with valid PK samples: N=519). The PK of empagliflozin in patients with chronic heart failure with preserved ejection fraction in the EMPEROR-preserved trial was presented. Additionally, pharmacokinetic data from trial 1245.110 was compared with the data from trial 1245.121.

## Comparison of PK trial 1245.110 and 1245.121

After demographic and baseline characteristic stratifications, similar results were observed in patients with HFpEF when compared to patients with HFrEF: Empagliflozin exposure in both trials increased with a decrease in renal function or an increase in age and decreased with an increase in body weight or BMI. There were only minor differences in empagliflozin exposures between trials regarding all further demographic or baseline characteristics.

For all subgroups, the gMean steady state trough concentrations of empagliflozin 10 mg in trial 1245.110 were similar (0.71 to 1.24-fold) to those of empagliflozin 10 mg in trial 1245.121.

Table PK01 Fold differences in the gMean steady state trough concentrations of empagliflozin trial 1245.110 with respect to those in trial 1245.121 for different subgroups.

| stratification by   | subgroup                   | 1245.110 gMean (gCV[%]), N   | 1245.121 gMean (gCV[%]), N   | Ratio gMean 1245.110 vs. gMean 1245.121   |
|---------------------|----------------------------|------------------------------|------------------------------|-------------------------------------------|
|                     | All                        | 63.4 (80.6), 519             | 67.3 (91.8), 308             | 0.94                                      |
| Intrinsic factors   | Intrinsic factors          | Intrinsic factors            | Intrinsic factors            | Intrinsic factors                         |
| eGFR                | ≥ 90 mL/min/1.73m 2        | 38.5 (109), 30               | 42.1 (84.6), 40              | 0.91                                      |
| eGFR                | ≥60 and <90 mL/min/1.73m 2 | 54.0 (78.7), 222             | 51.9 (92.3), 119             | 1.04                                      |
| eGFR                | ≥30 and <60 mL/min/1.73m 2 | 73.3 (68.0), 242             | 92.5 (72.4), 125             | 0.79                                      |

<div style=\"page-break-after: always\"></div>

|                                      | ≥ 15 and <30 mL/min/1.73m 2          | 116 (75.9), 25                       | 103 (62.6), 24                       | 1.13                                    |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|-----------------------------------------|
| Age                                  | < 50 years                           | 48.5 (101), 12                       | 40.9 (95.0), 22                      | 1.19                                    |
| Age                                  | ≥ 50 and < 65 years                  | 52.8 (94.1), 68                      | 58.4 (98.5), 84                      | 0.90                                    |
| Age                                  | ≥ 65 and < 75 years                  | 64.0 (83.3), 189                     | 67.8 (82.0), 112                     | 0.94                                    |
| Age                                  | ≥ 75 years                           | 66.9 (72.8), 250                     | 86.1 (84.6), 90                      | 0.78                                    |
| Body Weight                          | ≤50 kg                               | 87.6 (69.4), 40                      | 90.4 (84.6), 34                      | 0.97                                    |
| Body Weight                          | >50 and ≤70 kg                       | 69.1 (72.4), 191                     | 73.6 (89.2), 126                     | 0.94                                    |
| Body Weight                          | >70 and ≤90 kg                       | 57.5 (86.8), 164                     | 63.1 (80.3), 101                     | 0.91                                    |
|                                      | >90 kg                               | 56.7 (82.1), 124                     | 49.3 (113), 47                       | 1.15                                    |
| BMI                                  | < 25 kg/m 2                          | 70.3 (68.2), 201                     | 74.7 (83.4), 160                     | 0.94                                    |
| BMI                                  | ≥ 25 and < 30 kg/m 2                 | 62.9 (94.4), 158                     | 62.9 (95.6), 88                      | 1.00                                    |
| BMI                                  | ≥ 30 and < 35 kg/m 2                 | 56.3 (89.3), 83                      | 61.0 (81.7), 43                      | 0.92                                    |
| BMI                                  | ≥ 35 kg/m 2                          | 55.7 (69.5), 77                      | 46.5 (164), 17                       | 1.20                                    |
| Sex                                  | Male                                 | 62.7 (81.3), 322                     | 67.2 (88.5), 243                     | 0.93                                    |
| Sex                                  | Female                               | 64.4 (79.5), 197                     | 67.9 (105), 65                       | 0.95                                    |
| stratification by                    | subgroup                             | 1245.110 gMean (gCV[%]), N           | 1245.121 gMean (gCV[%]), N           | Ratio gMean 1245.110 vs. gMean 1245.121 |
|                                      | All                                  | 63.4 (80.6), 519                     | 67.3 (91.8), 308                     | 0.94                                    |
|                                      | Asian                                | 71.0 (66.5), 235                     | 68.9 (82.2), 172                     | 1.03                                    |
|                                      | Black                                | 65.6 (59.9), 21                      | 63.9 (76.2), 13                      | 1.03                                    |
| Race                                 | White                                | 58.4 (88.6), 246                     | 65.8 (114), 110                      | 0.89                                    |
|                                      | Other                                | 44.8 (132), 16                       | 63.4 (55.6), 13                      | 0.71                                    |
| Lifestyle                            | Lifestyle                            | Lifestyle                            | Lifestyle                            | Lifestyle                               |
| Smoking Status                       | Current Smoker                       | 77.5 (65.1), 37                      | 62.4 (63.0), 39                      | 1.24                                    |
| Smoking Status                       | Ex-Smoker                            | 59.7 (76.3), 273                     | 68.4 (92.1), 150                     | 0.87                                    |
| Smoking Status                       | Never Smoked                         | 66.1 (87.7), 209                     | 66.7 (101), 113                      | 0.99                                    |
| Alcohol status                       | Drinks Alcohol                       | 62.2 (76.1), 245                     | 66.6 (89.7), 107                     | 0.93                                    |
|                                      | Does not Drink Alcohol               | 64.4 (84.6), 274                     | 68.6 (90.4), 192                     | 0.94                                    |
| Background disease and Co-medication | Background disease and Co-medication | Background disease and Co-medication | Background disease and Co-medication | Background disease and Co-medication    |
| T2DM status                          | Non-T2DM                             | 60.5 (74.3), 281                     | 63.5 (94.4), 145                     | 0.95                                    |
| T2DM status                          | T2DM                                 | 66.9 (87.5), 238                     | 71.0 (89.2), 163                     | 0.94                                    |
| NYHA classification                  | I                                    | 63.6 (53.6), 3                       | not reportable                       | ---                                     |
| NYHA classification                  | II                                   | 62.1 (79.9), 438                     | 68.6 (91.4), 240                     | 0.91                                    |
| NYHA classification                  | III                                  | 70.9 (84.9), 78                      | 63.0 (94.2), 67                      | 1.13                                    |
| ARNi use at baseline                 | With ARNi                            | 71.9 (80.6), 18                      | 63.3 (101), 52                       | 1.14                                    |
| ARNi use at baseline                 | Without ARNi                         | 63.1 (80.6), 501                     | 68.2 (90.0), 256                     | 0.93                                    |

--- not calculated

[Source data: c36415368 , Tables Z.11.3: 26, Tables Z.11.3: 8 -9, Tables Z.11.3: 11 -12, Table Z.11.3: 14, and

Tables Z.11.3: 16 to 17]

In general pharmacokinetic data generated for EMPEROR-Preserved/ study is comparable to previously collected pharmacokinetic data.

<div style=\"page-break-after: always\"></div>

Empagliflozin exposure in trial 1245.110 increased with a decrease in renal function (up to a 3.01-fold difference in gMean) or an increase in age (up to a 1.38-fold difference in gMean); This increase in exposure is correlated as average renal function decreases with an increase in age. In addition, empagliflozin exposure decreased with an increase in body weight (up to a 1.54-fold difference in gMean) or BMI (up to a 1.26-fold difference in gMean).

After demographic and baseline characteristic stratifications, similar results were observed in patients with HFpEF compared to patients with HFrEF. In addition, there were no differences (&lt;1.25-fold difference in gMean) in empagliflozin exposure by sex, race (comparison Asian versus White or Black versus White), NYHA classification, diabetes status or use of ARNi at baseline.

Differences in empagliflozin exposures were observed among different groups of geographic region (up to 1.38-fold difference in gMean) or investigator country (up to a 1.44-fold difference in gMean).

However, when all data from special groups were compared with results from trial 1245.121, the gMean steady-state trough concentration of empagliflozin 10 mg was not higher than that of empagliflozin 25 mg in any corresponding subgroup in 1245.25 [c32077394]. Since the gMean steady-state trough concentrations were similar between 1245.110 and 1245.121 in all subgroups, these data support that dose adjustment based on PK is not needed for renal function, age, body weight, BMI, sex, race, smoking status, or alcohol use.

## 2.3.3. Pharmacodynamics

## Mechanism of action

There were no new dedicated clinical pharmacology studies.

Empagliflozin is a reversible, highly potent (IC50 of 1.3 nmol) and selective competitive inhibitor of sodiumglucose co-transporter 2 (SGLT2). Empagliflozin does not inhibit other glucose transporters important for glucose transport into peripheral tissues and is 5000 times more selective for SGLT2 versus SGLT1, the major transporter responsible for glucose absorption in the gut. SGLT2 is highly expressed in the kidney, whereas expression in other tissues is absent or very low. As the predominant transporter, it is responsible for the reabsorption of glucose from the glomerular filtrate back into the circulation. In patients with type 2 diabetes and hyperglycaemia, a higher amount of glucose is filtered and reabsorbed.

Empagliflozin  improves  glycaemic  control  in  patients  with  type  2  diabetes  by  reducing  renal  glucose reabsorption.  The  amount  of  glucose  removed  by  the  kidney  through  this  glucuronic  mechanism  is dependent on blood glucose concentration and GFR. Inhibition of SGLT2 in patients with type 2 diabetes and hyperglycaemia leads to excess glucose excretion in the urine. In addition, initiation of empagliflozin increases excretion of sodium, resulting in osmotic diuresis and reduced intravascular volume.

Empagliflozin improves both fasting and post-prandial plasma glucose levels. The mechanism of action of empagliflozin is independent of beta-cell function and insulin pathway, and this contributes to a low risk of hypoglycaemia.  Improvement  of  surrogate  markers  of  beta-cell  function,  including  Homeostasis  Model Assessmentβ (HOMA -β) was noted. In addition, urinary glucose excretion triggers calorie loss, associated with body fat loss and body weight reduction. The glucosuria observed with empagliflozin is accompanied by diuresis, which may contribute to sustained and moderate reduction of blood pressure. Empagliflozin may impact on multiple pathophysiological pathways common for both HFrEF and HFpEF. Empagliflozin reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to: increasing tubuloglomerular feedback and reducing  intra-glomerular  pressure,  lowering  both  pre-  and  afterload  of  the  heart,  downregulating

<div style=\"page-break-after: always\"></div>

sympathetic activity, and reducing left ventricular wall stress as evidenced by lower NT-proBNP values with further beneficial effects on cardiac remodelling, filling pressures and diastolic function.

The exact molecular mechanisms of the beneficial cardiovascular effects of empagliflozin are, however, still under intense pharmacological investigation.

## 2.3.4. Discussion on clinical pharmacology

## Pharmacodynamics

The mode of action and pharmacodynamics of SGLT2i for the treatment of T2DM, in general, are well known. For the treatment of HFrEF, modes of action have also been described and discussed in a previous application. For HFrEF, it is thought that SGLT2i reduce sodium reabsorption, increase tubuloglomerular feedback and consequently lower both pre- and afterload of the heart and downregulating sympathetic activity.  The  Applicant  also  described  mechanisms  of  action  relevant  for  both  HFrEF  and  HFpEF,  e.g. reduction in left ventricular wall stress with further beneficial effects on cardiac remodelling, filling pressures and diastolic function.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

Not applicable.

Based on the data for the indication of T2DM and HFrEF it is acceptable that no dose-finding study has been performed, but it cannot be excluded that a lower dose than 10 mg is effective for the current indication.

## 2.4.2. Main study(ies)

BI initiated a Phase III program for empagliflozin 10 mg once daily in chronic heart failure regardless of diabetes status. There are two CV outcome trials ('EMPEROR'), two functional capacity trials ('EMPERIAL'), and a mechanistic Phase III trial ('EMPA-VISION') in patients with HFrEF (reduced ejection fraction) and HFpEF (preserved ejection fraction). All 5 trials are placebo-controlled, randomised (empagliflozin 10 mg to placebo 1:1), double-blind, and parallel-group by design ( Table 2. ).

The EMPEROR trials are pivotal outcome trials investigating the long-term effect of empagliflozin in reducing the risk of hospitalisation for HF and cardiovascular death in patients with heart failure. The EMPERIAL trials are  additional  trials  that  investigated  the  short-term  (12  weeks)  effect  of  empagliflozin  on  functional capacity, signs and symptoms of heart failure, and quality of life. The EMPA-VISION trial is a supporting trial investigating the short-term (12 weeks) effect of empagliflozin on mechanistic cardiac physiology and metabolism. All 5 trials have been completed and the clinical trial reports are available.

The EMPEROR-Reduced and the EMPERIAL trials have been previously submitted. The EMPEROR-Preserved trial results are described in this document, along with a brief summary of EMERIAL and EMPA-VISION and the pre-specified meta-analysis of efficacy endpoints based on both EMPEROR trials. Safety assessments in this document mainly focuses on pooled results from all 5 trials.

Based on the results of the pivotal trial 1245.110 (EMPEROR-Preserved), BI sought a new indication for empagliflozin in adult patients with heart failure (NYHA class II-IV) with preserved ejection fraction.

Where the indication for patients with heart failure with reduced ejection fraction has already been approved (which  was  based  on  the  previously  submitted  pivotal  trial  1245.121,  EMPEROR-Reduced),  BI  aims  to

<div style=\"page-break-after: always\"></div>

combine both indications to an indication for adult patients with symptomatic chronic heart failure (NYHA class II-IV).

Table 2. Clinical trials in patients with chronic heart failure

| Trial no.                                                     | Pha se                                                        | No. randomised                                                | Patient population                                            | Treatment duration                                            | First patient screened                                        | Last patient completed                                        | CTR                                                           |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               | CV outcome trials ('EMPEROR-Preserved/Reduced')               |
| 1245.1 21                                                     | III                                                           | 3730                                                          | HFrEF (LVEF ≤40%)                                             | Event- driven                                                 | Apr 2017                                                      | May 2020                                                      | [c28576542]                                                   |
| 1245.1 10                                                     | III                                                           | 5988                                                          | HFpEF (LVEF >40%)                                             | Event- driven                                                 | Mar 2017                                                      | Apr 2021                                                      | [c31803238]                                                   |
| Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     | Functional capacity trials ('EMPERIAL-preserved/reduced')     |
| 1245.1 68                                                     | III                                                           | 312                                                           | HFrEF                                                         | 12 weeks                                                      | Mar 2018                                                      | Oct 2019                                                      | [c26554767]                                                   |
| 1245.1 67                                                     | III                                                           | 315                                                           | HFpEF                                                         | 12 weeks                                                      | Apr 2018                                                      | Oct 2019                                                      | [c26554599]                                                   |
| Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') | Mechanistic cardiac physiology and metabolism ('EMPA-VISION') |
| 1245.1 48                                                     | III                                                           | 72                                                            | HFrEF/HFpEF separate cohorts                                  | 12 weeks                                                      | Mar 2018                                                      | May 2020                                                      | [c31537568]                                                   |

## Title of Study: EMPEROR-preserved (1245.110)

## Methods

## Study participants

Trial 1245.110 was carried out at 622 clinical sites in 23 countries in Europe, Latin America, North America, Asia, and other (South Africa, Australia, India). In total, 5988 patients were randomised to double-blind empagliflozin 10 mg (2997 patients) or placebo (2991 patients) once daily treatment. Randomisation was stratified  by  region,  diabetes  history,  LVEF,  and  eGFR  (CKD-EPI)cr  at  screening.  All  but  3  randomised patients (1 in the empagliflozin 10 mg group and 2 in the placebo group) were treated with at least 1 dose of study medication.

## Inclusion criteria

The key eligibility criteria for the EMPEROR-Preserved (1245.110), in comparison with EMPEROR-Reduced (1245.121), are shown in Table 3.

Table 3. Key eligibility criteria for the EMPEROR trials

| 1245.121 (HFrEF)                      | 1245.110 (HFpEF)   |
|---------------------------------------|--------------------|
| Age ≥18 years                         |                    |
| Chronic HF NYHA class II to IV        |                    |
| eGFR (CKD-EPI) cr ≥20 mL/min/1.73 m 2 |                    |

<div style=\"page-break-after: always\"></div>

Reduced EF (LVEF ≤40%) and elevated NT -proBNP for patients with/without atrial fibrillation or atrial flutter (AF):

| LVEF                     | NT-proBNP without AF   | NT-proBNP with AF   |
|--------------------------|------------------------|---------------------|
| 36 to 40%                | ≥2500 pg/mL            | ≥5000 pg/mL         |
| 31 to 35%                | ≥1000 pg/mL            | ≥2000 pg/mL         |
| ≤30%                     | ≥600 pg/mL             | ≥1200 pg/mL         |
| ≤40% and HHF ≤12 months* | ≥600 pg/mL             | ≥1200 pg/mL         |

* For patients not meeting the categories above

Stable  therapy  for HF  consistent  with  local  and international cardiology guidelines

Preserved EF (LVEF &gt;40%) and elevated NT -proBNP: &gt;300 pg/mL for patients without AF; &gt;900 pg/mL for patients with AF

Structural heart disease or HHF ≤12 months Appropriate and  stable dose  of oral diuretics if prescribed

NYHA, New York heart association;  LVEF,  left  ventricular  ejection  fraction;  HHF,  hospitalisation  for  heart  failure;  AF,  atrial fibrillation  or  atrial  flutter;  NT-proBNP, N-terminal pro-brain natriuretic peptide; eGFR (CKD-EPI)cr, glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement

## Exclusion criteria

Patients were excluded if they had a disorder that could change their clinical course, independent of heart failure, or if they had any condition that might jeopardize patient safety or limit their participation in the trial. The key exclusion criteria are listed below.

Cardiovascular diseases or treatments that increase the unpredictability of or change the patients' clinical course, independent of heart failure

- Myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischemia or new ischemic ECG changes), coronary artery bypass graft surgery, or other major cardiovascular surgery, stroke or transient ischemic attack in the past 90 days
- Heart transplant recipient or listed for a heart transplant.  Currently implanted left ventricular assist device.
- Cardiomyopathy  based  on  infiltrative  diseases  (e.g.  amyloidosis),  accumulation  diseases  (e.g. hemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g.  stress  cardiomyopathy),  hypertrophic  obstructive  cardiomyopathy  or  known  pericardial constriction.
- Any severe (obstructive or regurgitant) valvular heart disease, expected to lead to surgery during the trial period
- Acute decompensated heart failure requiring intravenous diuretics, vasodilators, inotropic agents or  mechanical  support  within  1  week  of  screening  and  during  the  screening  period  prior  to randomization
- Implanted cardioverter defibrillator within 3 months prior to screening
- Cardiac resynchronization therapy

Untreated or undertreated cardiovascular conditions that might influence the course of heart failure or tolerability of the study medications

<div style=\"page-break-after: always\"></div>

- Atri al  fibrillation  or  atrial  flutter  with  a  resting  heart  rate  &gt;110  bpm  documented  by  ECG  at screening
- Systolic blood pressure ≥ 180 mmHg at randomization. If the systolic blood pressure is 151-179 mmHg, the patient should be receiving ≥ 3 antihypertensive drugs
- Symptomatic  hypotension  and/or  a  systolic  blood  pressure  &lt;100  mmHg  at  screening  or  at randomization Significant comorbid conditions that might influence the clinical course, independent of heart failure
- Chronic pulmonary disease requiring home oxygen, oral corticosteroid therapy or hospitalisation for exacerbation within 12 months; significant chronic pulmonary disease; or primary pulmonary arterial hypertension
- Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening
- Impaired renal function, defined as eGFR &lt; 20 mL/min/1.73 m2 (CKD-EPI) or requiring dialysis at the time of screening
- Haemoglobin &lt;9 g/dL at screening
- Major surgery (major according to the investigator's assessment) performed within 90 days prior to  screening,  or  major  scheduled  elective  surgery  (e.g.  hip  replacement)  within  90  days  after screening.
- Gastrointestinal  surgery  or  gastrointestinal  disorder  that  could  interfere  with  trial  medication absorption.
- Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix, or low risk prostate cancer (patients with pre-treatment PSA &lt;10 ng/mL, and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a)
- Presence of any other disease than heart failure with a life expectancy of less than one year (in the opinion of the investigator) Any condition that might jeopardize patient safety, limit the patients' participation in the trial, or undermine the interpretation of trial data.

## Treatments

Trial 1245.110 is a placebo-controlled, randomised (empagliflozin 10 mg to placebo 1:1), double-blind, and parallel-group  by  design.  Patients  were  to  be  treated  with  randomised  study  medication  in  addition to standard of care (in accordance with local/international guidelines) until the required number of patients with adjudicated primary endpoint events was expected to be reached. The median observation time of the trial was about 26 months, with the median exposure to study medication about 23 months. After the last intake of study medication, patients were to be followed up for 30 days.

<div style=\"page-break-after: always\"></div>

Design of EMPEROR trials in patients with chronic heart failure

## CV outcome trials ('EMPEROR-Reduced/Preserved')

Aim: To investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced or preserved ejection fraction

Population: T2DM and non-T2DM, aged ≥18 years, chronic HF (NYHA class II-IV)

<!-- image -->

qd,  once  daily;  LVEF,  left  ventricular  ejection  fraction;  6MWT,  6 -minute  walk  test;  CMR,  cardiac  magnetic  resonance;  CPET, cardiopulmonary exercise test

## Objectives

The  EMPEROR-Preserved  trial  is  a  pivotal  CV  outcome  trial  that  investigates  the  long-term  effect  of empagliflozin in reducing the risk of hospitalisation for HF and of cardiovascular death in patients with HFpEF. The objective of this event-driven trial is to demonstrate the superiority of empagliflozin 10 mg versus placebo in patients with symptomatic, chronic HF and preserved ejection fraction (LVEF &gt; 40%) under stable treatment of HF symptoms.

## Outcomes/endpoints

The following endpoints were pre-specified for 1245.110:

- Primary endpoint (confirmatory):
- o Time to first event of adjudicated CV death or adjudicated HHF
- Key secondary endpoints (confirmatory):
- o Occurrence of adjudicated HHF (first and recurrent)
- o eGFR (CKD-EPI)cr slope of change from baseline
- Other secondary endpoints (exploratory):
- o Time to the first event in the composite renal endpoint: chronic dialysis 1 , renal transplant, or sustained 2  reduction in eGFR (CKD-EPI)cr 3
- o Time to first adjudicated HHF
- o Time to adjudicated CV death
- o Time to all-cause mortality
- o Time to onset of DM (defined as HbA1c ≥ 6.5% or as diagnosed by the investigator) in patients with pre-DM 4

<div style=\"page-break-after: always\"></div>

- o Change from baseline in KCCQ clinical summary score 5  at Week 52
- o Occurrence of all-cause hospitalisation (first and recurrent)

1  Chronic dialysis was defined as dialysis with a frequency of twice per week or more for at least 90 days

2  Sustained was determined by two or more consecutive post-baseline central laboratory measurements separated by at least 30 days (the first to last of the consecutive eGFR values)

3   Reduction in eGFR (CKD-EPI)cr was defined as reduction in eGFR from baseline of ≥ 40%, eGFR &lt;15 mL/min/1.73 m2 for patients  with  baseline  eGFR ≥ 30  mL/min/1.73  m2,  or  eGFR  &lt;10  mL/min/1.73  m2  for  patients  with  baseline  eGFR  &lt;30 mL/min/1.73 m2

4  Pre-DM was defined as no history of DM and no HbA1c ≥ 6.5% before treatment, and a pretreatment HbA1c value of ≥ 5.7% and &lt;6.5%

5  KCCQ, Kansas City cardiomyopathy questionnaire; clinical summary score measures HF symptoms (frequency and burden) and physical limitations

· Further  endpoints  (exploratory)  include  time  to  or  occurrence  of  CV  and/or  renal  events, progression or reversal of albuminuria, changes from baseline in eGFR, KCCQ scores, NYHA class, EQ-5D, NT-proBNP, albuminuria, body weight, blood pressure, pulse rate, HbA1c, FPG, etc.

## Sample size

For the sample size calculation, a yearly event rate in the placebo group of 10% is assumed. The assumption is based on the CHARM-Preserved study and part of the TOPCAT study from the Americas. The annual event rates in CHARM-Preserved were 8.1% in the candesartan group and 9.1% in the placebo group. The annual rates from the Americas in the TOPCAT study were 10.4 in the spironolactone group and 12.6 in the placebo group. The trial is designed to achieve a power of 90% for a twosided test at level α = 0.05. The number of required events together with the number of to be randomised and treated patients were calculated assuming an accrual period of 18 months and a follow-up period of 20 months. The follow-up period was not fixed, but the trial would continue until the necessary number of events has been observed, which are confirmed by the adjudication committee. A hazard ratio of 0.8 was chosen as a conservative estimate based on the results of the EMPA-REG OUTCOME trial drop-out rate from the trial is assumed to be low (&lt; 1% per year) and is therefore not further considered for the determination of sample size. An interim analysis was performed by the independent DMC. The EMPEROR-preserved trial included 5988 subjects (empagliflozin 10 mg: 2997 patients, placebo: 2991 patients).

## Randomisation

Subjects who fulfilled all eligibility criteria were randomized double -blind in a 1:1 manner. Randomisation was performed with a permuted block design and was stratified by geographic region, diabetes status, estimated glomerular filtration rate (eGFR) of less than 60 ml per minute per 1.73 m 2  of body-surface area or 60 ml or more per minute per 1.73 m 2 , and left ventricular ejection fraction of less than 50% or 50% or more; all measured at screening.

## Blinding (masking)

Patients, Investigators and everyone involved in trial conduct or analysis or with any other interest in this double-blind trial remain blinded with regard to the randomised treatment assignments until after database lock. The DMC is provided with unblinded data in order to allow them to review efficacy and safety and to fulfil their tasks as outlined in the data monitoring committee charter. An independent team, not otherwise involved in the conduct of the trial, provided the unblinded results to the DMC. The randomisation code is kept secret by Clinical Trial Support up to database lock.

<div style=\"page-break-after: always\"></div>

## Statistical methods

The EMPEROR-Preserved (1245.110) trial was designed to have a power of 90% for the primary endpoint at twosided α of 0.05 to detect a hazard ratio of 0.8 between empagliflozin and placebo, which required at least 841 adjudicated primary endpoint events. After 494 events (planned approximately 500 events or about 60% of anticipated events), an interim analysis was performed by the independent DMC. Based on the interim results, the DMC recommended continuing the trial as planned. The α -level for the final analysis was 0.0497 (2-sided). A hierarchical procedure (see Figure 2) was applied to the primary and key secondary endpoints. If a confirmatory endpoint was successful (i.e. empagliflozin superior to placebo), the α would be used for the subsequent step(s). If a confirmatory endpoint was not successful, all subsequent endpoints would  be  evaluated  in  an  exploratory  manner.  After  evaluation  of  the  first  key  secondary  endpoint (recurrent HHF), α was to be split into 0.001 (two -sided) for the analysis of eGFR slope, and the rest transferred to an efficacy meta-analysis. If the eGFR slope analysis was successful, the α of this branch would also be transferred to the meta-analysis.

Planned hierarchical testing strategy and alpha spending for the individual trials 1245.121 and 1245.110 and the meta-analysis

<div style=\"page-break-after: always\"></div>

<!-- image -->

Unless otherwise specified, efficacy analyses followed the ITT principle and included all randomised patients (RS; treatment assigned as randomised) and all available data up to the planned treatment discontinuation (including 'off-treatment' data during unplanned treatment interruptions and after premature treatment discontinuations). Unless otherwise specified, the outcome events were based on adjudication results from the clinical event committee (CEC), according to prespecified definitions in the CEC charter.

<div style=\"page-break-after: always\"></div>

## Primary endpoint (time to adjudicated CV death or HHF)

The primary analysis was a Cox regression with factors treatment, region (Asia, Europe, Latin America, North America, and other), baseline status of DM (diabetic, pre-diabetes, and normal), age (continuous), sex, LVEF (continuous), and baseline eGFR (CKD-EPI)cr(continuous). Region, status of DM, LVEF (&lt;50% or ≥ 50%),  and  eGFR  (CKD-EPI)cr  (&lt;60  or ≥ 60  mL/min/1.73  m ² )  at  screening  are  randomisation stratification factors. Following the ITT principle, all data up to the end of the planned treatment period (including the data after the end of treatment for patients not completing the treatment period as planned) from  all  randomised  patients  were  used.  Patients  without  a  specific  endpoint  event  were  considered censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Cumulative incidence function curves that account for competing risks (i.e. non-CV deaths) and Kaplan-Meier curves of time to censoring were displayed. The individual components that contributed to the primary endpoint were summarised descriptively. Subgroup analyses by predefined demographic and baseline characteristics (e.g. comorbidities, risk factors, and background medications) were carried out.

## Key secondary endpoint 1 (adjudicated recurrent HHF)

The  analysis  for  recurrent  HHF  used  a  joint  frailty  model  that  accounts  for  the  dependence  between recurrent HHF and CV death, with the same covariates used for the primary endpoint. All data up to the end  of  the  planned  treatment  period  (including  the  data  after  the  end  of  treatment  for  patients  not completing the treatment period as planned) from all randomised patients were used. The number of HHF events per patient was summarised descriptively. Negative binomial models were additionally fitted for recurrent  HHF  events.  The  mean  cumulative  incidence  was  displayed  for  adjudicated  recurrent  HHF. Subgroup analyses were carried out.

## Key secondary endpoint 2 (eGFR slope of change from baseline)

The analysis was a random coefficient model allowing for random intercept and random slope per patient, with the same factors used for the primary endpoint and additional factors 'time', 'treatment-by-time interaction', and 'baseline eGFR (CKD-EPI)cr-by-time interaction'. Only 'on-treatment' data from treated patients (i.e. measurements up to 1 day after the last intake of study medication) were used. Subgroup analyses were carried out.

## Other secondary and further endpoints (exploratory)

Exploratory efficacy endpoints were analysed in the following way in general:

- Time-to-event  endpoints:  similar  to  the  primary  analysis  of  the  primary  endpoint.  Subgroup analyses were performed for time to CV death and time to first HHF
- Recurrent events endpoints: similar to the primary analysis of the first key secondary Endpoint
- Continuous endpoints: a mixed model repeated measure (MMRM) analysis
- Categorical endpoints: descriptive

## Results

## Disposition of patients

This trial was a multicentre trial conducted globally (Table 4).

<div style=\"page-break-after: always\"></div>

Table 4. Overview of screened and randomised patients by region in 1245.110 - SCR

| Geographical region   | Countries                                                                               | Patients screened      |   Patients randomised |
|-----------------------|-----------------------------------------------------------------------------------------|------------------------|-----------------------|
| Total                 | 23 countries                                                                            | 11583                  |                  5988 |
| Europe                | Poland, Czech Republic, Hungary, the Netherlands, Italy, Romania, Spain, United Kingdom | Germany, Belgium, 4568 |                  2689 |
| Latin America         | Brazil, Argentina, Colombia, Mexico                                                     | 3636                   |                  1515 |
| North America         | United States, Canada                                                                   | 1632                   |                   719 |
| Asia                  | Japan, China, Korea, Singapore                                                          | 968                    |                   686 |
| Other                 | South Africa, Australia, India                                                          | 779                    |                   379 |

About half of the screened patients (48.3%) were not randomised, most commonly because of NT-proBNP levels being below protocol-specified thresholds at screening (37.6% of screened patients) (Table 5.)

Of the 5988 randomised patients, 5816 patients (97.1%) had complete follow-up for the primary endpoint and the final vital status was known for 5952 patients (99.4%); see Table 5. Of the 5985 patients treated with study medication, 1888 patients prematurely discontinued treatment (31.5%, including patients who died).

The most common reason for premature discontinuation of study medication was an AE (10.6% of patients with non-fatal events and 8.2% with fatal events). The next most common reason was refusal to continue study medication, which was balanced across the placebo (10.2%) and empagliflozin (9.5%) groups.

Table 5. Disposition of patients in 1245.110 - SCR

|                                                    | Placebo N (%)   | Empa 10 mg N (%)   | Total N (%)   |
|----------------------------------------------------|-----------------|--------------------|---------------|
| Screened                                           |                 |                    | 11583         |
| Randomised                                         | 2991 (100.0)    | 2997 (100.0)       | 5988 (100.0)  |
| Final vital status known                           | 2972 (99.4)     | 2980 (99.4)        | 5952 (99.4)   |
| Alive                                              | 2527 (84.5)     | 2543 (84.9)        | 5070 (84.7)   |
| Deceased                                           | 445 (14.9)      | 437 (14.6)         | 882 (14.7)    |
| Vital status unknown                               | 19 (0.6)        | 17 (0.6)           | 36 (0.6)      |
| Completed trial or died 1                          | 2903 (97.1)     | 2913 (97.2)        | 5816 (97.1)   |
| Prematurely discontinued trial                     | 88 (2.9)        | 84 (2.8)           | 172 (2.9)     |
| Consent withdrawn                                  | 25 (0.8)        | 27 (0.9)           | 52 (0.9)      |
| Site closure 2                                     | 15 (0.5)        | 8 (0.3)            | 23 (0.4)      |
| Limited follow-up agreed 3                         | 33 (1.1)        | 25 (0.8)           | 58 (1.0)      |
| Lost to follow-up to the primary endpoint 4        | 15 (0.5)        | 24 (0.8)           | 39 (0.7)      |
| Treated                                            | 2989 (100.0)    | 2996 (100.0)       | 5985 (100.0)  |
| Not prematurely discontinued from trial medication | 2046 (68.5)     | 2051 (68.5)        | 4097 (68.5)   |
| Prematurely discontinued study medication          | 943 (31.5)      | 945 (31.5)         | 1888 (31.5)   |
| Adverse event                                      | 553 (18.5)      | 575 (19.2)         | 1128 (18.8)   |
| Non-fatal events                                   | 309 (10.3)      | 326 (10.9)         | 635 (10.6)    |
| Worsening of HF                                    | 26 (0.9)        | 21 (0.7)           | 47 (0.8)      |
| Worsening of other pre-existing disease            | 47 (1.6)        | 49 (1.6)           | 96 (1.6)      |
| Other                                              | 236 (7.9)       | 256 (8.5)          | 492 (8.2)     |
| Fatal events                                       | 244 (8.2)       | 249 (8.3)          | 493 (8.2)     |
| Worsening of HF                                    | 57 (1.9)        | 36 (1.2)           | 93 (1.6)      |
| Worsening of other pre-existing disease            | 8 (0.3)         | 13 (0.4)           | 21 (0.4)      |

<div style=\"page-break-after: always\"></div>

| Other                                      | 179 (6.0)   | 200 (6.7)   | 379 (6.3)   |
|--------------------------------------------|-------------|-------------|-------------|
| Non-compliance with protocol               | 30 (1.0)    | 24 (0.8)    | 54 (0.9)    |
| Lost to follow-up                          | 6 (0.2)     | 16 (0.5)    | 22 (0.4)    |
| Patient refusal to continue, not due to AE | 304 (10.2)  | 284 (9.5)   | 588 (9.8)   |
| Other reason                               | 44 (1.5)    | 45 (1.5)    | 89 (1.5)    |
| Reason missing 5                           | 6 (0.2)     | 1 (<0.1)    | 7 (0.1)     |

1 Patients with primary event (HHF or CV death) or follow -up for the primary endpoint until study end/death.

2 Including patients from Site no. 1156007 (see [CTR 1245.110, c31803238, Section 9.6]) and closed sites (who did not complete the trial or die and did not withdraw consent).

3 Patients not from a closed site who discontinued all trial activities but did not withdraw consent to vital status collection at treatment termination.

4 Other patients with incomplete follow -up for the primary endpoint.

5 Includes 7 patients from closed sites.

Patients who discontinued study medication prematurely were to be followed up for outcome events and vital status until the end of the trial. Vital status was known for 99.4% of the randomised patients, and 97.1% completed follow up  for  the  primary  endpoint,  with  balanced  distribution  between  groups.  The proportion  of  patients  who  prematurely  discontinued  study  medication  (including  due  to  death)  was balanced between the empagliflozin group and the placebo group (both 31.5%), with the most frequent reasons to discontinue study medication being adverse events (10.6% of total patients with non-fatal events and 8.2% with fatal events) and refusal to continue (9.8%).

The number of subjects that prematurely discontinued study medication was similar between empagliflozin vs placebo.

## Conduct of the study

The Applicant states that the trials are carried out in compliance with the clinical trial protocol (CTP), in accordance  with  the  principles  of  the  Declaration  of  Helsinki,  in  accordance  with  the  ICH  GCP,  and  in accordance with applicable regulatory requirements and BI's standard operating procedures.

Impact of COVID-19 pandemic on clinical visits and study medication supply

Before the onset of the COVID-19 outbreak, 5896 patients (98.5%) had been randomised in this trial, and 92 patients were randomised thereafter.

Information  on  the  disruption  due  to  COVID-19  to  the  clinical  visits  and  study  medication  supply  was collected on the CRF and summarised. About one-third of patients (31.8%) had at least one visit affected by COVID-19. The majority of these patients (25.7% overall) had at least one visit performed by phone instead of on-site, and 4.6% had at least one visit performed outside the protocol-defined window. A total of 1.4% of patients had an interruption of trial medication for more than 7 days due to COVID-19 and 0.8% had permanent treatment discontinuation due to COVID-19 infection.

## Baseline data

Slightly more than half of the patients were men (55.3%). The majority of the patients were White (75.9%) and elderly (64.1% of patients were ≥ 70 years old). See Table 6.  for details.

Table 6. Demographic data in 1245.110 - RS

|                           | Placebo      | Empa 10 mg   | Total        |
|---------------------------|--------------|--------------|--------------|
| Number of patients, N (%) | 2991 (100.0) | 2997 (100.0) | 5988 (100.0) |
| Sex, N (%)                |              |              |              |

<div style=\"page-break-after: always\"></div>

| Male                       | 1653 (55.3)   | 1659 (55.4)   | 3312 (55.3)   |
|----------------------------|---------------|---------------|---------------|
| Female                     | 1338 (44.7)   | 1338 (44.6)   | 2676 (44.7)   |
| Race (summary), N (%)      |               |               |               |
| White                      | 2256 (75.4)   | 2286 (76.3)   | 4542 (75.9)   |
| Black/African American     | 125 (4.2)     | 133 (4.4)     | 258 (4.3)     |
| Asian                      | 411 (13.7)    | 413 (13.8)    | 824 (13.8)    |
| Other including mixed race | 198 (6.6)     | 164 (5.5)     | 362 (6.0)     |
| Ethnicity, N (%)           |               |               |               |
| Not Hispanic/Latino        | 2236 (74.8)   | 2227 (74.3)   | 4463 (74.5)   |
| Hispanic/Latino            | 754 (25.2)    | 770 (25.7)    | 1524 (25.5)   |
| Region, N (%)              |               |               |               |
| North America              | 359 (12.0)    | 360 (12.0)    | 719 (12.0)    |
| Latin America              | 757 (25.3)    | 758 (25.3)    | 1515 (25.3)   |
| Europe                     | 1343 (44.9)   | 1346 (44.9)   | 2689 (44.9)   |
| Asia                       | 343 (11.5)    | 343 (11.4)    | 686 (11.5)    |
| Other                      | 189 (6.3)     | 190 (6.3)     | 379 (6.3)     |
| Age [years], mean (SD)     | 71.9 (9.6)    | 71.8 (9.3)    | 71.9 (9.4)    |
| Age [years], N (%)         |               |               |               |
| <50                        | 72 (2.4)      | 67 (2.2)      | 139 (2.3)     |
| 50 to <65                  | 533 (17.8)    | 527 (17.6)    | 1060 (17.7)   |
| 65 to <75                  | 1092 (36.5)   | 1122 (37.4)   | 2214 (37.0)   |
| 75 to <85                  | 1088 (36.4)   | 1103 (36.8)   | 2191 (36.6)   |
| ≥85                        | 206 (6.9)     | 178 (5.9)     | 384 (6.4)     |
| Age [years], N (%)         |               |               |               |
| <70                        | 1084 (36.2)   | 1066 (35.6)   | 2150 (35.9)   |
| ≥70                        | 1907 (63.8)   | 1931 (64.4)   | 3838 (64.1)   |

Patients with information missing are not shown; for data, see [CTR 1245.110, c31803238, Table 15.1.4: 1]

Source data: [CTR 1245.110, c31803238, Section 10.4]

## Baseline characteristics and variables

Patients with an LVEF of &gt;40% could participate in the trial . The mean LVEF was 54.3%. About a third of patients were in each of the predefined LVEF categories (LVEF &lt;50%, 50 to &lt;60%, and ≥60%). Median NT-proBNP was 974 pg/mL (Q1, Q3 499, 1731). The majority of patients had SBP &lt;140 mmHg and DBP &lt;90 mmHg. eGFR &lt;60 mL/min/1.73 m2 was reported for 49.9% of patients, with eGFR &lt;30 mL/min/1.73 m2 reported for 309 patients (5.2%). Normal UACR was reported for 58.0% of patients, while 31.1% had microalbuminuria and 10.5% had macroalbuminuria. A history of atrial fibrillation or atrial flutter was reported for 52.4% of patients. Half of the patients were reported with type 2 diabetes, and 10 patients (0.2%) were reported with type 1 diabetes ( Table 7. ).

Table 7. Baseline characteristics in 1245.110 - RS

|                               | Placebo         | Empa 10 mg      | Total           |
|-------------------------------|-----------------|-----------------|-----------------|
| Number of patients, N (%)     | 2991 (100.0)    | 2997 (100.0)    | 5988 (100.0)    |
| LVEF [%], mean (SD)           | 54.3 (8.8)      | 54.3 (8.8)      | 54.3 (8.8)      |
| <50%, N (%)                   | 988 (33.0)      | 995 (33.2)      | 1983 (33.1)     |
| 50 to <60%, N (%)             | 1030 (34.4)     | 1028 (34.3)     | 2058 (34.4)     |
| ≥60%, N (%)                   | 973 (32.5)      | 974 (32.5)      | 1947 (32.5)     |
| NT-proBNP [pg/mL]             |                 |                 |                 |
| All patients, median (Q1, Q3) | 946 (498, 1725) | 994 (501, 1740) | 974 (499, 1731) |

<div style=\"page-break-after: always\"></div>

| Patients with no atrial fibrillation or flutter from 1966       | Patients with no atrial fibrillation or flutter from 1966       | 1924              | 3890              |
|-----------------------------------------------------------------|-----------------------------------------------------------------|-------------------|-------------------|
| baseline ECG, N Median (Q1, Q3)                                 | 643 (386, 1212)                                                 | 654 (380, 1197)   | 649 (382, 1200)   |
| Patients with atrial fibrillation or flutter from baseline 1016 | Patients with atrial fibrillation or flutter from baseline 1016 | 1064              | 2080              |
| ECG, N                                                          |                                                                 |                   |                   |
| Median (Q1, Q3)                                                 | 1582 (1132, 2366)                                               | 1611 (1135, 2312) | 1603 (1134, 2339) |
| Blood pressure                                                  |                                                                 |                   |                   |
| SBP [mmHg], mean (SD)                                           | 131.9 (15.7)                                                    | 131.8 (15.6)      | 131.8 (15.6)      |
| DBP [mmHg], mean (SD)                                           | 75.7 (10.5)                                                     | 75.7 (10.6)       | 75.7 (10.6)       |
| SBP <140 mmHg and DBP <90 mmHg, N (%)                           | 1917 (64.1)                                                     | 1909 (63.7)       | 3826 (63.9)       |
| SBP ≥140 mmHg or DBP ≥90 mmHg, N (%)                            | 1074 (35.9)                                                     | 1088 (36.3)       | 2162 (36.1)       |
| Heart rate [bpm], mean (SD)                                     | 70.3 (11.8)                                                     | 70.4 (12.0)       | 70.4 (11.9)       |
| BMI [kg/m 2 ], mean (SD)                                        | 29.90 (5.92)                                                    | 29.77 (5.81)      | 29.84 (5.87)      |
| <30 kg/m 2 , N (%)                                              | 1642 (54.9)                                                     | 1654 (55.2)       | 3296 (55.0)       |
| ≥30 kg/m 2 , N (%)                                              | 1349 (45.1)                                                     | 1343 (44.8)       | 2692 (45.0)       |
| eGFR (CKD-EPI) [mL/min/1.73 m 2 ], mean (SD)                    | 60.6 (19.9)                                                     | 60.6 (19.8)       | 60.6 (19.8)       |
| ≥60, N (%)                                                      | 1505 (50.3)                                                     | 1493 (49.8)       | 2998 (50.1)       |
| ≥90                                                             | 237 (7.9)                                                       | 231 (7.7)         | 468 (7.8)         |
| 60 to <90                                                       | 1268 (42.4)                                                     | 1262 (42.1)       | 2530 (42.3)       |
| <60, N (%)                                                      | 1484 (49.6)                                                     | 1504 (50.2)       | 2988 (49.9)       |
| 45 to <60                                                       | 773 (25.8)                                                      | 792 (26.4)        | 1565 (26.1)       |
| 30 to <45                                                       | 550 (18.4)                                                      | 564 (18.8)        | 1114 (18.6)       |
| <30, N (%)                                                      | 161 (5.4)                                                       | 148 (4.9)         | 309 (5.2)         |
| 20 to <30                                                       | 152 (5.1)                                                       | 142 (4.7)         | 294 (4.9)         |
| <20                                                             | 9 (0.3)                                                         | 6 (0.2)           | 15 (0.3)          |
| UACR [mg/g], N (%)                                              |                                                                 |                   |                   |
| Normal (<30)                                                    | 1747 (58.4)                                                     | 1727 (57.6)       | 3474 (58.0)       |
| Microalbuminuria (30 to ≤300)                                   | 921 (30.8)                                                      | 939 (31.3)        | 1860 (31.1)       |
| Macroalbuminuria (>300)                                         | 311 (10.4)                                                      | 318 (10.6)        | 629 (10.5)        |
| Patients with a history of atrial fibrillation or flutter 1 ,   | 1559 (52.1)                                                     | 1576 (52.6)       | 3135 (52.4)       |
| , N (%)                                                         |                                                                 |                   |                   |
| Investigator-reported medical history                           |                                                                 |                   |                   |
| Atrial fibrillation, N (%)                                      | 1510 (50.5)                                                     | 1543 (51.5)       | 3053 (51.0)       |
| Atrial flutter, N (%)                                           | 200 (6.7)                                                       | 206 (6.9)         | 406 (6.8)         |
| Baseline ECG, N (%)                                             | 1016 (34.0)                                                     | 1064 (35.5)       | 2080 (34.7)       |
| Atrial flutter, N (%)                                           | 41 (1.4)                                                        | 54 (1.8)          | 95 (1.6)          |
| Atrial fibrillation, N (%)                                      | 986 (33.0)                                                      | 1033 (34.5)       | 2019 (33.7)       |
| Patients with history of atrial fibrillation 1 , N (%)          | 1514 (50.6)                                                     | 1543 (51.5)       | 3057 (51.1)       |
| Diabetes status, N (%)                                          |                                                                 |                   |                   |
| Without diabetes, N (%)                                         | 1519 (50.8)                                                     | 1531 (51.1)       | 3050 (50.9)       |
| Without diabetes or pre-diabetes, N (%)                         | 540 (18.1)                                                      | 530 (17.7)        | 1070 (17.9)       |
| With pre-diabetes 2 , N (%)                                     | 979 (32.7)                                                      | 1001 (33.4)       | 1980 (33.1)       |
| With diabetes, N (%)                                            | 1472 (49.2)                                                     | 1466 (48.9)       | 2938 (49.1)       |
| T2DM 3 , N (%)                                                  | 1467 (49.0)                                                     | 1461 (48.7)       | 2928 (48.9)       |
| Investigator-reported medical history, N (%)                    | 1329 (44.4)                                                     | 1322 (44.1)       | 2651 (44.3)       |
| Previously undiagnosed diabetes, N (%)                          | 138 (4.6)                                                       | 139 (4.6)         | 277 (4.6)         |
| T1DM 4 , N (%)                                                  | 5 (0.2)                                                         | 5 (0.2)           | 10 (0.2)          |
| HbA 1c [%], mean (SD)                                           | 7.27 (1.52)                                                     | 7.24 (1.47)       | 7.26 (1.50)       |

Patients with missing information are not shown; refer to [CTR 1245.110, c31803238, Tables 15.1.4: 2 and 4 to 8] for these data.

<div style=\"page-break-after: always\"></div>

1  Investigator-reported medical history or baseline ECG finding

2  Including patients with no investigator-reported medical history of diabetes and pretreatment HbA1c ≥5.7% and &lt;6.5%, or patients stratified to the group of pre-diabetes via IRT and pretreatment HbA1c &lt;6.5% (if available), or patients stratified to the group of no diabetes via IRT and pretreatment HbA1c ≥5.7% and &lt;6.5%

3   Patients without T1DM and with investigator-reported medical history of diabetes or patients with previously undiagnosed diabetes (pretreatment HbA1c ≥6.5%)

4  Patients with investigator-reported medical history of diabetes and the type was T1DM

Source data: [CTR 1245.110, c31803238, Section 10.4]

## Heart failure-related medical history

To qualify for this trial, patients had to have chronic HF with preserved ejection fraction as defined in the inclusion criteria of the trial protocol.

Most patients were in NYHA class II (81.5%). About 30% of patients had been diagnosed with HF more than 5 years before the trial. The cause of HF was ischaemic for 35.4% of patients and hypertensive for 36.5% of patients. With regard to conditions met for inclusion into the trial, the majority of patients (77.1%) had structural heart disease only, 6.4% of patients had HHF within 12 months of screening only, and 16.4% of patients met both of these conditions ( Table 8. ).

Table 8. Heart failure-related medical history in 1245.110 - RS

|                                                                                 | Placebo      | Empa 10 mg   | Total        |
|---------------------------------------------------------------------------------|--------------|--------------|--------------|
| Number of patients, N (%)                                                       | 2991 (100.0) | 2997 (100.0) | 5988 (100.0) |
| NYHA class at baseline, N (%)                                                   |              |              |              |
| I                                                                               | 1 (<0.1)     | 3 (0.1)      | 4 (0.1)      |
| II                                                                              | 2451 (81.9)  | 2432 (81.1)  | 4883 (81.5)  |
| III                                                                             | 531 (17.8)   | 552 (18.4)   | 1083 (18.1)  |
| IV                                                                              | 8 (0.3)      | 10 (0.3)     | 18 (0.3)     |
| Time since diagnosis of HF [years], mean (SD)                                   | 4.3 (5.0)    | 4.5 (5.2)    | 4.4 (5.1)    |
| ≤1, N (%)                                                                       | 782 (26.1)   | 730 (24.4)   | 1512 (25.3)  |
| >1 to 5, N (%)                                                                  | 1325 (44.3)  | 1368 (45.6)  | 2693 (45.0)  |
| >5 to 10, N (%)                                                                 | 553 (18.5)   | 550 (18.4)   | 1103 (18.4)  |
| >10, N (%)                                                                      | 331 (11.1)   | 349 (11.6)   | 680 (11.4)   |
| Cause of HF, N (%)                                                              |              |              |              |
| Ischaemic                                                                       | 1038 (34.7)  | 1079 (36.0)  | 2117 (35.4)  |
| Hypertensive                                                                    | 1120 (37.4)  | 1066 (35.6)  | 2186 (36.5)  |
| Valvular heart disease                                                          | 168 (5.6)    | 187 (6.2)    | 355 (5.9)    |
| Diabetic                                                                        | 58 (1.9)     | 67 (2.2)     | 125 (2.1)    |
| Alcoholism                                                                      | 7 (0.2)      | 6 (0.2)      | 13 (0.2)     |
| Idiopathic                                                                      | 262 (8.8)    | 289 (9.6)    | 551 (9.2)    |
| Other                                                                           | 338 (11.3)   | 302 (10.1)   | 640 (10.7)   |
| HHF within 12 months before screening and/or structural heart disease 1 , N (%) |              |              |              |
| HHF within 12 months before screening only                                      | 187 (6.3)    | 199 (6.6)    | 386 (6.4)    |
| Structural heart disease only                                                   | 2317 (77.5)  | 2297 (76.6)  | 4614 (77.1)  |
| Both                                                                            | 482 (16.1)   | 499 (16.6)   | 981 (16.4)   |

Patients with information missing are not shown; refer to [CTR 1245.110, c31803238,Tables 15.1.4: 3 and 4] for these data.

1  Evidence of HF as defined in inclusion criterion 6

Source data: [CTR 1245.110, c31803238, Section 10.4]

## Concomitant therapies

## Concomitant therapies at baseline

<div style=\"page-break-after: always\"></div>

A total of 78.6% of patients used ACE inhibitors/ARBs at baseline, and 2.2% used ARNi, 86.3% used betablockers, and 86.2% used diuretics, including 37.5% who used MRAs and 67.7% who used loop or high ceiling diuretics ( Table 9. ).

Table 9. Patients taking drugs used in heart failure, other anti-hypertensives, lipid-lowering drugs, or antithrombotic drugs at baseline in 1245.110 - RS

|                                               | Placebo N (%)   | Empa 10 mg N (%)   | Total N (%)   |
|-----------------------------------------------|-----------------|--------------------|---------------|
| Number of patients                            | 2991 (100.0)    | 2997 (100.0)       | 5988 (100.0)  |
| Drugs used in heart failure                   | 2972 (99.4)     | 2985 (99.6)        | 5957 (99.5)   |
| ACE inhibitors/ARBs/ARNi                      | 2404 (80.4)     | 2428 (81.0)        | 4832 (80.7)   |
| ACE inhibitors/ARBs                           | 2338 (78.2)     | 2367 (79.0)        | 4705 (78.6)   |
| ARNi                                          | 69 (2.3)        | 65 (2.2)           | 134 (2.2)     |
| Beta-blockers                                 | 2569 (85.9)     | 2598 (86.7)        | 5167 (86.3)   |
| Diuretics                                     | 2600 (86.9)     | 2563 (85.5)        | 5163 (86.2)   |
| Mineralocorticoid receptor antagonists (MRAs) | 1125 (37.6)     | 1119 (37.3)        | 2244 (37.5)   |
| Loop or high ceiling diuretics                | 2024 (67.7)     | 2030 (67.7)        | 4054 (67.7)   |
| Ivabradine                                    | 31 (1.0)        | 40 (1.3)           | 71 (1.2)      |
| Cardiac glycosides                            | 263 (8.8)       | 293 (9.8)          | 556 (9.3)     |
| Nitrates                                      | 338 (11.3)      | 408 (13.6)         | 746 (12.5)    |
| Hydralazine                                   | 74 (2.5)        | 82 (2.7)           | 156 (2.6)     |
| Other anti-hypertensives                      | 883 (29.5)      | 943 (31.5)         | 1826 (30.5)   |
| Lipid-lowering drugs                          | 2139 (71.5)     | 2103 (70.2)        | 4242 (70.8)   |
| Anti-thrombotic drugs                         | 2609 (87.2)     | 2631 (87.8)        | 5240 (87.5)   |

ARB: excluding valsartan when taken with sacubitril, because sacubitril/valsartan is shown as ARNi.

Source data: [CTR 1245.110, c31803238,  Section 10.4]

## Concomitant therapies during the trial

Concomitant therapies at baseline or any time up to the end of the planned treatment period were balanced across the treatment groups (Table 10. ).

Table 10. Patients taking drugs used in heart failure, other anti-hypertensives, lipid-lowering drugs, or anti-thrombotic drugs at baseline or any time up to the end of the planned treatment period in 1245.110 RS

|                                | Placebo N (%)   | Empa 10 mg N (%)   | Total N (%)   |
|--------------------------------|-----------------|--------------------|---------------|
| Number of patients             | 2991 (100.0)    | 2997 (100.0)       | 5988 (100.0)  |
| Drugs used in heart failure    | 2984 (99.8)     | 2994 (99.9)        | 5978 (99.8)   |
| ACE inhibitors/ARBs/ARNi       | 2535 (84.8)     | 2539 (84.7)        | 5074 (84.7)   |
| ACE inhibitors/ARBs            | 2467 (82.5)     | 2481 (82.8)        | 4948 (82.6)   |
| ARNi                           | 148 (4.9)       | 116 (3.9)          | 264 (4.4)     |
| Beta-blockers                  | 2661 (89.0)     | 2686 (89.6)        | 5347 (89.3)   |
| Diuretics                      | 2746 (91.8)     | 2703 (90.2)        | 5449 (91.0)   |
| MRAs                           | 1395 (46.6)     | 1360 (45.4)        | 2755 (46.0)   |
| Loop or high ceiling diuretics | 2293 (76.7)     | 2227 (74.3)        | 4520 (75.5)   |
| Ivabradine                     | 52 (1.7)        | 51 (1.7)           | 103 (1.7)     |
| Cardiac glycosides             | 361 (12.1)      | 377 (12.6)         | 738 (12.3)    |
| Nitrates                       | 536 (17.9)      | 548 (18.3)         | 1084 (18.1)   |
| Hydralazine                    | 129 (4.3)       | 131 (4.4)          | 260 (4.3)     |

<div style=\"page-break-after: always\"></div>

| Other anti-hypertensives   | 1142 (38.2)   | 1136 (37.9)   | 2278 (38.0)   |
|----------------------------|---------------|---------------|---------------|
| Lipid-lowering drugs       | 2268 (75.8)   | 2232 (74.5)   | 4500 (75.2)   |
| Anti-thrombotic drugs      | 2710 (90.6)   | 2728 (91.0)   | 5438 (90.8)   |

ARB: excluding valsartan when taken with sacubitril, because sacubitril/valsartan is shown as ARNi.

Source data: [CTR 1245.110, c31803238, Section 10.4]

Intensification of diuretic therapy after baseline was less frequent in the empagliflozin group vs placebo (16.1 vs 20.4% of patients), while a decrease of diuretic therapy was more frequent in the empagliflozin group vs placebo (14.1 vs 12.0%)

## Extent of exposure

Median observation time up to the end of the planned treatment period was about 26 months in both treatment groups, with 94% of patients observed for at least 1 year ( Table 11. ).

Table 11. Observational period up to the end of the planned treatment period in 1245.110 - RS

|                                    | Placebo           | Empa 10 mg        | Total             |
|------------------------------------|-------------------|-------------------|-------------------|
| Number of patients, N (%)          | 2991 (100.0)      | 2997 (100.0)      | 5988 (100.0)      |
| Observation time categories, N (%) |                   |                   |                   |
| ≥12 weeks                          | 2952 (98.7)       | 2973 (99.2)       | 5925 (98.9)       |
| ≥26 weeks                          | 2899 (96.9)       | 2913 (97.2)       | 5812 (97.1)       |
| ≥52 weeks                          | 2814 (94.1)       | 2816 (94.0)       | 5630 (94.0)       |
| ≥78 weeks                          | 2248 (75.2)       | 2230 (74.4)       | 4478 (74.8)       |
| ≥104 weeks                         | 1673 (55.9)       | 1663 (55.5)       | 3336 (55.7)       |
| ≥156 weeks                         | 405 (13.5)        | 403 (13.4)        | 808 (13.5)        |
| Observation time [month]           |                   |                   |                   |
| Median (Q1, Q3)                    | 26.1 (18.2, 33.0) | 26.2 (18.0, 33.1) | 26.2 (18.1, 33.1) |
| Mean (SD)                          | 25.6 (9.3)        | 25.6 (9.4)        | 25.6 (9.3)        |
| Total observation time [year]      | 6293.4            | 6304.8            | 12598.2           |

Source data: [CTR 1245.110, c31803238, Section 10.5]

Median exposure to study medication was the same (about 23 months) in both treatment groups, with 84% of patients treated for at least 1 year ( Table 12. ).

Table 12. Exposure to study medication in 1245.110 - TS

|                              | Placebo           | Empa 10 mg        | Total             |
|------------------------------|-------------------|-------------------|-------------------|
| Number of patients, N (%)    | 2989 (100)        | 2996 (100.0)      | 5985 (100.0)      |
| Exposure categories, N (%)   |                   |                   |                   |
| ≥12 weeks                    | 2830 (94.7)       | 2854 (95.3)       | 5684 (95.0)       |
| ≥26 weeks                    | 2699 (90.3)       | 2726 (91.0)       | 5425 (90.6)       |
| ≥52 weeks                    | 2511 (84.0)       | 2524 (84.2)       | 5035 (84.1)       |
| ≥78 weeks                    | 1930 (64.6)       | 1911 (63.8)       | 3841 (64.2)       |
| ≥104 weeks                   | 1389 (46.5)       | 1379 (46.0)       | 2768 (46.2)       |
| ≥156 weeks                   | 308 (10.3)        | 303 (10.1)        | 611 (10.2)        |
| Duration of exposure [month] |                   |                   |                   |
| Median (Q1, Q3)              | 23.3 (15.3, 31.4) | 23.3 (15.4, 31.4) | 23.3 (15.4, 31.4) |
| Mean (SD)                    | 22.7 (10.8)       | 22.7 (10.7)       | 22.7 (10.7)       |
| Total exposure [year]        | 5569.5            | 5595.3            | 11164.7           |

Exposure was calculated as date of last intake of study medication minus date of first intake, plus 1 day.

Source data: [CTR 1245.110, c31803238, Section 10.5]

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary outcome, CV death or HHF

The primary endpoint was the time to the first event of adjudicated CV death or adjudicated hospitalisation for heart failure.

CV death or HHF occurred in a lower proportion of patients in the empagliflozin group (415 of 2997 patients, 13.8%) than in the placebo group (511 of 2991 patients, 17.1%), and the risk of CV death or HHF was significantly reduced with empagliflozin treatment compared with placebo (HR empagliflozin vs placebo 0.79; 95% CI 0.69 to 0.90, p = 0.0003; Table 13. ).

Table 13. Time to the first event of adjudicated CV death or HHF, Cox regression, trial 1245.110 - RS

|                                      | Placebo      | Empa 10 mg        |
|--------------------------------------|--------------|-------------------|
| Analysed patients, N (%)             | 2991 (100.0) | 2997 (100.0)      |
| Patients with event, N (%)           | 511 (17.1)   | 415 (13.8)        |
| HHF as the first event               | 352 (11.8)   | 258 (8.6)         |
| CV death as the first event          | 159 (5.3)    | 156 (5.2)         |
| Both on the same day                 | 0            | 1 (<0.1)          |
| Incidence rate per 100 years at risk | 8.67         | 6.86              |
| Hazard ratio vs placebo (95% CI)     |              | 0.79 (0.69, 0.90) |
| (95.03% CI) 1                        |              | (0.69, 0.90)      |
| p-value                              |              | 0.0003            |

Cox regression model included factors age, baseline eGFR (CKD-EPI)cr, region, baseline diabetes status, sex, baseline LVEF, and treatment

1 Based on the reduced 2sided α level of 0.0497 resulting from the interim analysis

Source data: [CTR 1245.110, c31803238, Section 11.1]

The separation of the estimated cumulative incidence of CV death or first HHF (considering non-CV death as  a  competing  risk)  between  empagliflozin  and  placebo  started  shortly  after  randomisation  and  was maintained throughout the trial ( 0 ). The cumulative probability for censoring of patients without endpoint events was similar between treatment groups. The number of patients with a HHF or CV death during the 30 days after treatment discontinuation was similar in each treatment arm (empagliflozin: 147 patients, 5.1%; placebo: 153 patients, 5.3%).

Time  to  the  first  event  of  adjudicated  CV  death  or  HHF,  estimated  cumulative  incidence  function (considering non-CV death as a competing risk), trial 1245.110 - RS

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source data: [CTR 1245.110, c31803238, Section 11.1]

## Key secondary outcomes, first and recurrent HHF and eGFR slope

## Key secondary endpoint 1: first and recurrent HHF

The first key secondary endpoint in the hierarchical testing procedure was the occurrence of adjudicated HHF (first and recurrent).

The primary analysis consisted of a joint frailty model that accounted for the dependence between recurrent HHF and CV death and was based on all data up to the end of the planned treatment period from all randomised patients.

Adjudicated HHF occurred in fewer patients in the empagliflozin group than in the placebo group. The total number of HHF events (first and recurrent) was also lower in the empagliflozin group than in the placebo group. The risk of recurrent HHF was significantly reduced for empagliflozin versus placebo (HR 0.73, 95.03% CI 0.61 to 0.88, p = 0.0009). The hazard of recurrent HHF was positively correlated to that of CV death (indicated by a frailty exponent &gt;0). For further information, refer to Table 14.

Table 14. Adjudicated HHF and CV death, joint frailty model, trial 1245.110 - RS

|                                    | Placebo      | Empa 10 mg   |
|------------------------------------|--------------|--------------|
| Analysed patients, N (%)           | 2991 (100.0) | 2997 (100.0) |
| Patients with HHF, N (%)           | 352 (11.8)   | 259 (8.6)    |
| Patients with HHF then CV death    | 85 (2.8)     | 63 (2.1)     |
| Patients with HHF only             | 267 (8.9)    | 196 (6.5)    |
| Patients with CV death only, N (%) | 159 (5.3)    | 156 (5.2)    |
| Total number of HHF events         | 541          | 407          |

<div style=\"page-break-after: always\"></div>

| Hazard ratio vs placebo of recurrent HHF (95% CI)   | 0.73 (0.61, 0.88)   |
|-----------------------------------------------------|---------------------|
| (95.03% CI) 1                                       | (0.61, 0.88)        |
| p-value                                             | 0.0009              |
| Hazard ratio vs placebo of CV death (95% CI)        | 0.89 (0.71, 1.12)   |
| Frailty exponent (alpha) 2                          | 1.02                |

Joint frailty model included factors age, baseline eGFR (CKD-EPI)cr, region, baseline diabetes status, sex, baseline LVEF, treatment; variance of frailty (omega) 5.09

1 Based on the reduced 2sided α level of 0.0497 resulting from the interim analysis

2 Positive correlation between the hazard s for the recurrent (HHF) and terminal events (CV death) if alpha is &gt;0

Source data: [CTR 1245.110, c31803238, Section 11.1]

The mean cumulative number of HHF events in the empagliflozin and placebo groups started to diverge shortly after randomisation and continued to separate over the course of the trial ( 0 ).

Occurrence of adjudicated HHF (first and recurrent), mean cumulative function, trial 1245.110 - RS

<!-- image -->

Source data: [CTR 1245.110, c31803238, Section 11.1]

The results of  the  sensitivity  analyses  were  consistent  with  the  results  of  the  primary  analysis  for  the occurrence of adjudicated HHF (first and recurrent).

## Key secondary endpoint 2: eGFR slope

The second key secondary endpoint in the hierarchical testing procedure was eGFR (CKD-EPI)cr slope of change from baseline. The primary analysis was a random coefficient model allowing for random intercept and random slope per patient. Only 'on-treatment' data (based on TS and using measurements up to 1 day after the last intake of study medication) were included.

Placebo (N=2991)

--

Empa 10mg (N=2997)

<div style=\"page-break-after: always\"></div>

In the empagliflozin group, there was an initial dip in eGFR [mL/min/1.73 m 2 ] (intercept -3.016, 95% CI 3.280, -2.752). Thereafter, the estimated slope was -1.253 per year (95% CI -1.465, -1.041). In the placebo group, eGFR declined more steeply over time, with an estimated slope of -2.616 per year (95% CI -2.827, -2.405). Over the treatment period, eGFR decline in the empagliflozin group was significantly slower than in the placebo group, with an estimated difference in slope of 1.363 per year (99.9% CI 0.861, 1.865; 95% CI 1.064, 1.662; p&lt;0.0001); see Table 15. .

Table 15. eGFR (CKD-EPI)cr [ml/min/1.73 m 2 ] slope of change from baseline, random intercept random slope model, trial 1245.110 - TS (on-treatment)

|                                  | Placebo                 | Empa 10 mg              |
|----------------------------------|-------------------------|-------------------------|
| Analysed patients                | 2911                    | 2925                    |
| Intercept, estimate (95% CI)     | -0.180 (-0.445, 0.084)  | -3.016 (-3.280, -2.752) |
| Slope [/year], estimate (95% CI) | -2.616 (-2.827, -2.405) | -1.253 (-1.465, -1.041) |
| Difference vs placebo (95% CI)   |                         | 1.363 (1.064, 1.662)    |
| (99.9% CI) 1                     |                         | (0.861, 1.865)          |
| p-value                          |                         | <0.0001                 |

Model included factors age, baseline eGFR (CKD-EPI)cr, region, baseline diabetes status, sex, baseline LVEF, baseline eGFR (CKD-EPI)cr-by-time interaction, treatment-by-time interaction, and treatment. Intercept and slope allowed to vary randomly between patients.

1 Based on 2sided α level of 0.001

Source data: [CTR 1245.110, c31803238, Section 11.1]

A histogram of the individual patient slopes showed a uniform shift in the empagliflozin group to slower eGFR decline compared with the placebo group, supporting that the effect of empagliflozin vs placebo treatment was observed across the population ( 0 ).

Distribution  of  individual  patient  eGFR  (CKD-EPI)cr  [mL/min/1.73 m 2 ]  slopes  of  change  from  baseline, trial 1245.110 - TS

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source data: [CTR 1245.110, c31803238, Section 11.1]

See below for renal outcome endpoints, including sustained eGFR.

The change of eGFR slope from baseline was a key secondary endpoint and showed a slower decline in eGFR in the empagliflozin group, with an estimated difference in slope of 1.363 mL/min/1.73 m2 per year vs placebo (99.9% CI 0.861 to 1.865; p&lt;0.0001). The Applicant also analysed change form baseline using ANCOVA, comparable to the previous application for the HFrEF indication. This will be discussed below (Secondary/Exploratory endpoints).

As discussed above, the effect on the renal composite endpoint is actually preferred for the evaluation of renal effects. Results on this endpoint will be discussed below. The effect on slope data should support the effect on the renal composite endpoint and will be evaluated in conjunction. If this confirms the overall treatment effect on GFR change, the primary analysis model can be reported in section 5.1 of the product information; however, the complete model should be presented, i.e. change in intercept and slope, to inform the prescriber on both the initial dip and subsequent change in slope.

## Mortality endpoints

Fewer patients were reported with CV death and more patients were reported with non-CV death in the empagliflozin group than in the placebo group, and the treatment differences were not significant. The incidence of all-cause mortality was similar between treatment groups ( 0 ).

A little more than half of all deaths (55% total) were due to CV causes and most of the CV deaths were classified as sudden cardiac death (empagliflozin: 99 patients, 3.3%; placebo: 114 patients, 3.8%) and

<div style=\"page-break-after: always\"></div>

heart  failure  death  (empagliflozin:  40  patients,  1.3%;  placebo:  51  patients,  1.7%),  as  expected  in  a population with heart failure.

Time to all-cause mortality, CV death, and non-CV death, Cox regression, trial 1245.110 - RS

<!-- image -->

Source data: [CTR 1245.110, c31803238, Section 11.1.2.4]

|                     | Empagliflozin 10 mg   | Empagliflozin 10 mg   | Placebo          | Placebo     |                       |                   |
|---------------------|-----------------------|-----------------------|------------------|-------------|-----------------------|-------------------|
|                     | N with events         | Rate/ 100 PY          | N with events    | Rate/ 100PY |                       | HR (95% CI)       |
| All-cause mortality | 422/2997 (14.1%)      | 6.60                  | 427/2991 (14.3%) | 6.67        |                       | 1.00 (0.87, 1.15) |
| CV death            | 219/2997 (7.3%)       | 3.42                  | 244/2991 (8.2%)  | 3.81        |                       | 0.91 (0.76, 1.09) |
| Non-CV death        | 203/2997 (6.8%)       | 3.17                  | 183/2991 (6.1%)  | 2.86        |                       | 1.13 (0.92, 1.38) |
|                     |                       |                       |                  | 0.5         | 1                     | 2                 |
|                     |                       |                       |                  |             | Favours empagliflozin | Favours placebo   |

All-cause mortality was similar in both treatment groups (HR 1.00, 95%CI 0.87 - 1.15). The number of non-CV  death  was  larger  with  empagliflozin,  but  this  difference  was  not  statistically significant (empagliflozin 203/2997, placebo 183/2991, HR 1.13, 95%CI 0.92 - 1.38). The Applicant provided an evaluation of the causes of non-CV death and could not show a specific increase in a cause of death during empagliflozin treatment.

## Secondary/Exploratory endpoints

## Other HHF-related endpoints

Exploratory HHF-related endpoints corroborated the treatment benefit of empagliflozin on reducing the risk of first and recurrent HHF ( 0 ).

HHF-related endpoints, trial 1245.110 - RS

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                         | Empagliflozin 10 mg   | Empagliflozin 10 mg   | Placebo          | Placebo     |     |                       |                   |
|-----------------------------------------|-----------------------|-----------------------|------------------|-------------|-----|-----------------------|-------------------|
|                                         | N with events         | Rate/ 100 PY          | N with events    | Rate/ 100PY |     |                       | HR (95% CI)       |
| First and recurrent HHF1 (confirmatory) | 407HHFevents          |                       | 541HHFevents     |             |     | 1                     | 0.73 (0.61, 0.88) |
| First HHF2                              | 259/2997 (8.6%)       | 4.28                  | 352/2991 (11.8%) | 5.97        |     | 1                     | 0.71 (0.60, 0.83) |
| First investigator- defined HHF2        | 362/2997 (12.1%)      | 6.11                  | 485/2991 (16.2%) | 8.48        |     |                       | 0.72 (0.63, 0.82) |
|                                         |                       |                       |                  |             | 0.5 | 1                     | 2                 |
|                                         |                       |                       |                  |             |     | Favours empagliflozin | Favours placebo   |

1 Key secondary endpoint; joint frailty model that accounts for the dependence between occurrence of HHF and CV death

2 Cox regression, time-to-event analysis

Source data: [CTR 1245.110, c31803238, Sections 11.1.2.1 and 11.1.2.3]

The HHF results were supported by a higher win ratio for empagliflozin vs placebo (1.25,  95% CI 1.08, 1.42) when accounting for clinical hierarchies, where CV death was considered more important than HHF.

In  line  with  the  improvements  in  HF  outcomes,  there  was  a  decrease  in  NT-proBNP  levels  in  the empagliflozin group compared with placebo (adjusted gMean ratio of the relative change to baseline at Week 52 for empagliflozin vs placebo 0.95, 95% CI 0.91, 0.99).

## Hospitalisation endpoints

The  total  number  of  hospitalisation  events  was  lower  with  empagliflozin  treatment  than  with  placebo. Treatment with empagliflozin reduced the risk of all-cause hospitalisations based on the time to the first event ( 0 ). The treatment effect of empagliflozin started to appear after about 90 days after randomisation and was maintained throughout the trial.

<div style=\"page-break-after: always\"></div>

## Hospitalisation endpoints, trial 1245.110 - RS

<!-- image -->

|                                                         | Empagliflozin 10 mg   | Empagliflozin 10 mg   | Placebo               | Placebo               |                       |                   |                   |
|---------------------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-------------------|-------------------|
|                                                         | N with events         | Rate/ 100PY           | N with events         | Rate/ 100 PY          |                       | HR (95% CI)       |                   |
| First and recurrent all-cause hospitalisation1          | 2566 hospitalisations | 2566 hospitalisations | 2769 hospitalisations | 2769 hospitalisations |                       | 0.93 (0.85, 1.01) | 0.93 (0.85, 1.01) |
| First all-cause hospitalisation?                        | 1271/2997 (42.4%)     | 26.85                 | 1340/2991 (44.8%)     | 29.18                 |                       | 0.92 (0.85, 0.99) | 0.92 (0.85, 0.99) |
| First all-cause mortality or all-cause hospitalisation? | 1356/2997 (45.2%)     | 28.65                 | 1431/2991 (47.8%)     | 31.16                 |                       | 0.92 (0.85, 0.99) | 0.92 (0.85, 0.99) |
| First investigator- defined CV hospitalisation2         | 669/2997 (22.3%)      | 12.15                 | 765/2991 (25.6%)      | 14.31                 |                       | 0.85 (0.77, 0.94) |                   |
|                                                         |                       |                       |                       | 0.5                   |                       | 1                 | 2                 |
|                                                         |                       |                       |                       |                       | Favours empagliflozin | Favours placebo   |                   |

1 Joint frailty model that accounts for the dependence between occurrence of all-cause hospitalisation and all-cause mortality

2 Cox regression, time-to-event analysis

Source data: [CTR 1245.110, c31803238, Section 11.1.2.5]

## Further eGFR analyses

An exploratory MMRM analysis of eGFR change from baseline including on-treatment values showed a similar trend of slowing of eGFR decline over time, consistent with the results of the slope analysis.

In  the  empagliflozin  group,  there  was  an  initial  dip  in  eGFR  at  Week  4  of  about  4 mL/min/1.73  m 2 . Thereafter, a slower decrease in the empagliflozin group compared with placebo was observed. Due to the initial dip, the slower decrease in eGFR in the empagliflozin group resulted in a higher mean eGFR than in the placebo group only after about 148 weeks (Figure 9).

<div style=\"page-break-after: always\"></div>

eGFR (CKD-EPI)cr [mL/min/1.73 m 2 ] value over time MMRM results, trial 1245.110 - TS (OC-OT)

<!-- image -->

The graphical display excludes Week 196, when only 26 patients were analysed; in the underlying MMRM model, all time points were included in the analysis

Source data: [CTR 1245.110, c31803238, Section 11.1.3.7]

In an analysis of patients with valid baseline, last-value-on-treatment, and follow-up values, eGFR partially returned towards the baseline level in the empagliflozin group at the follow-up visit, about 30 days after treatment stop, while the decrease in eGFR in the placebo group persisted. The placebo-corrected eGFR change over the total study duration, i.e. from pre-treatment (baseline) to post-treatment (follow-up visit), was 2.4 mL/min/1.73 m 2  for empagliflozin (95% CI 1.6, 3.2; Table 16).

<div style=\"page-break-after: always\"></div>

Table 16. ANCOVA results for eGFR (CKD-EPI)cr [mL/min/1.73 m 2 ] change from baseline to last value ontreatment and follow-up, trial 1245.110 - TS-FU

|                                                 | Placebo           | Empa 10 mg        |
|-------------------------------------------------|-------------------|-------------------|
| Analysed patients                               | 1608              | 1568              |
| Baseline, mean (SE)                             | 62.6 (0.5)        | 62.4 (0.5)        |
| Last value on-treatment, adjusted mean (95% CI) | 56.5 (56.0, 57.1) | 56.1 (55.6, 56.7) |
| Change from baseline                            | -6.0 (-6.5, -5.4) | -6.4 (-6.9, -5.8) |
| Comparison vs placebo                           |                   | -0.4 (-1.2, 0.3)  |
| Follow-up, adjusted mean (95% CI)               | 56.8 (56.3, 57.4) | 59.2 (58.7, 59.8) |
| Change from baseline                            | -5.7 (-6.2, -5.1) | -3.3 (-3.8, -2.7) |
| Comparison vs placebo                           |                   | 2.4 (1.6, 3.2)    |

Including only patients with valid baseline, last value on-treatment, and follow-up values; patients who took open-label SGLT-2 inhibitors in the follow-up period were excluded

Adjusted with a model including baseline value, age, and baseline LVEF as linear covariates, and region, baseline diabetes status, sex, and treatment as fixed effects

Source data: [CTR 1245.110, c31803238, Section 11.1.3.7]

## Further renal outcomes

The composite renal endpoint (chronic dialysis, renal transplant, or sustained reduction in eGFR) occurred in similar proportions of patients in both groups. For most patients, the first recorded renal event was a sustained reduction in eGFR from a baseline of ≥40% ( Table 17. ).

Table 17. Time to the first event of the composite renal endpoint, Cox regression, trial 1245.110 - RS

|                                                                                                                                               | Placebo      | Empa 10 mg        |
|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------------|
| Analysed patients, N (%)                                                                                                                      | 2991 (100.0) | 2997 (100.0)      |
| Patients with the composite renal endpoint , N (%)                                                                                            | 112 (3.7)    | 108 (3.6)         |
| Only sustained eGFR reduction ≥40% as the first event                                                                                         | 102 (3.4)    | 95 (3.2)          |
| Chronic dialysis as the first event                                                                                                           | 8 (0.3)      | 10 (0.3)          |
| Sustained eGFR reduction ≥40% and s ustained eGFR <15 mL/min/1.73 m 2 (baseline ≥30) or <10 mL/min/1.73 m 2 (baseline <30) as the first event | 2 (0.1)      | 3 (0.1)           |
| Incidence rate per 100 years at risk Hazard ratio vs placebo (95% CI)                                                                         | 2.23         | 2.13              |
|                                                                                                                                               |              | 0.95 (0.73, 1.24) |
| Nominal p-value                                                                                                                               |              | 0.7243            |

The composite renal endpoint: chronic dialysis (with a frequency of twice per week or more for at least 90 days), renal transplant, sustained reduction in eGFR from baseline of ≥40%, sustained eGFR &lt;15 mL/min/1.73 m2 for patients with baseline eGFR ≥30 mL/min/1.73 m2, or sustained eGFR &lt;10 mL/min/1.73 m2. For patients with baseline eGFR &lt;30 mL/min/1.73 m2. Sustained was determined by two or more consecutive post-baseline central laboratory measurements separated by at least 30 days (the first to last of the consecutive eGFR values)

Cox regression model included factors age, baseline eGFR (CKD-EPI)cr, region, baseline diabetes status, sex, baseline LVEF, and treatment

Source data: [CTR 1245.110, c31803238, Section 11.1.2.6]

The estimated cumulative incidence function graph for the first event of the composite renal endpoint is shown in Figure 10. It is noted that the median follow-up for this endpoint was about 90 weeks (630 days).

<div style=\"page-break-after: always\"></div>

Time  to  the  first  event  of  the  composite  renal  endpoint,  estimated  cumulative  incidence  function (considering all-cause mortality as a competing risk), trial 1245.110 - RS

<!-- image -->

Source data: [CTR 1245.110, c31803238, Figure 15.2.3.1: 1]

## Albuminuria

In this trial, 629 patients (10.5%) had macroalbuminuria (UACR &gt;300 mg/g), 1860 patients (31.1%) had microalbuminuria (30 to ≤300 mg/g), and 3474 patients (58.0%) had normoalbuminuria (&lt;30 mg/g) at baseline. There were improvements in the empagliflozin group versus placebo with regard to progression to or reversal of macroalbuminuria. Fewer patients in the empagliflozin group (220 of 2666 patients, 8.3%) than in the placebo group (267 of 2668 patients, 10.0%) progressed to macroalbuminuria from normo- or microalbuminuria at baseline (HR 0.82, 95% CI 0.68, to 0.98). More patients in the empagliflozin group (123  of  318  patients,  38.7%)  than  in  the  placebo  group  (96  of  311  patients,  30.9%)  reversed  from macroalbuminuria to sustained normo- or microalbuminuria (HR 1.40, 95% CI 1.06, 1.83).

An initial dip in eGFR was observed with empagliflozin treatment, followed by a slower decrease in eGFR over time. This is in line with other trials performed with SGLT2i. As described above, the key secondary renal endpoint was the eGFR slope, but the effect on slope can only be interpreted if seen in conjunction with intercept. The applicant, therefore, provided an analysis of change from baseline using ANCOVA. This resulted  in  a  larger  of  similar  decrease  in  eGFR  for  empagliflozin  vs  placebo  (change  from  baseline: empagliflozin -6.4, placebo -6.0, comparison -0.4 (-1.2, 0.3)). But after the 30 day follow up period after treatment stop, the decrease in eGFR was smaller for the empagliflozin group (change from baseline: empagliflozin -3.3, placebo -5.7, comparison 2.4 (1.6, 3.2)), supporting that the initial dip is reversible.

As described above, the effect on the renal composite endpoint is preferred to evaluate renal effects. The effect of empagliflozin on the eGFR slope is not supported or confirmed by the observed effects on the composite renal endpoint (i.e. chronic dialysis, renal transplant, or sustained reduction in eGFR), as the results are similar for empagliflozin vs. placebo (empagliflozin 108/2997 (3.6%), placebo 112/2991 (3.7%), HR 0.95 95%CI 0.73, 1.24). The effect on renal endpoints are therefore not robust. However, the proportion

<div style=\"page-break-after: always\"></div>

of patients progressing to macroalbuminuria was less with empagliflozin vs. placebo, but this is also as expected from other trials with SGLT2i.

## Patient-reported outcomes measured by KCCQ at Week 52

The KCCQ comprises 7 domains and 3 summary scores as shown in 0 Each patient was also asked to identify the domain that was the most difficult to cope with at baseline (patient-preferred outcome). The scores of the KCCQ domains and summary scores range from 0 to 100, with higher score indicating better outcome.

## KCCQ individual domains and summary scores

<!-- image -->

Treatment  with  empagliflozin  improved  the  KCCQ  clinical  summary  score  (an  exploratory  secondary endpoint) from baseline to Week 52 compared with placebo (placebo-corrected adjusted mean change from baseline 1.32, 95% CI 0.45 to 2.19; 0 ). The score was higher at the first post-baseline assessment (Week 12) in the empagliflozin group than the placebo group, and the difference was sustained up to the last assessment (Week 52; 0 green box).

At Week 52, more patients in the empagliflozin group (1126 patients, 41.7%) than in the placebo group (1034 patients, 38.7%) showed a clinically meaningful improvement in KCCQ clinical summary score of at least 5 points from baseline (odds ratio empagliflozin vs placebo 1.120, 95% CI 0.996, 1.259). Consistently, a lower proportion of patients in the empagliflozin group (820 patients, 30.3%) than in the placebo group (906 patients, 33.9%) showed clinically meaningful deterioration of at least 5 points from baseline (odds ratio 0.852, 95% CI 0.759, 0.957).

The  favourable  effect  of  empagliflozin  vs  placebo  in  clinical  summary  score  was  mainly  driven  by  the domains symptom frequency and symptom burden; a positive trend in favour of empagliflozin was observed for the third component domain, physical limitation. Supportive analyses of other KCCQ summary scores (overall summary score and total symptoms score) were in line with these results (Figure 12 and Figure 13).

<div style=\"page-break-after: always\"></div>

KCCQ individual domains and summary scores change from bas eline at Week 52 MMRM, trial 1245.110 TS (on-treatment)

<!-- image -->

| Endpoint                                 | N analysed   | N analysed   | Adjusted mean diff.   | p-value   | Placebo better                         | Empa better                            |
|------------------------------------------|--------------|--------------|-----------------------|-----------|----------------------------------------|----------------------------------------|
|                                          | Empa 10mg vs | Placebo      | (95% CI)              |           | 个                                      |                                        |
| KCCQ clinical summary score at week52    | 2814         | 2799         | 1.32 ( 0.45,2.19)     | 0.0028    |                                        |                                        |
| KCCQphysicallimitation at week52         | 2762         | 2755         | 0.58 (-0.47,1.63)     | 0.2816    |                                        |                                        |
| KCCQ symptom stability at week 52        | 2814         | 2799         | -0.23 (-1.32,0.86)    | 0.6796    |                                        |                                        |
| KCCQ symptom frequency at week 52        | 2814         | 2799         | 1.91 ( 0.89,2.93)     | 0.0002    |                                        |                                        |
| KCCQsymptomburden atweek52               | 2814         | 2799         | 1.89 (0.92,2.87)      | 0.0001    |                                        |                                        |
| KCCQ total symptom score (TSS) at week52 | 2814         | 2799         | 1.94 ( 1.01,2.88)     | <0.0001   |                                        |                                        |
| KCCQ self efficacy at week 52            | 2813         | 2798         | -0.24 (-1.30,0.82)    | 0.6543    |                                        |                                        |
| KCCQ quality of life at week 52          | 2814         | 2799         | 1.23 ( 0.20,2.25)     | 0.0191    |                                        |                                        |
| KCCQsociallimitationatweek52             | 2620         | 2635         | 1.46 ( 0.20,2.71)     | 0.0233    |                                        |                                        |
| KCCQoverall summary score at week 52     | 2814         | 2799         | 1.37 ( 0.52,2.21)     | 0.0015    |                                        |                                        |
| KCCQpatientpreferredoutcome at week52    | 2334         | 2375         | 1.19 (0.03,2.36)      | 0.0443    |                                        |                                        |
|                                          |              |              |                       |           | -1.5 -1.0-0.50.0 00.51.01.52.0 2.5 3.0 | -1.5 -1.0-0.50.0 00.51.01.52.0 2.5 3.0 |

Source data: [CTR 1245.110, c31803238, Section 11.1.2.7]

The improvement in HF symptoms was in line with the HF clinical outcome results and consistent with the observed improvements in NYHA class with empagliflozin treatment.  More patients in the empagliflozin group (609 patients, 22.6%) than in the placebo group (490 patients, 18.3%) improved in NYHA class from baseline to Week 52, and fewer patients in the empagliflozin group (92 patients, 3.4%) than in the placebo group (130 patients, 4.8%) worsened.

<div style=\"page-break-after: always\"></div>

KCCQ  summary  scores  and  domains  change  from  baseline  MMRM  results,  trial  1245.110  -  TS  (on -treatment)

<!-- image -->

Placebo (N=2989)

---Empagliflozin(N=2996)

The summary scores were based on the domains enclosed by the matching coloured boxes, also see 0 .

The  change  from  baseline  in  KCCQ  clinical  summary  score  at  Week  52  was  a  secondary/exploratory endpoint. The mean treatment difference in change was 1.32, 95% CI 0.45 to 2.19. Although statistically significant,  the  treatment  difference  appears  modest,  and  the  clinical  relevance  is  questionable.  The Applicant also provided the proportion of patients achieving a clinically relevant change (i.e. 5 points). This endpoint was not defined as a secondary endpoint but resulted in a larger proportion of patients with clinically relevant change (empagliflozin 1126 patients, 41.7%; placebo 1034 patients, 38.7%), but the difference  in  percentage  is  small.  For  other  KCCQ  scores,  a  treatment  difference  was  also  observed, supporting a consistent finding. Nevertheless, the treatment differences are again considered small and not clinically relevant.

## Other efficacy endpoints

## Diabetes-related endpoints

The onset of DM in patients with pre-DM occurred in fewer patients in the empagliflozin group (120 of 1001 patients, 12.0%) than in the placebo group (137 of 979 patients, 14.0%; HR 0.84, 95% CI 0.65, 1.07). A reduction  in  HbA1c  of  about  0.2%  was  only  seen  in  the  empagliflozin  group  compared  with  placebo  in patients with diabetes at baseline. The results for the onset of DM in patients with pre-DM and in patients without  DM  in  the  meta-analysis  of  the  EMPEROR  trials  showed  consistent  favourable  trends  for empagliflozin.

<div style=\"page-break-after: always\"></div>

## Other clinical cardiovascular outcome events

The following clinical events are described in this section:

- 3-point MACE (adjudicated CV death, adjudicated non-fatal MI, or adjudicated nonfatal

## stroke)

- Adjudicated MI (fatal or non-fatal)
- Composite of adjudicated CV death or adjudicated non-fatal MI
- Adjudicated stroke (fatal or non-fatal)
- Composite of adjudicated CV death or adjudicated non-fatal stroke
- Adjudicated TIA
- Time to new onset of atrial fibrillation (as ECG findings or as AEs with PT 'atrial fibrillation')

The results for both treatment groups were similar for all endpoints as based on Cox regression analysis and estimated cumulative incidence analysis; see Table 18.

<div style=\"page-break-after: always\"></div>

Table 18. Time to 3-point MACE, MI, stroke, TIA, and new onset of atrial fibrillation, Cox regression, trial 1245.110 - RS

|                                                                       | Placebo      | Empa 10 mg             |
|-----------------------------------------------------------------------|--------------|------------------------|
| Analysed patients, N (%)                                              | 2991 (100.0) | 2997 (100.0)           |
| Patients with 3-point MACE, N (%)                                     | 331 (11.1)   | 319 (10.6)             |
| Incidence rate per 100 years at risk                                  | 5.38         | 5.17                   |
| Hazard ratio vs placebo (95% CI)                                      |              | 0.97 (0.83, 1.13)      |
| Nominal p-value                                                       |              | 0.6744                 |
| Patients with CV death or non-fatal MI, N (%)                         | 273 (9.1)    | 254 (8.5)              |
| Incidence rate per 100 years at risk                                  | 4.38         | 4.07                   |
| Hazard ratio vs placebo (95% CI)                                      |              | 0.94 (0.79, 1.11)      |
| Nominal p-value                                                       |              | 0.4423                 |
| Patients with MI (fatal or non-fatal), N (%)                          | 40 (1.3)     | 49 (1.6)               |
| Incidence rate per 100 years at risk                                  | 0.64         | 0.78                   |
| Hazard ratio vs placebo (95% CI)                                      |              | 1.23 (0.81, 1.86)      |
| Nominal p-value                                                       |              | 0.3375                 |
| Patients with CV death or non-fatal stroke, N (%)                     | 302 (10.1)   | 287 (9.6)              |
| Incidence rate per 100 years at risk                                  | 4.86         | 4.62                   |
| Hazard ratio vs placebo (95% CI)                                      |              | 0.96 (0.81, 1.12)      |
| Nominal p-value                                                       |              | 0.5809                 |
| Patients with stroke (fatal or non-fatal), N (%)                      | 84 (2.8)     | 92 (3.1)               |
| Ischaemic                                                             | 74 (2.5)     | 83 (2.8)               |
| Haemonrhagic                                                          | 8 (0.3)      | 7 (0.2)                |
| Unclassified                                                          | 2 (0.1)      | 2 (0.1)                |
| Incidence rate per 100 years at risk                                  | 1.35         | 1.48                   |
| Hazard ratio vs placebo (95% CI)                                      |              | 1.10 (0.82, 1.47)      |
| Nominal p-value                                                       |              | 0.5393                 |
| Patients with TIA, N (%)                                              | 27 (0.9)     | 20 (0.7)               |
| Incidence rate per 100 years at risk                                  | 0.43         | 0.32                   |
| Hazard ratio vs placebo (95% CI)                                      |              | 0.74 (0.41, 1.32)      |
| Nominal p-value                                                       |              | 0.3050                 |
| Patients without baseline or history of Afib', N (%)                  | 1477 (100.0) | 1454 (100.0)           |
| Patients with new onset of atrial fibrillation as ECG                 | 119 (8.1)    | 116 (8.0)              |
| Incidence rate per 100 years at risk Hazard ratio vs placebo (95% CI) | 4.04         | 3.95 1.00 (0.77, 1.29) |
| Nominal p-value                                                       |              | 0.9790                 |

Cox regression model included factors age, baseline eGFR (CKD-EPI)er, region, baseline diabetes status, sex, baseline LVEF, and treatment

Doa aumlaseq ro frostu ieopam paprodai-roeaysanm uo paseg1

Source data: [CTR 1245.110, c31803238, Section 11.1]

## NYHA class change from baseline

More patients in the empagliflozin group (609 patients, 22.6%) than in the placebo group (490 patients, 18.3%)  had  an  improved  NYHA  class  at  Week  52  compared  with  baseline,  and  fewer  patients  in  the empagliflozin group (92 patients, 3.4%) than in the placebo group (130 patients, 4.8%) had a worsened NYHA class.

<div style=\"page-break-after: always\"></div>

## Body weight change from baseline

There was a small decrease in body weight in the empagliflozin group, with a placebo-corrected adjusted mean change at Week 52 from baseline of -1.28 kg (95% CI -1.54, -1.03).

## Blood pressure change from baseline

There  was  no  marked  change  in  blood  pressure  in  the  empagliflozin  group,  with  a  placebo-corrected adjusted mean change at Week 52 from baseline of -1.2 mmHg (95% CI -2.1, -0.3) for SBP and -0.2 mmHg (95% CI -0.7, 0.3) for DBP.

The  effects  of  empagliflozin  were  accompanied  by  effects  on  body  weight,  improvement  in  NYHA classification and reduction in systolic blood pressure. This is in line with previous observations with SGLT2i treatment. The HR &gt; 1 for myocardial infarction and strokes will be discussed in the safety sect ion.

## Ancillary analyses

## Subgroup analyses

## Primary endpoint: CV death or HHF

The  consistency  of  the  treatment  effect  was  investigated  in  predefined  subgroups  by  demographics, baseline characteristics, and baseline medications. The results were consistent across the subgroups, with the interaction p-values above 0.05 for all analysed subgroups, including diabetes status and LVEF ( 0 and 0 ). Note that the subgroup analyses were not adjusted for multiple testing and that effects observed in small subgroups are more prone to random variation. Age (interaction p-value = 0.5162), eGFR (interaction p-value = 0.6331),  or  LVEF  (interaction  p-value  =  0.4333)  analysed  as  a  continuous  variable  had  no relevant impact on the results of the primary analysis. (Figure 14, 15 and 16)

<div style=\"page-break-after: always\"></div>

Subgroup  analyses  for  the  time  to  the  first  event  of  adjudicated  CV  death  or  HHF,  Cox  regression, trial 1245.110 - RS

| Subgroup Category                               | N with event/N analysed Empa10mg vs Placebo   | N with event/N analysed Empa10mg vs Placebo   | Hazard ratio (95% CI)             | Interaction p-value   | Placebobetter   |
|-------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------|-----------------------|-----------------|
|                                                 | 415/2997                                      | 511/2991                                      | 0.79 (0.69,0.90)                  |                       | HH              |
| Overall                                         |                                               |                                               |                                   | 0.9224                |                 |
| BaselineDiabetesStatus Diabetic                 | 239/1466                                      | 291/1472                                      | 0.79 (0.67,0.94)                  |                       |                 |
| Non-Diabetic                                    | 176/1531                                      | 220/1519                                      | 0.78 (0.64,0.95)                  |                       |                 |
| Age[years]                                      |                                               |                                               |                                   | 0.2548                |                 |
| <70                                             | 134/1066                                      | 152/1084                                      | 0.88 (0.70,1.11)                  |                       |                 |
| ≥70                                             | 281/1931                                      | 359/1907                                      | 0.75 (0.64,0.87)                  |                       |                 |
| Sex                                             |                                               |                                               |                                   | 0.5360                |                 |
| Male                                            | 253/1659                                      | 297/1653                                      | 0.81 (0.69,0.96)                  |                       |                 |
| Female                                          | 162/1338                                      | 214/1338                                      | 0.75 (0.61,0.92)                  |                       | 工⊥              |
| Race                                            |                                               |                                               |                                   |                       |                 |
| White                                           |                                               |                                               |                                   | 0.5783                |                 |
|                                                 | 310/2286                                      | 370/2256                                      | 0.81 (0.69,0.94)                  |                       |                 |
| Black/African-American                          | 24/ 133                                       | 28/ 125                                       | 0.73 (0.42,1.25)                  |                       |                 |
| Asian                                           | 54/ 413                                       | 77/411                                        | 0.65 (0.46,0.92)                  |                       |                 |
| Otherincludingmixedrace                         | 27/ 164                                       | 36/ 198                                       | 0.95 (0.58,1.57)                  |                       |                 |
| Baseline BMI [kg/m2]                            |                                               |                                               |                                   | 0.3208                |                 |
| <30                                             | 223/1654                                      | 292/1642                                      | 0.74 (0.62,0.88)                  |                       |                 |
| ≥30                                             | 192/1343                                      | 219/1349                                      | 0.85 (0.70,1.03)                  |                       |                 |
| Baseline eGFR(CKD-EPI)                          |                                               |                                               |                                   |                       |                 |
| [mL/min/1.73m2]                                 |                                               |                                               |                                   | 0.7673                |                 |
| ≥60                                             | 152/1493                                      | 189/1505                                      | 0.81 (0.65,1.00)                  |                       | T               |
| <60                                             | 263/1504                                      | 321/1484                                      | 0.78 (0.66,0.91)                  |                       | 工H              |
| Baseline SBP (</≥median1)                       |                                               |                                               |                                   | 0.5841                |                 |
| <median                                         | 200/1496                                      | 249/1474                                      | 0.76 (0.63,0.91)                  |                       | 工⊥              |
| ≥median                                         | 215/1501                                      | 262/1517                                      | 0.82 (0.68,0.98)                  |                       |                 |
| History of atrial fibrillation or atrialflutter |                                               |                                               |                                   | 0.9588                |                 |
| No                                              | 170/1417                                      | 219/1427                                      | 0.78 (0.64,0.95)                  |                       |                 |
| Yes                                             | 244/1576                                      | 292/1559                                      | 0.78 (0.66,0.93)                  |                       |                 |
| Baseline LVEF [%]                               |                                               |                                               |                                   | 0.2098*               |                 |
| <50                                             | 145/ 995                                      | 193/988                                       | 0.71 (0.57,0.88)                  |                       |                 |
| 50 to<60                                        | 138/1028                                      | 173/1030                                      | 0.80 (0.64,0.99)                  |                       |                 |
| ≥60                                             | 132/ 974                                      | 145/ 973                                      | 0.87 (0.69,1.10)                  |                       |                 |
| History of HHF (in the last 12                  |                                               |                                               |                                   | 0.4441                |                 |
| months) No                                      | 258/2298                                      | 319/2321                                      | 0.81 (0.68,0.95)                  |                       |                 |
| Yes                                             | 157/ 699                                      | 192/ 670                                      | 0.73 (0.59,0.90)                  |                       |                 |
| Baseline NYHA                                   |                                               |                                               |                                   | 0.3081                |                 |
| II                                              | 275/2435                                      | 361/2452                                      | 0.75 (0.64,0.87)                  |                       |                 |
| II/IV                                           | 140/ 562                                      | 150/ 539                                      | 0.86 (0.68,1.09)                  |                       |                 |
| Baseline NT-proBNP [pg/mL]                      |                                               |                                               |                                   |                       |                 |
| (</≥median² by atrial                           |                                               |                                               |                                   | 0.8887                |                 |
| fibrillation/flutter status)                    |                                               |                                               |                                   |                       |                 |
| <median                                         | 126/1477                                      | 168/1508                                      | 0.76 (0.61,0.96)                  |                       |                 |
| ≥median                                         | 288/1516                                      | 341/1476                                      | 0.78 (0.67,0.91)                  |                       |                 |
| Baseline uric acid[mg/dL]                       |                                               |                                               |                                   |                       |                 |
| (tertiles3)                                     |                                               |                                               |                                   | 0.2367*               |                 |
| <T1                                             | 96/963                                        | 147/ 975                                      | 0.65 (0.50,0.84)                  |                       |                 |
| ≥T1 and <T2 ≥T2                                 | 130/1032 184/ 970                             | 132/ 966 226/1018                             | 0.92 (0.72,1.17) 0.81 (0.67,0.98) |                       | T               |
| Baseline use of ACE-inhibitor,                  |                                               |                                               |                                   | 0.6939                |                 |
| ARB or ARNi                                     | 90/569                                        | 121/ 587                                      | 0.75 (0.57,0.99)                  |                       |                 |
| No Yes                                          | 325/2428                                      | 390/2404                                      | 0.80 (0.69,0.93)                  |                       |                 |
| Baseline use of MRA                             |                                               |                                               |                                   | 0.2169                |                 |
|                                                 | 233/1878                                      | 306/1866                                      | 0.73 (0.62,0.87)                  |                       | 工IH             |
| No Yes                                          | 182/1119                                      | 205/1125                                      | 0.87 (0.71,1.06)                  |                       | 工⊥ 口            |
|                                                 |                                               |                                               |                                   | 0.125                 | 0.5 1 2         |

Interaction p-values are nominal. The subgroup analyses were not adjusted for multiple testing.

* Trend test. Other footnotes are explained in [CTR 1245 .110, c31803238, Figure 15.2.1.3: 1]. Source data: [CTR 1245.110, c31803238, Section 11.1]

Subgroup analysis for the time to the first event of adjudicated CV death or HHF by baseline eGFR (5 categories), Cox regression, trial 1245.110 - RS

Hazard ratio

<div style=\"page-break-after: always\"></div>

<!-- image -->

The subgroup analysis was not adjusted for multiple testing.

* Trend test nominal p -value

Source data: [CTR 1245.110, c31803238, Appendix 16.1.13.2, Figure 1.3.3]

Hazard ratio for time to first event of adjudicated HHF or CV death by baseline LVEF [%] ( continuous ), trial 1245.110 - RS

<!-- image -->

The treatmentbyLVEFp-value=0.4333

Source data: [CTR 1245.110, c31803238, Figure 15.2.1.3.3: 1]

<div style=\"page-break-after: always\"></div>

## Key secondary endpoint 1: first and recurrent HHF

In general, the subgroup analyses of first and recurrent HHF showed similar trends to those observed for the primary endpoint. Forest plots of the subgroup analyses are presented in Figure 17 and 0 Interaction p-values of &lt;0.05 were observed in the subgroup analyses by LVEF and the use of MRAs.

Patients with LVEF &lt;60% at baseline appeared to have a greater effect of empagliflozin versus placebo than patients with LVEF values ≥60%. When the time to first HHF was analysed (i.e. not including recurrent events), this trend was less pronounced. With regard to the use of MRAs, patients taking MRAs at baseline showed a smaller effect of empagliflozin vs placebo than patients who were not taking MRAs. However, the HR was below 1 for both subcategories, and there was considerable overlap in the confidence intervals.

<div style=\"page-break-after: always\"></div>

## Subgroup analyses for the time to the occurrence of adjudicated HHF (first and recurrent), joint frailty model, trial 1245.110 - RS

<!-- image -->

| Subgroup Category                                                                                                             | Total HHF/ N analysed                        |                                                       | Hazard ratio (95% CI)                                                                                                                   | Interaction Empa better      | Placebobetter   |
|-------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------|-----------------|
|                                                                                                                               | Empa10mg vs                                  | Placebo                                               |                                                                                                                                         | p-value                      |                 |
| Overall                                                                                                                       | 407/2997                                     | 541/2991                                              | 0.73 (0.61,0.88)                                                                                                                        | 0.9697                       |                 |
| Baselinediabetesstatus Diabetic Non-Diabetic                                                                                  | 250/1466 157/1531                            | 335/1472 206/1519                                     | 0.73 (0.57,0.94) 0.74 (0.56,0.97)                                                                                                       |                              |                 |
| Age[years]                                                                                                                    |                                              |                                                       |                                                                                                                                         | 0.0832                       |                 |
|                                                                                                                               |                                              | 159/1084                                              |                                                                                                                                         |                              |                 |
| <70 ≥70                                                                                                                       | 141/1066                                     | 382/1907                                              | 0.92 (0.67,1.26) 0.65 (0.52,0.82)                                                                                                       |                              |                 |
| Sex                                                                                                                           | 266/1931                                     |                                                       |                                                                                                                                         | 0.7800                       |                 |
| Male                                                                                                                          | 253/1659 154/1338                            | 308/1653 233/1338                                     | 0.75 (0.59,0.95)                                                                                                                        |                              |                 |
| Female                                                                                                                        |                                              |                                                       | 0.71 (0.53,0.94)                                                                                                                        |                              |                 |
| Race White Black/African-American Asian                                                                                       | 282/2286 27/ 133 76/ 413 22/ 164             | 368/2256 21/ 125 119/ 411 33/198                      | 0.74 (0.59,0.92) 1.30 (0.55,3.11) 0.58 (0.37,0.91)                                                                                      | 0.4276                       |                 |
| ≥30 Baseline eGFR(CKD-EPI) [mL/min/1.73m2] ≥60 <60 Baseline SBP (</≥median1) <median ≥median                                  | 211/1654 196/1343                            | 312/1642 229/1349 178/1505 363/1484                   | 0.79 (0.37,1.69) 0.63 (0.49,0.81) 0.88 (0.67,1.15) 0.88 (0.66,1.18) 0.66 (0.52,0.85) 0.74 (0.57,0.95) 0.72 (0.55,0.94)                  | 0.0749 0.1369                |                 |
| Otherincluding mixedrace Baseline BMI [kg/m2] <30                                                                             | 164/1417 243/1576 122/ 995 129/1028 156/ 974 | 150/ 973 271/2321                                     | 0.72 (0.54,0.95) 0.73 (0.57,0.94) 0.57 (0.42,0.79) 0.66 (0.48,0.91) 1.06 (0.76,1.46) 0.76 (0.56,1.04) 0.67 (0.54,0.83) 0.84 (0.59,1.19) | 0.8612                       |                 |
| Historyof atrialfibrillation or atrialflutter No Yes Baseline LVEF [%] <50 50to<60 ≥60 History of HHF (in the last 12 months) | 150/1493 257/1504                            | 290/1474 251/1517 223/1427 318/1559 209/ 988 182/1030 | 0.67 (0.47,0.95) 0.82 (0.58,1.16)                                                                                                       | 0.0077* 0.6868 0.2899 0.7560 |                 |
| <median ≥median (tertiles3) <T1 ≥T1 and <T2 ≥T2                                                                               | 215/1496 192/1501                            | 270/ 670 347/2452 194/539                             |                                                                                                                                         |                              |                 |
|                                                                                                                               |                                              | 281/1018                                              | 0.70 (0.56,0.88)                                                                                                                        | 0.9094 0.9424                |                 |
| No Yes Baseline NYHA II                                                                                                       | 104/1477 303/1516                            | 390/2404 308/1866                                     | 0.69 (0.51,0.94) 0.73 (0.58,0.93) 0.75 (0.56,0.99)                                                                                      |                              |                 |
| Baseline use of ACE-inhibitor, ARB or ARNi No Yes Baseline use of MRA No                                                      |                                              | 233/1125                                              | 0.60 (0.47,0.77)                                                                                                                        |                              |                 |
| Yes                                                                                                                           |                                              |                                                       |                                                                                                                                         |                              |                 |
|                                                                                                                               | 206/1119                                     |                                                       | 0.90 (0.68,1.19)                                                                                                                        |                              |                 |
|                                                                                                                               | 201/1878                                     |                                                       |                                                                                                                                         |                              |                 |
|                                                                                                                               | 200/2298 207/ 699                            |                                                       |                                                                                                                                         |                              | 1               |
| II/IV Baseline NT-proBNP [pg/mL] (</≥median²byatrial fibrillation/flutter status)                                             | 235/2435 172/ 562                            |                                                       |                                                                                                                                         | 0.6194* 0.74 (0.60,0.91)     |                 |
| Baseline uric acid[mg/dL]                                                                                                     | 92/963 99/1032 213/ 970 117/569              | 152/1508 388/1476 131/ 975 124/ 966                   |                                                                                                                                         | 0.0379                       |                 |
|                                                                                                                               | 290/2428                                     |                                                       |                                                                                                                                         |                              |                 |
|                                                                                                                               |                                              | 151/ 587                                              | 0.71 (0.48,1.04)                                                                                                                        |                              |                 |
|                                                                                                                               |                                              |                                                       |                                                                                                                                         |                              | 0.5 2           |
|                                                                                                                               |                                              |                                                       |                                                                                                                                         | 0.125                        |                 |
|                                                                                                                               |                                              |                                                       |                                                                                                                                         | 0.25                         |                 |

Interaction p-values are nominal. The subgroup analyses were not adjusted for multiple testing.

The footnotes are explained in [CTR 1245.110, c31803238, Figure 15.2.2.1.3: 1].

Source data: [CTR 1245.110, c31803238, Section 11.1]

Hazard ratio

<div style=\"page-break-after: always\"></div>

Subgroup analysis for the time to the occurrence of adjudicated HHF (first and recurrent) by baseline eGFR (5 categories), joint frailty model, trial 1245.110 - RS

<!-- image -->

| Subgroup Category                    | TotalHHF/N analysed Empa10mg vs   | Placebo   | Hazardratio (95% CI)   | Interaction p-value   | Empabetter   | Placebobetter   |
|--------------------------------------|-----------------------------------|-----------|------------------------|-----------------------|--------------|-----------------|
| Overall                              | 407/2997                          | 541/2991  | 0.73 (0.61,0.88)       |                       |              |                 |
| BaselineeGFR(CKD-EPI) [mL/min/1.73m] |                                   |           |                        | 0.4654*               |              |                 |
| ≥90                                  | 19/231                            | 31/237    | 0.79 (0.38,1.64)       |                       |              |                 |
| 60to<90                              | 131/1262                          | 147/1268  | 0.90 (0.66,1.22)       |                       |              |                 |
| 45 to<60                             | 94/792                            | 157/ 773  | 0.56 (0.39,0.81)       |                       |              |                 |
| 30 to<45                             | 112/564                           | 134/ 550  | 0.82 (0.56,1.21)       |                       |              |                 |
| <30                                  | 51/ 148                           | 72/161    | 0.63 (0.33,1.23)       |                       |              |                 |
|                                      |                                   |           |                        |                       | 0.25         | 2               |

The subgroup analysis was not adjusted for multiple testing.

* Trend test n ominal p-value

Source data: [CTR 1245.110, c31803238, Appendix 16.1.13.2, Figure 1.3.4]

## Post hoc analyses of HF outcomes by LVEF

The Applicant analysed subgroups by LVEF in more detail for the HF outcomes, using a 5% increment of LVEF to categorise patients. Patients with LVEF ≥ 70% (N = 319; max 88%) were grouped together to avoid very small subgroups. No consistent trend by LVEF is observed for any endpoint analysed, with all trend test pvalues &gt;0.05, indicating that the results for the subgroups were consistent with the results in the overall trial population. However, only for patients with LVEF of 65 to &lt;70%, was the HR above 1 for the first HHF and the occurrence of HHF (first and recurrent). The HR for CV death was consistent across the subgroups. As the majority of the primary endpoint events were HHF, accordingly the HR for the primary endpoint in the subgroup with LVEF of 65 to &lt;70% for HHF or CV death was also above 1 (Figure 19). For the analysis of the first HHF, a numerically higher proportion of patients in the empagliflozin arm (33 of 263, 12.5%) than in the placebo arm (22 of 283, 7.8%) had an event in the subgroup with LVEF of 65 to &lt;70%, while it was the opposite for all other subgroups (e.g. in the subgroup with LVEF ≥ 70%: 15 of 165 patients, 9.1% in the empagliflozin arm and 23 of 154 patients, 14.9% in the placebo arm had HHF). The incidence rates per 100 patient-years among the subgroups were similar within the respective treatment arm (ranging from 3.67 to 4.44 in the empagliflozin arm and 5.55 to 7.75 in the placebo arm), except in the subgroup with LVEF of 65 to &lt;70%. In this subgroup, the incidence rate was highest (6.49) among all subgroups in the empagliflozin arm while lowest (3.96) among all subgroups in the placebo arm (Figure 19).

<div style=\"page-break-after: always\"></div>

## Subgroup analyses of HF outcomes by baseline LVEF -RS, post hoc

<!-- image -->

Overall, for patients who had HHF events, fewer in the empagliflozin arm had 1, 2, and 3 HHF events, but a similar number had 4 or more HHF events compared with placebo (Figure 20 upper part). For patients who had 4 or more events, in the subgroup of LVEF of 65 to &lt;70%, 6 patients in the empagliflozin arm had 31 events while 1 patient in the placebo arm had 5 events, which substantially contributed to the imbalance in the analysis of the first and recurrent HHF in this subgroup (Figure 20 lower part).

<div style=\"page-break-after: always\"></div>

Contribution of HHF events by number of events experienced per patient (upper) and from patients with 4 or more events by baseline LVEF subgroups (lower)

ContributionofHHFeventsbynumberofeventsexperiencedperpatient

<!-- image -->

ContributionofHHFeventsfrompatientswith≥4eventsbybaselineLVEF

<!-- image -->

## Key secondary endpoint 2: eGFR slope

The results for  the  eGFR  slope  analysis  were  generally  consistent  across  the  predefined  subgroups  by demographics, baseline characteristics, and baseline medications (Figure 21. and 0 ). Patients with diabetes showed a larger effect of empagliflozin vs placebo than patients without diabetes. However, in both of these subgroups, the eGFR decline was slower with empagliflozin treatment than with placebo.

<div style=\"page-break-after: always\"></div>

Subgroup  analyses  for  eGFR  (CKD-EPI)cr  [mL/min/1.73  m 2 ]  slope  of  change  from  baseline,  random intercept random slope model, trial 1245.110 - TS (on-treatment)

| Subgroup Category                                  | Empa 10mg vs   | N analysed Placebo   | Estimate (95% CI)                         | eHeterogeneity p-value   |                                   |
|----------------------------------------------------|----------------|----------------------|-------------------------------------------|--------------------------|-----------------------------------|
| Overall                                            | 2925           | 2911                 | 1.363 ( 1.064,1.662)                      |                          |                                   |
| BaselineDiabetesStatus                             |                |                      |                                           | 0.0103                   |                                   |
| Diabetic                                           | 1429           | 1430                 | 1.766 ( 1.336,2.195)                      |                          |                                   |
| Non-Diabetic                                       | 1496           | 1481                 | 0.983( 0.567,1.398)                       |                          |                                   |
| Age[years]                                         |                |                      |                                           | 0.7076                   |                                   |
| <70                                                | 1043           | 1056                 | 1.289 ( 0.795,1.783)                      |                          |                                   |
| ≥70                                                | 1882           | 1855                 | 1.408 ( 1.032,1.784)                      |                          |                                   |
| Sex                                                |                |                      |                                           | 0.5684                   |                                   |
| Male                                               | 1624           | 1608                 | 1.288 ( 0.890,1.686)                      |                          |                                   |
| Female                                             | 1301           | 1303                 | 1.463 ( 1.012,1.914)                      |                          |                                   |
| Race                                               |                |                      |                                           | 0.5738                   |                                   |
| White                                              | 2232           | 2198                 | 1.398 ( 1.050,1.745)                      |                          |                                   |
| Black/African-American                             | 129            | 121                  | 2.067 (0.549,3.586)                       |                          |                                   |
| Asian                                              | 404            | 401                  | 1.063 ( 0.335,1.792)                      |                          |                                   |
| Otherincluding mixedrace                           | 159            | 191                  | 0.922 (-0.300,2.143)                      |                          |                                   |
| Baseline BMI[kg/m2]                                |                |                      |                                           | 0.7437                   |                                   |
| <30                                                | 1607           | 1594                 | 1.411 ( 1.009,1.813)                      |                          |                                   |
| 0                                                  | 1318           | 1317                 | 1.311 ( 0.864,1.758)                      |                          |                                   |
| Baseline eGFR(CKD-EPI)                             |                |                      |                                           | 0.8586                   |                                   |
| [mL/min/1.73m2] ≥60                                | 1454           | 1468                 | 1.390 ( 0.976,1.803)                      |                          |                                   |
| <60                                                | 1471           | 1443                 | 1.335 ( 0.902,1.768)                      |                          |                                   |
| Baseline SBP(</≥median)1                           |                |                      |                                           | 0.7579                   |                                   |
| <median                                            | 1465           | 1438                 | 1.413 ( 0.989,1.837)                      |                          |                                   |
| ≥median                                            | 1460           | 1473                 | 1.319 ( 0.897,1.740)                      |                          |                                   |
| History of atrialfibrillation                      |                |                      |                                           | 0.9887                   |                                   |
| or atrialflutter No                                | 1381           | 1384                 | 1.372 ( 0.940,1.804)                      |                          |                                   |
| Yes                                                | 1540           | 1523                 | 1.368 ( 0.955,1.780)                      |                          |                                   |
| Baseline LVEF [%]                                  |                |                      |                                           | 0.1238*                  |                                   |
| <50                                                | 973            | 954                  | 1.611 ( 1.092,2.130)                      |                          |                                   |
| 50 to<60                                           | 1001           | 1002                 | 1.436 ( 0.924,1.949)                      |                          |                                   |
| ≥60                                                | 951            | 955                  | 1.034 ( 0.512,1.555)                      |                          |                                   |
| History of HHF (in the last 12 months)             |                |                      |                                           | 0.9622                   |                                   |
| No                                                 | 2245           | 2264                 | 1.360 ( 1.021,1.698)                      |                          |                                   |
| Yes                                                | 680            | 647                  | 1.377 ( 0.739,2.015)                      |                          |                                   |
| Baseline NYHA                                      |                |                      |                                           | 1.0000                   |                                   |
| II^                                                | 2386           | 2390                 | 1.362( 1.035,1.688)                       |                          |                                   |
| II/IV                                              | 539            | 521                  | 1.362 ( 0.616,2.107)                      |                          |                                   |
| Baseline NT-proBNP [pg/mL]                         |                |                      |                                           | 0.7361                   |                                   |
| (</≥median by atrial fibrillation/flutter status)2 |                |                      |                                           |                          |                                   |
| <median                                            | 1440           | 1477                 | 1.421 ( 1.011,1.832)                      |                          |                                   |
| ≥median                                            | 1481           | 1429                 | 1.319 ( 0.884,1.753)                      |                          |                                   |
| Baseline uric acid[mg/dL]                          |                |                      |                                           | 0.7248*                  |                                   |
| (tertiles)3                                        |                |                      |                                           |                          |                                   |
| <T1                                                | 941            | 952                  | 1.299 ( 0.777,1.822)                      |                          |                                   |
| ≥T1 and <T2 ≥T2                                    | 1004 951       | 942 988              | 1.301 ( 0.788,1.813) 1.434 ( 0.906,1.962) |                          |                                   |
| Baseline use of ACE-inhibitor,                     |                |                      |                                           | 0.4137                   |                                   |
| ARB or ARNi No                                     | 558            | 567                  | 1.633 ( 0.932,2.334)                      |                          |                                   |
| Yes                                                | 2367           | 2344                 | 1.310 ( 0.979,1.641)                      |                          |                                   |
| Baseline use of MRA No Yes                         | 1836           | 1807                 | 1.504 ( 1.127,1.882)                      | 0.2322                   |                                   |
|                                                    | 1089           | 1104                 | 1.127 ( 0.638,1.617)                      |                          |                                   |
|                                                    |                |                      |                                           |                          | -0.5 0.00.5 1.0 1.52.0 2.53.0 3.5 |

Interaction p-values are nominal. The subgroup analyses were not adjusted for multiple testing.

* Trend test. Other footnotes are explained in [CTR 1245.110, c31803238, Figure 15.2.2.2.2: 1].

Source data: [CTR 1245.110, c31803238, Section 11.1]

Differencein slope estimate[/year]

<div style=\"page-break-after: always\"></div>

Subgroup analysis for eGFR (CKD-EPI)cr [mL/min/1.73 m 2 ] slope of change from baseline by baseline eGFR (5 categories), random intercept random coefficient model, trial 1245.110 - TS (on-treatment)

<!-- image -->

| Subgroup                             |            | Nanalysed   | EstimateHeterogeneity (95% CI)   |                                  |
|--------------------------------------|------------|-------------|----------------------------------|----------------------------------|
| Category                             | Empa10mgvs | Placebo     | p-value                          |                                  |
| Overall                              | 2925       | 2911        | 1.363 (1.064,1.662)              |                                  |
| BaselineeGFR(CKD-EPI) [mL/min/1.73m] |            |             | 0.4892*                          |                                  |
| 06                                   | 229        | 228         | 1.140 (0.094,2.187)              |                                  |
| 60 to<90                             | 1225       | 1240        | 1.435(0.984,1.885)               |                                  |
| 45 to<60                             | 776        | 753         | 1.557 ( 0.975,2.140)             |                                  |
| 30to<45                              | 554        | 536         | 1.258 (0.541,1.974)              |                                  |
| <30                                  | 141        | 154         | 0.224 (-1.299,1.746)             |                                  |
|                                      |            |             |                                  | -1.5-1.0-0.50.00.51.0 1.52.0 2.5 |

The subgroup analysis was not adjusted for multiple testing.

* Trend test nominal p -value

Source data: [CTR 1245.110, c31803238, Appendix 16.1.13.2, Figure 1.3.6]

## Primary endpoint sensitivity analyses

The sensitivity analyses were exploratory, and the results were generally consistent with the results of the primary analysis. The treatment effect was more pronounced for the period before COVID-19 outbreak, i.e. before the dates specified in the TSAP (01 Dec 2019 for China and 01 Jan 2020 for all other countries). As shown  by  the  sensitivity  analyses  including  events  after  the  end  of  treatment  until  individual  trial completion, the modification of the primary analysis had no impact on the results ( 0 ).

Sensitivity  analyses for the primary endpoint: time to the first event of adjudicated CV death or HHF, trial 1245.110

<!-- image -->

|                                                             | N with event / N analysed   | N with event / N analysed   | Hazard ratio     | Empa better   | Placebo better   |
|-------------------------------------------------------------|-----------------------------|-----------------------------|------------------|---------------|------------------|
|                                                             | Empa 10mg vs                | Placebo                     | (95% CI)         | ←             |                  |
| Primary endpoint                                            | 415/2997                    | 511/2991                    | 0.79 (0.69,0.90) |               |                  |
| Sensitivity analyses                                        |                             |                             |                  |               |                  |
| Analysisrepeated withno covariateadjustment-RS              | 415/2997                    | 511/2991                    | 0.79 (0.70,0.90) |               |                  |
| Treated patients while on treatment +30 days-TS             | 361/2996                    | 439/2989                    | 0.80 (0.69,0.91) |               |                  |
| Multiple imputation for lost tofollow-up-RS*                | /2997                       | /2991                       | 0.79 (0.70,0.90) |               |                  |
| Basedoninvestigatordefinedevents-RS                         | 516/2997                    | 642/2991                    | 0.77 (0.69,0.87) |               |                  |
| Competingrisk model byFine-Gray-RS                          | 415/2997                    | 511/2991                    | 0.78 (0.69,0.89) | +             |                  |
| Until individual trial completion-RS                        | 431/2997                    | 525/2991                    | 0.79 (0.70,0.90) |               |                  |
| Excludingeventswithoutdocumentedphysical signs/symptoms- RS | 396/2997                    | 486/2991                    | 0.79 (0.69,0.90) |               |                  |
| Including additional prognostic covariates-RS               | 415/2997                    | 511/2991                    | 0.76 (0.67,0.87) |               |                  |
| IncludingonlyeventsbeforeCOVID-19outbreak-RS                | 226/2946                    | 316/2950                    | 0.70 (0.59,0.83) |               |                  |
| Includingtime-dependentcovariateforonset                    | 415/2997                    | 511/2991                    | 0.79 (0.69,0.90) |               |                  |
| of COVID-19outbreak-RS                                      |                             |                             |                  |               |                  |
| TreatmenteffectbeforeandafterCOVID-19outbreak               |                             |                             |                  |               |                  |
| BeforeCOVID-19outbreak-RS                                   | 226/2946                    | 316/2950                    | 0.70 (0.59,0.83) |               |                  |
| AfterCOVID-19outbreak-RS                                    | 189/2663                    | 195/2577                    | 0.93 (0.76,1.13) |               |                  |
| Including eventsup to7days prior to                         | 415/2997                    | 507/2991                    | 0.79 (0.70,0.90) |               |                  |
| SARS-Cov2infection-RS                                       |                             |                             |                  |               |                  |

COVID-19 onset dates are 01 Dec 2019 for China and 01 Jan 2020 for all other countries.

SARS-CoV-2 infection was defined by broad scope BIcMQ SARS-CoV-2 infection including PT 'Suspected Covid-19'.

* There is no single definition of number of patients with an event because each imputation can produce a different number of events; 88 patients in the placebo group and 84 patients in the empagliflozin groups were lost to follow-up for the primary endpoint (prematurely discontinued trial) and had imputed data [CTR 1245.110, c31803238, Tables 10.1: 2 and 15.2.1.2: 3].

Hazard ratio

<div style=\"page-break-after: always\"></div>

In the sensitivity analyses the treatment effect for the primary endpoint appears larger before vs. after COVID-19 outbreak (before HR 0.70, 95%CI 0.59-0.83; after HR 0.93, 95%CI 0.76-1.13), with a similar number of subjects included before and after. The treatment difference may, at least partly, be explained by that during COVID outbreak, less patients were accepted for hospitalisation, but this is speculative.

## Summary of main study(ies)

The following table summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 19. Summary of Efficacy for trial 1245.110

| Title: EMPEROR-preserved                       | Title: EMPEROR-preserved                                                                                      | Title: EMPEROR-preserved                                                                                      | Title: EMPEROR-preserved                                                                                      | Title: EMPEROR-preserved                                                                                                                     |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                               | trial 1245.110                                                                                                | trial 1245.110                                                                                                | trial 1245.110                                                                                                | trial 1245.110                                                                                                                               |
| Design                                         | Phase III international, multi-centre, double-blind, parallel-group, placebo- controlled, event-driven trials | Phase III international, multi-centre, double-blind, parallel-group, placebo- controlled, event-driven trials | Phase III international, multi-centre, double-blind, parallel-group, placebo- controlled, event-driven trials | Phase III international, multi-centre, double-blind, parallel-group, placebo- controlled, event-driven trials                                |
| Design                                         | Duration of main phase: Duration of Run-in phase:                                                             | Duration of main phase: Duration of Run-in phase:                                                             | Extension phase:                                                                                              | event driven, median follow up of 23 months of treatment 4-28 days 30 days                                                                   |
| Hypothesis                                     | Superiority                                                                                                   | Superiority                                                                                                   | Superiority                                                                                                   | Superiority                                                                                                                                  |
| Treatments groups                              | Empagliflozin 10mg                                                                                            | Empagliflozin 10mg                                                                                            | Empagliflozin 10mg                                                                                            | Empagliflozin 10mg once daily during study duration (median follow up of 23 months of treatment), n=2997 randomized                          |
| Treatments groups                              | placebo                                                                                                       | placebo                                                                                                       | placebo                                                                                                       | Placebo during study duration (median follow up of 23 months of treatment), n=2991 randomized                                                |
| Endpoints and definitions                      | Primary endpoint                                                                                              | Primary endpoint                                                                                              | CV death or HHF                                                                                               | Time to the first event of adjudicated CV death or adjudicated hospitalisation for heart failure                                             |
| Endpoints and definitions                      | Key Secondary endpoint                                                                                        | Key Secondary endpoint                                                                                        | first and recurrent HHF                                                                                       | Occurrence of adjudicated HHF (first or recurrent)                                                                                           |
| Endpoints and definitions                      |                                                                                                               |                                                                                                               | eGFR slope, change from baseline                                                                              | eGFR (CKD-EPI) cr slope of change from baseline                                                                                              |
| Endpoints and definitions                      | Secondary/                                                                                                    | Secondary/                                                                                                    | CV death                                                                                                      | Time to adjudicated CV death                                                                                                                 |
| Endpoints and definitions                      | Exploratory endpoint                                                                                          | Exploratory endpoint                                                                                          | All-cause mortality                                                                                           | Time to all-cause mortality                                                                                                                  |
| Endpoints and definitions                      |                                                                                                               |                                                                                                               | Composite renal event                                                                                         | Time to the first event in the composite renal endpoint: chronic dialysis 1 , renal transplant, or sustained 2 reduction in eGFR (CKD-EPI) 3 |
| Endpoints and definitions                      |                                                                                                               |                                                                                                               | All-cause hospitalisation                                                                                     | Occurrence of all-cause hospitalisation (first and recurrent)                                                                                |
| Endpoints and definitions                      |                                                                                                               |                                                                                                               | Patient reported outcome                                                                                      | Change from baseline in KCCQ clinical summary score 4 at Week 52                                                                             |
| Database lock                                  | <date>                                                                                                        | <date>                                                                                                        | <date>                                                                                                        | <date>                                                                                                                                       |
| Results and Analysis                           | Results and Analysis                                                                                          | Results and Analysis                                                                                          | Results and Analysis                                                                                          | Results and Analysis                                                                                                                         |
| Analysis description                           | Analysis description                                                                                          | Primary Analysis                                                                                              | Primary Analysis                                                                                              | Primary Analysis                                                                                                                             |
| Analysis population and time point description | Analysis population and time point description                                                                | Intent to treat                                                                                               | Intent to treat                                                                                               | Intent to treat                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Descriptive and variability   | statistics estimate   | Treatment group                                                     | Empagliflozin 10 mg           | placebo                       |
|-------------------------------|-----------------------|---------------------------------------------------------------------|-------------------------------|-------------------------------|
|                               |                       | Number of subject                                                   | 2297                          | 2291                          |
|                               |                       | CV death or HHF, n (%)                                              | 415 (13.8)                    | 511 (17.1)                    |
|                               |                       | empagliflozin vs. placebo HR, 95% CI, p-value                       | 0.79 0.69 to 0.90 P= 0.0003   | 0.79 0.69 to 0.90 P= 0.0003   |
|                               |                       | first and recurrent HHF, n                                          | 407                           | 541                           |
|                               |                       | HR, 95% CI, p-value                                                 | 0.73 0.61 to 0.88 P=0.0009    | 0.73 0.61 to 0.88 P=0.0009    |
|                               |                       | eGFR slope, change from baseline, Slope2 [/year], estimate (95% CI) | -1.253 (-1.465, -1.041)       | -2.616 (-2.827, -2.405)       |
|                               |                       | Difference vs. placebo (95% CI) , p-value                           | 1.363 1.064 to 1.662 P<0.0001 | 1.363 1.064 to 1.662 P<0.0001 |
|                               |                       | CV death, n (%)                                                     | 219 (7.3)                     | 244 (8.7)                     |
|                               |                       | HR (95% CI)                                                         | 0.91 (0.76 to 1.09)           | 0.91 (0.76 to 1.09)           |
|                               |                       | All-cause mortality, n (%)                                          | 422 (14.1)                    | 427 (14.3)                    |
|                               |                       | HR (95% CI)                                                         | HR 1.00 (0.87 - 1.15)         | HR 1.00 (0.87 - 1.15)         |
|                               |                       | Composite renal event, n (%)                                        | 108 (3.6)                     | 112 (3.7)                     |
|                               |                       | HR (95% CI)                                                         | 0.95 (0.73 to 1.24)           | 0.95 (0.73 to 1.24)           |
|                               |                       | First all-cause hospitalization, n (%)                              | 1271 (42.4)                   | 1340 (44.8)                   |
|                               |                       | HR (95% CI)                                                         | 0.92 (0.85 to 0.99)           | 0.92 (0.85 to 0.99)           |
|                               |                       | KCCQ clinical summary score, change from baseline (95% CI)          | 4.73 (3.89 to 5.12)           | 3.26 (2.57 tot 3.80)          |
|                               |                       | mean diff. (95% CI)                                                 | 1.32 (0.45 to 2.19)           | 1.32 (0.45 to 2.19)           |

1  Chronic dialysis was defined as dialysis with a frequency of twice per week or more for at least 90 days

2  Sustained was determined by two or more consecutive post-baseline central laboratory measurements separated by at least 30 days (the first to last of the consecutive eGFR values)

3  Reduction in eGFR (CKDEPI)cr was defined as reduction in eGFR from baseline of ≥40%, eGFR &lt;15 mL/min/1.73 m2 for patients with baseline eGFR ≥30 mL/min/1.73 m2, or eGFR &lt;10 mL/min/1.73 m2 for patients with baseline eGFR &lt;30 mL/min/1.73 m2

4   KCCQ, Kansas City cardiomyopathy questionnaire; clinical summary score measures HF symptoms (frequency and burden) and physical limitations

## Analysis performed across trials (pooled analyses and meta-analysis)

## Meta-analysis of EMPEROR trials (1245.121 and 1245.110)

The two outcome trials were conducted globally in 24 countries. A total of 9718 randomised patients from the two trials were included in this meta-analysis. Vital status was known for 99.4% of the randomised patients. The median observation time (Q1, Q3) up to the end of the planned treatment period was about 21 (15, 29) months. Disposition, demographics, and baseline characteristics were balanced between the treatment groups; some differences were observed between EMPEROR-Preserved and EMPEROR-Reduced studies.  The  meta-analysis  was  carried  out  using  individual  patient  data  after  both  trials  had  been completed. The methods in the meta-analysis were consistent with those used at trial level.

<div style=\"page-break-after: always\"></div>

## Endpoints

The following endpoints were pre-specified for the meta-analysis:

- Primary endpoint (confirmatory): the time to the first event in the composite renal endpoint
- Key secondary endpoints (confirmatory):
- o Time to adjudicated CV death
- o Time to onset of diabetes mellitus (DM; defined as HbA1c ≥ 6.5% or as diagnosed by the investigator) in patients with pre-DM (defined as no history of DM and no HbA1c ≥ 6.5% before treatment, and a pre-treatment HbA1c value of ≥ 5.7% and &lt;6.5%)
- o Time to all-cause mortality
- Other secondary endpoints (exploratory):
- o Time to the first event in the composite renal endpoint and all-cause mortality
- o Time to onset of DM in non-diabetic patients (including pre-DM and normal)
- o eGFR (CKD-EPI)cr slope of change from baseline (chronic slope)
- o eGFR annualised change from baseline (pre-treatment) to FU value (post-treatment) (true slope)

## Results

Since empagliflozin was superior to placebo based on all confirmatory endpoints in the hierarchical testing in  both trials, all alpha of the final analysis from the 2 trials (0.0496 from 1245.121 and 0.0497 from 1245.110) was transferred to this metaanalysis. The actual α for the meta -analysis was 0.0496 (2-sided).

In this meta-analysis, the hierarchical testing stopped after the primary endpoint (the composite renal endpoint), which did not show a statistically significant difference between empagliflozin and placebo. The 3 key secondary endpoints were therefore analysed in an exploratory manner.

For the primary endpoint, the pooled HR estimates are considered not meaningful as the 2 EMPEROR trials showed different results (treatment-by-trial interaction p = 0.0157; Figure 24). The risk was reduced with empagliflozin compared with placebo in trial 1245.121 (HFrEF) but not in 1245.110 (HFpEF; also see Figure 16), which may be attributed to differences in patient characteristics between the two studies.

<div style=\"page-break-after: always\"></div>

Time to composite renal endpoint, overall and by trial - RS

<!-- image -->

| Subgroup Category   | Nwithevent/N analysed Empa 10mg vs   | Placebo   | Hazardratio (95% CI)   | Interaction p-value   | Empabetter   |             | Placebobetter   |
|---------------------|--------------------------------------|-----------|------------------------|-----------------------|--------------|-------------|-----------------|
| Overall             | 138/4860                             | 170/4858  | 0.80 (0.64,1.00)       |                       |              |             |                 |
| Study 1245-0110     | 108/2997                             | 112/2991  | 0.95 (0.73,1.24)       | 0.0157                |              |             |                 |
| 1245-0121           | 30/1863                              | 58/1867   | 0.51 (0.33,0.79)       |                       |              |             |                 |
|                     |                                      |           |                        |                       |              | 0.5         | 2 4 8           |
|                     |                                      |           |                        |                       | 0.125        | 0.25        |                 |
|                     |                                      |           |                        |                       |              | Hazardratio | Hazardratio     |

Estimates for the trial level results in the pooled analysis could differ slightly from the results in the individual trial reports due to the combined analysis and different covariate adjustments.

Source data: [MA report, c31556490, Appendix 10, Figure 2.1.4.1.1]

For the 3 key secondary endpoints (exploratory), there was no interaction in the by-trial subgroup analyses and the pooled results showed that CV death or onset of diabetes (in patients with pre-diabetes) occurred in numerically fewer patients in the empagliflozin group than in the placebo group. The results for all-cause mortality were similar between empagliflozin and placebo.

As a secondary endpoint (exploratory), the onset of diabetes in patients without diabetes also occurred in numerically fewer patients in the empagliflozin group than in the placebo group (HR 0.85, 95% CI 0.70, 1.02), which was consistent between trials.

As another secondary endpoint (exploratory), eGFR [mL/min/1.73 m2] decline (i.e. chronic slope) was shown to be slower in the empagliflozin group than in the placebo group (difference to placebo 1.45 per year, 95% CI 1.18, 1.73), which was supported by a weighted ANCOVA analysis (difference to placebo 1.03 per year, 95% CI 0.71, 1.34) of annualised change from pre-treatment (baseline) to post-treatment (followup). These results were consistent between the trials.

A meta-analysis of the EMPEROR-reduced and -preserved was performed, with as primary endpoint the time to the first event in the composite renal endpoint. The hierarchical testing stopped after the primary endpoint, which did not show a statistically significant difference between empagliflozin and placebo. The Applicant describes that the pooled HR estimates are considered not meaningful as the 2 EMPEROR trials showed different results (treatment-by-trial interaction p = 0.0157). Based on the additional data provided by the Applicant, there is  a  smaller  treatment  effect  of  empagliflozin  on  the  eGFR  slope  in  EMPERORPreserved compare to in the EMPEROR-Reduced. Explanations for this finding are speculative but may be related  to  the  higher  SBP  in  patients  with  HFpEF,  which  may  lead  to  different  vessel  architecture  or intrarenal  patho-mechanisms  such  as  less  inflammation.  This  could  be  important  in  view  of  antiinflammatory effects being proposed for SGLT2i.

## Clinical studies in special populations

A subgroup analysis based on age was performed (see above). This showed a similar or possible larger treatment effect on the primary en dpoint for patients ≥70 years vs &lt;70 years (&lt;70 years HR 0.88, 95%CI 0.70 1.11; ≥70 years HR 0.75, 95%CI 0.64 - 0.87).

The applicant was requested to discuss if the recommendation in section 4.2 and 4.4 of the SmPC for the population aged ≥85 years is st ill suitable based on the efficacy and safety data collected for empagliflozin and if this may differ per indication. In the response, the applicant provided the efficacy data below.

<div style=\"page-break-after: always\"></div>

As pre-specified in the individual EMPEROR CTRs, the subgroup analyses showed consistent results for the confirmatory endpoints by age categories (&lt; and ≥65 years in EMPEROR -Reduced; &lt; and ≥70 years in EMPEROR-Preserved). Moreover, age analysed as a continuous variable had no relevant impact on the results  of  the  primary  endpoint  (treatment-by-age  interaction  p  =  0.2366  for  EMPEROR-Reduced  and 0.5162 for EMPEROR-Preserved).

In the two EMPEROR trials, a meaningful number of patients aged ≥85 years were included ( a total of 483 patients),  with  fewer  patients  from  EMPEROR-Reduced  (58  patients  in  the  empagliflozin  group  and  41 patients  in  the  placebo  group)  than  EMPEROR-Preserved  (178  and  206  patients)  [CTR  1245.121, c28576542, Table 15.1.4: 1; CTR 1245.110, c31803238, Table 15.1.4: 1].

In order to increase the sample size for more precise estimations in smaller subgroups, the two trials were pooled  for  the  analyses  by  age  using  5  categories.  The  results  showed  that  the  beneficial  effects  of empagliflozin treatment compared with placebo were independent of age (see Figure 25).

<div style=\"page-break-after: always\"></div>

Figure 25. Efficacy endpoints by age categories in pooled EMPEROR trials ( post hoc )

## Primary endpoint: time to the first CV death or HHF and components, Cox regression, RS

N with event / N analysed

Hazard ratio

Interaction

<!-- image -->

Hazard ratio

## Key secondary endpoint: HHF (first and recurrent), joint frailty model, RS

<!-- image -->

Hazardratio

## Key secondary endpoint: eGFR [mL/min/1.73 m2] slope, random intercept random slope model, TS (on-treatment)

<!-- image -->

For renal function subgroup analyses have also been performed, described above, showing a similar result across eGFR subgroups.

<div style=\"page-break-after: always\"></div>

## Supportive study(ies)

## EMPA-VISION (trial 1245.1480)

Trial  1245.148  (EMPA-VISION) was a randomised, placebo-controlled, double-blind, parallel-group, 12week trial to assess the effect of empagliflozin on cardiac physiology and metabolism. A total of 72 patients were randomised, with 36 each in the HFrEF cohort (LVEF ≤ 40%) or the HFpEF cohort (LVEF ≥ 50%), in a 1:1 ratio to empagliflozin 10 mg or placebo within the cohort. The primary endpoint was the change from baseline to Week 12 in phosphocreatine to adenosine triphosphate (PCr/ATP) ratio in the resting state measured by 31P cardiac magnetic resonance spectroscopy. The primary analysis was based on the perprotocol set of patients with PCr/ATP measurements at baseline and Week 12, and using an ANOVA model.

In the HFrEF cohort, 17 patients in the empagliflozin group and 18 in the placebo group were assessed for the  primary  endpoint.  There  was  no  significant  difference  between  empagliflozin  and  placebo,  with  an adjusted mean change of -0.179 (SE 0.117) for empagliflozin vs 0.068 (SE 0.114) for placebo. The adjusted mean treatment difference was -0.247 (95% CI: -0.582, 0.087; p = 0.1418).

In the HFpEF cohort, 13 patients in the empagliflozin group and 11 in the placebo group were assessed for the primary endpoint. The most common reason for missing data at Week 12, and consequent exclusion from the primary analysis, was that due to COVID-19 pandemic restrictions, patients were unable to attend face-to-face visits from 24 Mar 2020 onwards. There was no significant difference between empagliflozin and placebo, with an adjusted mean change of 0.100 (SE 0.143) for empagliflozin vs 0.259 (SE 0.156) for placebo. The adjusted mean treatment difference was -0.159 (95% CI: -0.604, 0.286; p = 0.4650).

Imbalances in important baseline characteristics, a study population with fewer than expected patients with a history of diabetes, along with fewer patients than planned contributing to the HFpEF analysis (due to COVID-19 restrictions), may have limited the efficacy findings of interest in this trial.

## EMPERIAL-preserved (1245.167)

The EMPERIAL-preserved trial (1245.167) was described in a previous application for the indication chronic heart failure with reduced ejection fraction. Trial 1245.167 was a randomised, placebo-controlled, double-blind, parallel-group, 12-week trial to assess the effect of empagliflozin on functional capacity. The eligibility criteria in the EMPERIAL-preserved trial were generally similar to those in the EMPERORpreserved trial. The additional EMPERIAL trial was comparable regarding the screening and treatment, except for the treatment duration. The EMPERIAL trials were not event-driven but were designed to investigate the short-term (12 weeks) effect of empagliflozin on functional capacity, signs and symptoms of heart failure, and quality of life. Therefore, a treatment duration of 12 weeks was implemented. The EMPERIAL-preserved trial included 315 subjects.

The following endpoints were pre-specified:

Primary endpoint:

- change from baseline to Week 12 in the 6-minute-walk test (6MWT) distance

Key secondary endpoints:

- Change from baseline to Week 12 in KCCQ-TSS (, total symptom score)
- Change from baseline to Week 12 in CHQ-SAS (chronic heart failure questionnaire selfadministered standardised format) dyspnoea score

<div style=\"page-break-after: always\"></div>

In 1245.167, of the 315 randomised patients treated with study medication, 301 (95.6%) completed the trial, and 291 (92.4%) completed the treatment with study medication. There were no relevant differences between the treatment groups.

The primary endpoint (change from baseline to Week 12 in the 6MWT distance) did not show a statistically significant difference between empagliflozin and placebo. The two key secondary endpoints (change from baseline to Week 12 in KCCQ-TSS and in CHQ-SAS dyspnoea score) were therefore tested in an exploratory fashion. No meaningful differences between treatment groups were observed in the efficacy endpoints in 1245.167 (HFpEF).

The EMPERIAL-preserved trial was designed to evaluate the effect of empagliflozin 10 mg versus placebo on functional capacity and HF-related symptoms. The results of these studies address whether symptomatology improves after short-term treatment. The primary endpoint (change from baseline to Week 12 in the 6MWT distance) did not show a statistically significant difference between empagliflozin and placebo. This, therefore, does not support a beneficial effect of empagliflozin on functional capacity. The EMPA-VISION was a trial to assess the effect of empagliflozin on cardiac physiology and metabolism and included a small number of subjects (empagliflozin n=17, placebo n=18). In this trial also, there was no significant difference between empagliflozin and placebo. The Applicant describes that imbalances in important baseline characteristics and the small number of subjects may have hampered the efficacy results.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The Applicant states that the trial was performed in accordance with the principles of the Declaration of Helsinki, in accordance with the ICH GCP.

No dose finding study has been performed. This is considered acceptable based on the data for the indication of T2DM and HFrEF, but it cannot be excluded that a lower dose than 10 mg is effective for the current indication.

The EMPEROR-preserved trial (1245.110) is a pivotal outcome trial and is an international, multi-centre, placebo-controlled, randomised (empagliflozin 10 mg to placebo 1:1), double-blind, and parallel-group by design in patients with HFpEF with or without T2DM. The aim of the trial is to demonstrate superiority of empagliflozin  10  mg  versus  placebo  (empagliflozin  10 mg  to  placebo  1:1)  in  reducing  the  risk  of hospitalisation for HF and of cardiovascular death in patients with symptomatic, chronic HF and preserved ejection fraction (LVEF &gt; 40%) under stable treatment of HF symptoms. The trial consisted of an event -driven study duration, followed by a 30-days period off study-drug. The design of the trial is acceptable and in line with the EMA guideline 'Clinical investigation of medicinal products in the treatment of chronic heart failure' (CPMP/EWP/235/95, Rev.2).

The inclusio n criteria consisted of age ≥ 18 years, eGFR ≥ 20 and a LVEF &gt;40%. Although HFpEF has been defined from a LVEF &gt;40%, the range between 40 and 50% is currently considered HFmEF and this group of  patients  may  differ  in  the  aetiology  and  treatment  response  compared  to  patients  with  LVEF &gt;50%/HFpEF. Retrospective analyses have suggested that the benefits of neurohormonal antagonists in patients with HFrEF extend to those with a mildly reduced ejection fraction (Dewan P et al. Eur J Heart Fail 2020). This may affect the interpretation of the overall efficacy results. However, stratified randomisation was performed for LVEF subgroups (i.e. LVEF &lt;50%, LVEF 50&lt;60% and LVEF ≥60%).

<div style=\"page-break-after: always\"></div>

Known causes for HFpEF are infiltrative diseases, such as amyloidosis, but this was an exclusion criteria. The Applicant has put forward several reasons for excluding these subjects from the study (diagnosis made quite late, poor prognosis or [Takotsubo cardiomyopathy] could completely resolve). It was assessed that patients known to have one of these conditions would have a substantially different risk of a primary outcome event than the rest of the study population. This implies that the B/R could be quite different from the rest of the study population and it has not been studied specifically. The Applicant included a warning in section 4.4 of the SmPC, describing that efficacy in these patients has not been established. This is acceptable.

The other described exclusion criteria are in general reasonable and do not seem to hamper the translation of the trial results to the general HFrEF population at large in clinical practice.

The primary endpoint, i.e. combined CV endpoint of adjudicated CV death or adjudicated HHF, is considered adequate for the current application and in line with the EMA guideline (CPMP/EWP/235/95, Rev.2). For the key secondary renal endpoint, the eGFR (CKD-EPI)cr slope of change from baseline was analysed. This endpoint has the limitation that a long treatment period, i.e. more than 2 years, is considered needed to confirm a beneficial effect. A combined renal endpoint (i.e. chronic dialysis, renal transplant, or sustained reduction in eGFR) would have been preferred, although it is acknowledged that an analysis based on this clinical endpoint is difficult in this population with a broad eGFR range and considering the time frame and number of patients needed to demonstrate any reasonable effect.

COVID-19 had effect on the conduct of the study as 31.8% of patients had at least one visit affected by COVID-19 and these visits were often performed by phone instead of on-site. It is not considered likely that this affected the primary endpoint or other endpoints related to HHF or CV death/all-cause mortality. The adjudication of outcome events by the CEC was performed based on uploaded source documents. The adjudicated endpoints were therefore protected from being impacted. Also, for the other endpoints, it is not considered likely that it affected the outcome, as data are considered to be missing completely at random.

## Statistical methods

The statistical analyses in the trial design are based on an intention to treat analysis, and the primary analysis was a Cox regression with adjudicated CV death or HHF as the primary endpoint with non-CV death as a competing event. This is acceptable. The secondary endpoint of recurrent hospitalisations is analysed using a joint frailty model. This will adjust the analysis of recurrent hospitalisations for the competing event of CV death and is acceptable. The MAH performed additional analyses testing the influence of using CV or overall mortality in the primary and key secondary composite endpoints, and the effect of the analysis model incorporating recurrent events in the secondary endpoint.

Cumulative incidence function curves that account for competing risks (i.e. non-CV deaths) and KaplanMeier curves of time to censoring were displayed.

The secondary endpoint eGFR slope is analysed with a random coefficient model. Since this allows for a random intercept, testing a difference in the (random) slope will not reflect the overall treatment effect, since the initial dip will be largely incorporated in the intercept. As a sensitivity analysis, an ANCOVA was performed to analyse the overall treatment effect of the change from baseline ignoring the path taken and this is considered acceptable.

## Efficacy data and additional analyses

Trial 1245.110 included a large number of subjects (n=5988). Demographics and baseline characteristics were balanced between the treatment groups. The proportion of female subjects (44.7%) is remarkably

<div style=\"page-break-after: always\"></div>

larger compared to trials performed with HFrEF and the EMPEROR-reduced trial (i.e. 23.9% female). This is not unexpected, as HFpEF is more common than HFrEF in female patients. The average age was 71.9 years (SD 9.4) and the majority of patients was White; 75.9% White, 13.8% Asian, and 4.3% Black/African American. About half of patients (48.9%) had T2DM, 10 patients (0.2%) had T1DM. Half of the patients (49.9%) had an eGFR of &lt;60 mL/min/1.73 m2 and half of the subjects had atrial fibrillation (51.0%). The majority of the patients were in NYHA class II (81.5%) and the cause of HF was hypertensive (36.5%) or ischaemic (35.4%). This appears in line with the target population, supporting external validity of the results.

The distribution of patients between the LVEF subgroups was also equal between the three subgroups (LVEF &lt;50% n=1983 (33.1%), LVEF 50%&lt;60% n=2058 (34.4%), LVEF &gt;60% n=1947 (32.5%)). As the group of LVEF &lt;50% may be considered as HFmEF and not comparable to the higher LVEF subgroups, it is relevant that the higher LVEF subgroups consist of a large proportion of the overall sample size.

Median exposure to study medication was about 23 months in both treatment groups, with 84% of patients treated for at least 1 year. This is an acceptable duration to evaluate the treatment effects on efficacy and safety for this application.

CV death or HHF (primary endpoint) occurred in a lower proportion of patients in the empagliflozin group than in the placebo group (empagliflozin 415/2997, 13.8%; placebo 511/2991, 17.1%), and the risk of CV death  or  HHF  was  reduced  with  empagliflozin  treatment  compared  with  placebo  (HR  empagliflozin  vs placebo 0.79; 95%CI 0.69 to 0.90, p = 0.0003). This effect appears similar to the effect of empagliflozin in patients with HFrEF in the EMPEROR-reduced trial (HR 0.75, 95%CI 0.65 - 0.86), but with higher NNT (EMPEROR-preserved NNT 31, EMPEROR-reduced NNT 19). The separation of the estimated cumulative incidence of CV death or first HHF between empagliflozin and placebo started shortly after randomisation and  was  maintained  throughout  the  trial.  These  findings  support  a  beneficial  effect  of  treatment  with empagliflozin. The difference in treatment effect appears mainly due to the decrease in HHF, as CV death as the first  did  not  differ  between  the  treatment  groups  (empagliflozin  n=156 (5.2%), placebo n=159 (5.3%)), but the total number of CV death (described below) was lower with empagliflozin vs placebo, but the difference was not statistically significant (empagliflozin 219/2997, placebo 244/2991, HR 0.91, 95%CI 0.76 - 1.09).

All-cause mortality was similar in both treatment groups (HR 1.00, 95%CI 0.87 - 1.15). The number of non-CV  death  was  larger  with  empagliflozin,  but  this  difference  was  not  statistically significant (empagliflozin 203/2997, placebo 183/2991, HR 1.13, 95%CI 0.92 - 1.38). The Applicant provided an evaluation of the causes of non-CV death, and this did not show a specific increase in a cause of death during empagliflozin treatment.

An initial dip in eGFR was observed with empagliflozin treatment, followed by a slower decrease in eGFR over time. This is in line with results in previous trials performed with SGLT2i. The change of eGFR slope from baseline was a key secondary endpoint and showed a slower decline in eGFR in the empagliflozin group, with an estimated difference in slope of 1.363 mL/min/1.73 m2 per year vs placebo (99.9% CI 0.861 to 1.865; p&lt;0.0001). But the effect on slope can only be interpreted if seen in conjunction with intercept. The applicant also provided an analysis of change from baseline using ANCOVA, similar to the previous application for the HFrEF indication. This resulted in a larger or similar decrease in eGFR for empagliflozin vs. placebo (change from baseline: empagliflozin -6.4, placebo -6.0, comparison -0.4 (-1.2, 0.3)). But after the 30 day follow-up period after stop of treatment, the decrease in eGFR was smaller for the empagliflozin group (change from baseline: empagliflozin -3.3, placebo -5.7, comparison 2.4 (1.6, 3.2)), supporting that the initial dip is reversable. The effect on the renal composite endpoint is, however, considered preferred for evaluation of renal effects. In the current trial, the effect of empagliflozin on the eGFR slope is not supported or confirmed by the observed effects on the composite renal endpoint (i.e. chronic dialysis, renal transplant,  or  sustained  reduction  in  eGFR),  as  the  results  are  similar  for  empagliflozin  vs.  placebo

<div style=\"page-break-after: always\"></div>

(empagliflozin 108/2997 (3.6%), placebo 112/2991 (3.7%), HR 0.95 95%CI 0.73, 1.24). However, the Applicants supports the findings with other additional pre-specified analyses, i.e. eGFR change from pretreatment (baseline) to post-treatment (follow-up; FU) analysed with ANCOVA, 'true slope' (annualised change from pre-treatment to post-treatment weighted by time of FU squared) and progression to or reversal from macro-albuminuria. Although all exploratory, these findings indicate a consistent finding and this appears clinical relevant.

A meta-analysis of the EMPEROR-reduced and -preserved was performed with as primary endpoint the time to  the  first  event  in  the  composite  renal  endpoint.  The  hierarchical  testing  stopped  after  the  primary endpoint, which did not show a statistically significant difference between empagliflozin and placebo. The Applicant describes that the pooled HR estimates are considered not meaningful as the 2 EMPEROR trials showed different results (treatment-by-trial interaction p = 0.0157). This composite of major adverse renal outcomes was significantly lower in the EMPEROR-Preserved trial than in the EMPEROR-Reduced trial. Based on the additional data provided by the Applicant, there is a smaller treatment effect of empagliflozin on the eGFR slope in EMPEROR-Preserved than in EMPEROR-Reduced. Explanations for this finding are speculative but may be related to the higher SBP in patients with HFpEF.

The  effects  of  empagliflozin  were  accompanied  by  effects  on  body  weight,  improvement  in  NYHA classification and reduction in systolic blood pressure. This is in line with previous observations with SGLT2i treatment.

The change from baseline in KCCQ clinical summary score at Week 52 was a secondary/exploratory endpoint. The mean treatment difference in change was 1.32, 95% CI 0.45 to 2.19. Although statistically significant, the treatment difference appears modest, and the clinical relevance is questionable. The Applicant also provided the proportion of patients achieving a clinically relevant change (i.e. 5 points). This endpoint resulted in a larger proportion of patients with clinically relevant change (empagliflozin 1126 patients, 41.7%; placebo 1034 patients, 38.7%), but the difference in percentage is small. For other KCCQ scores, a treatment difference was also observed, supporting a consistent finding, but the treatment differences are again considered small and not clinically relevant.

Subgroup analyses were performed for the primary and key secondary endpoints. Important is the subgroup analyses for LVEF. Although p for interaction was not significant (p=0.2098) for the primary endpoint (CV death or HHF), the effect was more pronounced in patients with LVEF &lt;50% compared to ≥60%, but was positive for all LVEF subgroups and still significant for the group LVEF 50-&lt;60% (LVEF &lt;50% empagliflozin 145/995, placebo 193/988, HR 0.71, 95%CI 0.57-0.88; LVEF 50-&lt;60% empagliflozin 138/1028, placebo 173/1030, HR 0.80, 95%CI 0.640.99; LVEF &gt;60% empagliflozin 132/974, placebo 145/973, HR 0.87, 95%CI 0.69-1.10). As the effect of empagliflozin on the primary endpoint was beneficial for all LVEF subgroups, the indication for the treatment of heart failure in patients with HFpEF is acceptable. As the indication for the treatment of heart failure is for all types of heart failure, the wording ' for the treatment of symptomatic chronic heart failure.' is considered acceptable.

It could, however, be suggested that there is a modification of the treatment effect in subjects with higher LVEF for the key secondary endpoint, i.e. adjudicated HHF (first and recurrent), where the point estimate for the subgroup LVEF ≥60% is HR 1.06 (95%CI 0.76 -1.46) and p for interaction 0.0077. This could indicate that patients with LVEF ≥60% benefit less from treat ment with empagliflozin. The Applicant performed additional post-hoc analyses with subgroups by LVEF in more detail for the HF outcomes, using a 5% increment of LVEF to categorise patients for this secondary endpoint and for the primary endpoint. For first HHF in the subgroup LVEF 60 to &lt;65% the hazard ratio was 0.75 (95%CI 0.51 - 1.10). The HR was &gt;1 in subgroup LVEF 65 to &lt;70% (HR 1.57, 95%CI 0.92 -2.70), but in subgroup LVEF ≥70% the HR was again &lt;1 (HR 0.55, 95%CI 0.29 to 1.06). Notably, the number of subjects is low in this latter subgroup (subjects n=319), but the lower HR in the subgroup ≥70%, contradicts the suggestions of a decrease in effect in higher LVEF subgroup. For the analyses of total occurrence of HHF (first and

<div style=\"page-break-after: always\"></div>

recurrent), the HR was &gt;1 f or two subgroups, i.e. subgroup LVEF 60 to &lt;65% (HR 1.04, 95%CI 0.66 1.65) and LVEF 65 to &lt;70% (HR 1.86, 95%CI 1.03 3.35). But again, the subgroup LVEF ≥70% had a HR &lt;1 (HR 0.42, 95%CI 0.20 - 0.88). The recurrent HHF appears to mainly contribute to the finding of a higher hazard ratio for the subgroup LVEF ≥60% in the secondary endpoint. The analyses on the contribution of HHF events by number of events experienced per patient showed that for patients who had 4 or more events, in the subgroup of LVEF of 65 to &lt;70% 6 patients in the empagliflozin arm had 31 events while 1 patient in the placebo arm had 5 events. This may contribute to the imbalance in the analysis of the recurrent HHF in this subgroup. This may be related to chance. Based on these findings it is not considered supported that there is a decrease in efficacy in patients with higher LVEF.

Although effectiveness of treatment with ACEi/ARB, MRA's and/or ARNI's have not been demonstrated in patients with HFpEF, the majority of the patients used these treatments during the trial, i.e. ACEi/ARB's, 82.6%, MRA's 46.0%, ARNI's 4.4%. Empagliflozin was, therefore, evaluated on top of these medication, but these medications are not registered for the treatment of HFpEF. The Applicant described the baseline use of these agents in the trial population in Section 5.1 of the SmPC. The subgroup analysis for baseline use of ACEi/ARB/ARNI's and/or MRA's resulted in a similar risk reduction with empagliflozin vs. placebo for the primary and key secondary endpoints for patients using these agents compared to patients not using these agents at baseline. As the efficacy of empagliflozin appears consistent with vs without the use of these agents, it is acceptable that the indication for the treatment of HFpEF is independent of the baseline use of these agents.

In elderly patients, i.e. age ≥ 70 years, the point estimate of treatment effect was larger compared to patients &lt; 70 for the primary endpoint (age ≥70 years HR 0.75, 95%CI 0.64 -0.95, age &lt;70 years HR 0.88, 95%CI 0.701.11) and key secondary endpoint (HHF) (age ≥70 years HR 0.65, 95%CI 0.52 -0.82, age &lt;70 years HR 0.92, 95%CI 0.67-1.26). This supports a beneficial effect in elderly patients.

In the sensitivity analyses the treatment effect for the primary endpoint appears larger before vs. after COVID-19 outbreak (before HR 0.70, 95%CI 0.59-0.83; after HR 0.93, 95%CI 0.76-1.13), with a similar number of subjects included before and after. The treatment difference may, at least partly, be explained by that during COVID outbreak, less patients were accepted for hospitalisation, but this is speculative.

The EMPERIAL-preserved trial (n=315) was designed to evaluate the effect of empagliflozin 10 mg versus placebo on functional capacity and HF-related symptoms. The results of these small sized studies address whether symptomatology improves after short-term treatment. The primary endpoint (change from baseline to Week 12 in the 6MWT distance) did not show a statistically significant difference between empagliflozin and placebo. This, therefore, does not support a beneficial effect of empagliflozin on functional capacity.

## 2.4.4. Conclusions on the clinical efficacy

The results of the well-designed pivotal outcome trial 1245.110 showed a risk reduction with empagliflozin vs. placebo in patients with HFpEF for the combined cardiovascular endpoint (HHF or CV death). For the primary endpoint, this was observed across the LVEF subgroups. The wording of indication is considered acceptable. The Applicant included a warning in section 4.4 of the SmPC, describing that efficacy in patients with infiltrative diseases has not been established. This is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

Currently, empagliflozin is registered for the treatment of T2DM and for chronic heart failure with reduced ejection fraction. Based on the placebo-controlled trials and post-marketing experience, known side-effects of treatment with empagliflozin are o.a. genital infections, keto-acidosis, hypoglycaemia, volume depletion and urinary tract infections. See also the table below from Section 4.8 of the current SmPC of Jardiance (Table 20).

Table 20. Tabulated list of adverse reactions (MedDRA) from reported placebo-controlled studies and from post-marketing experience

| System organ class                     | Very common                                             | Common                                                                                                                                     | Uncommon                                                                               | Rare                                                          |
|----------------------------------------|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Infections and infestations            |                                                         | Vaginal moniliasis, vulvovaginitis, balanitis and other genital infection Urinary tract infection (including pyelonephritis and urosepsis) |                                                                                        | Necrotising fasciitis of the perineum (Fournier´s gangrene) a |
| Metabolism and nutrition disorders     | Hypoglycaemia (when used with sulphonylurea or insulin) | Thirst                                                                                                                                     |                                                                                        | Diabetic ketoacidosis                                         |
| Gastrointestin al disorders            |                                                         | Constipation                                                                                                                               |                                                                                        |                                                               |
| Skin and subcutaneous tissue disorders |                                                         | Pruritus (generalised) Rash                                                                                                                | Urticaria Angioedema                                                                   |                                                               |
| Vascular disorders                     | Volume depletion                                        |                                                                                                                                            |                                                                                        |                                                               |
| Renal and urinary disorders            |                                                         | Increased urination                                                                                                                        | Dysuria                                                                                |                                                               |
| Investigations                         |                                                         | Serum lipids increased                                                                                                                     | Blood creatinine increased/ Glomerular filtration rate decreased Haematocrit increased |                                                               |

a In the EMPEROR-Reduced heart failure study, one case (&lt;0.1%) of necrotising fasciitis of the perineum (Fournier´s gangrene) was observed in a patient with heart failure and diabetes mellitus treated with empagliflozin.

The main objective of the below described safety evaluation is to present and evaluate safety data on the clinical  use  of  empagliflozin  in  patients  with  chronic  heart  failure.  The trials included patients  with  and without T2DM.

The described safety analyses followed the 'treatment-emergent' principle and included all treated patients (TS). Unless otherwise specified, treatment was assigned as randomised and the analyses of AEs were based on the number of patients with AEs. AE analyses were restricted to 'on-treatment' AEs, defined as

<div style=\"page-break-after: always\"></div>

AEs with an onset date between the first trial medication intake and 7 days after the last intake, unless otherwise stated. Exposure-adjusted AEs were also displayed as incidence rates per 100 patient-years.

In addition to the safety analyses of trials 1245.110 (EMPEROR-Preserved) and 1245.148 (EMPA-VISION) presented in CTRs, safety data of 5 trials in patients with chronic HF were pooled as 'SAF-HF1', regardless of LVEF category.

## Patient exposure

In SAF-HF1, 10408 patients were treated. The majority of the patients were from the two EMPEROR trials (Table 21).

Table 21. Number of treated patients in SAF-HF1

|                               | Placebo N (%)   | Empa 10 mg N (%)   | Total N (%)   |
|-------------------------------|-----------------|--------------------|---------------|
| SAF-HF1 - TS                  | 5202 (100.0)    | 5206 (100.0)       | 10408 (100.0) |
| 1245.110 (EMPEROR-Preserved)  | 2989 (57.5)     | 2996 (57.5)        | 5985 (57.5)   |
| 1245.121 (EMPEROR-Reduced)    | 1863 (35.8)     | 1863 (35.8)        | 3726 (35.8)   |
| 1245.148 (EMPA-VISION)        | 36 (0.7)        | 35 (0.7)           | 71 (0.7)      |
| 1245.167 (EMPERIAL-preserved) | 158 (3.0)       | 157 (3.0)          | 315 (3.0)     |
| 1245.168 (EMPERIAL-reduced)   | 156 (3.0)       | 155 (3.0)          | 311 (3.0)     |
| North America                 | 703 (13.5)      | 695 (13.3)         | 1398 (13.4)   |
| Latin America                 | 1402 (27.0)     | 1399 (26.9)        | 2801 (26.9)   |
| Europe                        | 2233 (42.9)     | 2242 (43.1)        | 4475 (43.0)   |
| Asia                          | 587 (11.3)      | 591 (11.4)         | 1178 (11.3)   |
| Other 1                       | 277 (5.3)       | 279 (5.4)          | 556 (5.3)     |

1  Included the countries Australia, India, and South Africa

Source data: [SCS appendix 2, c35146126, Tables 1.1.1 and 1.1.2]

Of the 10408 treated patients in SAF-HF1, 7472 patients (71.8%) completed treatment as planned, and 2936 patients prematurely discontinued study medication (28.2%, including patients who died). The most common reason for premature discontinuation of study medication was AE (17.7%, including fatal events; Table 22).

Table 22. Disposition of treated patients in SAF-HF1

|                                           | Placebo N (%)   | Empa 10 mg N (%)   | Total N (%)   |
|-------------------------------------------|-----------------|--------------------|---------------|
| Screened                                  |                 |                    | 20309         |
| Randomised                                |                 |                    | 10417         |
| Treated                                   | 5202 (100.0)    | 5206 (100.0)       | 10408 (100.0) |
| Completed treatment                       | 3722 (71.5)     | 3750 (72.0)        | 7472 (71.8)   |
| Prematurely discontinued study medication | 1480 (28.5)     | 1456 (28.0)        | 2936 (28.2)   |
| Adverse event                             | 916 (17.6)      | 931 (17.9)         | 1847 (17.7)   |
| Non-compliance with protocol              | 36 (0.7)        | 29 (0.6)           | 65 (0.6)      |
| Lost to follow-up                         | 17 (0.3)        | 34 (0.7)           | 51 (0.5)      |
| Withdrawal by patient                     | 432 (8.3)       | 378 (7.3)          | 810 (7.8)     |
| Other reason                              | 73 (1.4)        | 83 (1.6)           | 156 (1.5)     |
| Reason missing                            | 6 (0.1)         | 1 (<0.1)           | 7 (0.1)       |

Patients are presented as randomised except for trial 1245.148 (as treated).

<div style=\"page-break-after: always\"></div>

In SAF-HF1, the median exposure to study medication was about 18 months in both treatment groups, with 70.2% of patients treated for at least 1 yea r ( Table 23. ).

Table 23. Exposure to study medication in SAF-HF1 - TS

|                               | Placebo             | Empa 10 mg          | Total               |
|-------------------------------|---------------------|---------------------|---------------------|
| Number of patients, N (%)     | 5202 (100.0)        | 5206 (100.0)        | 10408 (100.0)       |
| Exposure categories, N (%)    |                     |                     |                     |
| ≥12 weeks                     | 4825 (92.8)         | 4865 (93.4)         | 9690 (93.1)         |
| ≥26 weeks                     | 4321 (83.1)         | 4370 (83.9)         | 8691 (83.5)         |
| ≥52 weeks                     | 3644 (70.0)         | 3659 (70.3)         | 7303 (70.2)         |
| ≥78 weeks                     | 2542 (48.9)         | 2520 (48.4)         | 5062 (48.6)         |
| ≥104 weeks                    | 1603 (30.8)         | 1589 (30.5)         | 3192 (30.7)         |
| ≥156 weeks                    | 308 (5.9)           | 303 (5.8)           | 611 (5.9)           |
| Duration of exposure [months] |                     |                     |                     |
| Median (Q1, Q3)               | 17.87 (9.63, 26.63) | 17.83 (9.87, 26.67) | 17.83 (9.78, 26.63) |
| Mean (SD)                     | 18.42 (10.95)       | 18.50 (10.86)       | 18.46 (10.90)       |
| Total exposure [years]        | 7871.7              | 7912.4              | 15784.1             |

Exposure was calculated as the time from the date of first intake until the date of permanent discontinuation of study medication.

Source data: [SCS appendix 2, c35146126, Table 1.3.1]

## Adverse events

In SAF-HF1, the frequencies of patients with at least one AE, severe AEs, and AEs leading to treatment discontinuation  were  similar  between  empagliflozin  and  placebo.  The  frequency  of  investigator-defined drug-related AEs was higher in the empagliflozin group than in the placebo group. The frequency of patients with SAEs was lower in the empagliflozin group than in the placebo group ( Table 24. ). The most frequent events in these categories are described below.

Table 24. Overall summary of adverse events in SAF-HF1 - TS

| Category of AEs                                    | Placebo N (%)   | Empa 10 mg N (%)   |
|----------------------------------------------------|-----------------|--------------------|
| Number of patients                                 | 5202 (100.0)    | 5206 (100.0)       |
| Patients with any AEs                              | 4234 (81.4)     | 4164 (80.0)        |
| Severe AEs                                         | 1378 (26.5)     | 1265 (24.3)        |
| Investigator defined drug-related AEs              | 669 (12.9)      | 810 (15.6)         |
| AEs leading to discontinuation of study medication | 899 (17.3)      | 912 (17.5)         |
| Serious AEs                                        | 2502 (48.1)     | 2250 (43.2)        |
| Results in death                                   | 481 (9.2)       | 472 (9.1)          |
| Is life threatening                                | 206 (4.0)       | 199 (3.8)          |
| Persistent or significant disability/incapacity    | 61 (1.2)        | 78 (1.5)           |
| Requires or prolongs hospitalisation               | 1912 (36.8)     | 1735 (33.3)        |
| Other medically important serious event            | 1129 (21.7)     | 970 (18.6)         |

Percentages calculated using total number of patients per treatment as the denominator.

A patient may be counted in more than 1 seriousness criterion.

Source data: [SCS, c35218777, Section 2.1.1]

<div style=\"page-break-after: always\"></div>

## Most frequently reported AEs

Adverse events were most frequently reported in the SOCs cardiac disorders (empagliflozin 1548 patients, 29.7%  vs  placebo  1822  patients,  35.0%),  infections  and  infestations  (1700 patients,  32.7%  vs  1732 patients, 33.3%), and metabolism and nutrition disorders (1241 patients, 23.8% vs 1446 patients, 27.8%) (Table 25). On the PT level, the most frequently reported AE were cardiac failure (795 patients, 15.3% vs 1065 patients, 20.5%), hypotension (372 patients, 7.1% vs 313 patients, 6.0%), and renal impairment (320 patients, 6.1% vs 312 patients, 6.0%). Preferred terms with a higher frequency in the empagliflozin group than in the placebo group were urinary tract infection and hypotension. Adverse events with PTs reported in ≥5.0% of patients in at least one group are summarised in the table below

Table 25. Patients with adverse events in SAFHF1 (frequency ≥5.0% in at least one treatment group at the PT level) - TS

| MedDRA SOC MedDRA PT                           | Placebo N (%)   | Rate/100 pt-yrs   | Empa 10 mg N (%)   | Rate/100 yrs   | pt-   |
|------------------------------------------------|-----------------|-------------------|--------------------|----------------|-------|
| Number of patients                             | 5202 (100.0)    |                   | 5206 (100.0)       |                |       |
| Total with adverse events                      | 4234 (81.4)     | 157.84            | 4164 (80.0)        | 142.94         |       |
| Cardiac disorders                              | 1822 (35.0)     | 29.17             | 1548 (29.7)        | 23.39          |       |
| Cardiac failure                                | 1065 (20.5)     | 15.20             | 795 (15.3)         | 10.78          |       |
| Atrial fibrillation                            | 318 (6.1)       | 4.14              | 283 (5.4)          | 3.66           |       |
| Infections and infestations                    | 1732 (33.3)     | 28.31             | 1700 (32.7)        | 27.23          |       |
| Urinary tract infection                        | 259 (5.0)       | 3.35              | 314 (6.0)          | 4.07           |       |
| Pneumonia                                      | 291 (5.6)       | 3.77              | 257 (4.9)          | 3.29           |       |
| Metabolism and nutrition disorders             | 1446 (27.8)     | 22.93             | 1241 (23.8)        | 18.76          |       |
| Hyperkalaemia                                  | 330 (6.3)       | 4.33              | 282 (5.4)          | 3.66           |       |
| Hyperuricaemia                                 | 329 (6.3)       | 4.35              | 197 (3.8)          | 2.54           |       |
| Diabetes mellitus                              | 263 (5.1)       | 3.43              | 191 (3.7)          | 2.45           |       |
| Renal and urinary disorders                    | 904 (17.4)      | 12.64             | 907 (17.4)         | 12.66          |       |
| Renal impairment                               | 312 (6.0)       | 4.05              | 320 (6.1)          | 4.15           |       |
| Vascular disorders                             | 899 (17.3)      | 12.74             | 847 (16.3)         | 11.89          |       |
| Hypotension                                    | 313 (6.0)       | 4.09              | 372 (7.1)          | 4.87           |       |
| Hypertension                                   | 299 (5.7)       | 3.92              | 264 (5.1)          | 3.43           |       |
| Injury, poisoning and procedural complications | 568 (10.9)      | 7.73              | 609 (11.7)         | 8.23           |       |
| Fall                                           | 249 (4.8)       | 3.24              | 261 (5.0)          | 3.37           |       |

Source data: [SCS appendix 2, c35146126, Table 2.1.1.3]

The number of AEs and severe AEs were similar for empagliflozin compared to placebo, but the number of cardiac events is lower for empagliflozin vs. placebo, and the similar number of total AEs could therefore result in a larger number of other AEs. Based on the most frequently reported AEs, this number of events is also similar for empagliflozin compared to placebo, except for hypotension (empagliflozin 372 (7.1%) placebo  313  (6.0%))  and  urinary  tract  infections  (empagliflozin  314  (6.0%)  placebo  259  (5.0%)). Hypotension is a known side-effect for SGLT2i treatment and can be related to other symptoms, such as syncope and fall, discussed below. Urinary tract infections are also known side effects of SGLT2i treatment.

## AEs by worst intensity

Adverse events were primarily of mild or moderate intensity (Table 26). The frequencies of patients with severe AEs were similar between treatment groups. On the PT level, proportions of patients with AEs of

<div style=\"page-break-after: always\"></div>

severe intensity with a frequency ≥1.0% in at least one treatment g roup were also similar between groups and are summarised in the table below

Table 26. Patients with AEs by worst intensity and the most frequent severe AEs (frequency &gt;1.0% in at least one treatment group at the PT level) in SAF-HF1 - TS

|                                           | Placebo N (%)   | Empa 10 mg N (%)   |
|-------------------------------------------|-----------------|--------------------|
| Number of patients                        | 5202 (100.0)    | 5206 (100.0)       |
| Patients with any AEs                     |                 |                    |
| Mild                                      | 1167 (22.4)     | 1243 (23.9)        |
| Moderate                                  | 1689 (32.5)     | 1656 (31.8)        |
| Severe                                    | 1378 (26.5)     | 1265 (24.3)        |
| Patients with severe AEs                  |                 |                    |
| MedDRA SOC                                |                 |                    |
| Cardiac disorders                         | 692 (13.3)      | 561 (10.8)         |
| Cardiac failure                           | 398 (7.7)       | 293 (5.6)          |
| Infections and infestations               | 248 (4.8)       | 271 (5.2)          |
| Pneumonia                                 | 90 (1.7)        | 76 (1.5)           |
| General disorders and administration site | 138 (2.7)       | 144 (2.8)          |
| Death 1                                   | 65 (1.2)        | 76 (1.5)           |
| Renal and urinary disorders               | 147 (2.8)       | 121 (2.3)          |
| Acute kidney injury                       | 69 (1.3)        | 49 (0.9)           |

1 Deaths not attributed to another PT by the investigator. The frequencies of patients with fatal AEs were balanced between treatment. Source data: [SCS appendix 2, c35146126, Table 2.1.1.4]

The number of AEs with worst intensity were not more frequent during empagliflozin treatment compared to placebo.

## Adverse events of special interest (AESIs) and specific AEs

The safety analyses were also focused on AESIs and specific AEs that represent specific medical concepts of interest with all relevant PTs analysed together.

In SAF-HF1, the overall frequencies of patients with acute renal failure, ketoacidosis, AEs leading to LLA, confirmed  hypoglycaemic  events,  bone  fractures,  and  urinary  tract  malignancies  were  similar  in  the empagliflozin group and in the placebo group (Table 27). Urinary tract infections, genital infections, and volume depletion, including hypotension, were more common in the empagliflozin group than in the placebo group. Fewer patients in the empagliflozin group had hepatic injury events. The frequencies of patients with AEs leading to treatment discontinuation were below 1% in any category of AESIs or specific AEs except for acute renal failure (which was balanced between groups).

Table 27. Overall summary of AESIs and specific AEs in SAF-HF1 - TS

| Category of AESIs and specific AEs   | Placebo N (%)   |          | Empa 10 mg   |          |
|--------------------------------------|-----------------|----------|--------------|----------|
|                                      |                 | Rate/100 | N (%)        | Rate/100 |
| Number of patients                   | 5202 (100.0)    |          | 5206 (100.0) |          |
| Acute renal failure (narrow SMQ)     | 587 (11.3)      | 7.82     | 547 (10.5)   | 7.27     |
| Serious                              | 262 (5.0)       | 3.36     | 184 (3.5)    | 2.33     |

<div style=\"page-break-after: always\"></div>

| Leading to discontinuation                                            | 61 (1.2)       |   0.77 | 54 (1.0)       |   0.68 |
|-----------------------------------------------------------------------|----------------|--------|----------------|--------|
| Hepatic injury (narrow SMQs)                                          | 248 (4.8)      |   3.2  | 197 (3.8)      |   2.51 |
| Serious                                                               | 60 (1.2)       |   0.76 | 46 (0.9)       |   0.58 |
| Leading to discontinuation                                            | 12 (0.2)       |   0.15 | 10 (0.2)       |   0.12 |
| Up to 30 days after treatment discontinuation                         | 256 (4.9)      |   3.2  | 205 (3.9)      |   2.53 |
| Ketoacidosis (broad BIcMQ)                                            | 77 (1.5)       |   0.97 | 63 (1.2)       |   0.79 |
| Ketoacidosis (narrow BIcMQ)                                           | 6 (0.1)        |   0.08 | 4 (0.1)        |   0.05 |
| AEs leading to LLA up to trial completion (investigator-defined) 1, 2 | 33/4852 (0.7)  |   0.37 | 29/4859 (0.6)  |   0.32 |
| Urinary tract infection (BIcMQ)                                       | 335 (6.4)      |   4.37 | 402 (7.7)      |   5.27 |
| Complicated                                                           | 62 (1.2)       |   0.78 | 78 (1.5)       |   0.98 |
| Leading to discontinuation                                            | 21 (0.4)       |   0.26 | 34 (0.7)       |   0.42 |
| Genital infection (BIcMQ)                                             | 35 (0.7)       |   0.44 | 101 (1.9)      |   1.28 |
| Complicated                                                           | 14 (0.3)       |   0.18 | 14 (0.3)       |   0.18 |
| Leading to discontinuation                                            | 2 (<0.1)       |   0.03 | 15 (0.3)       |   0.19 |
| Volume depletion (narrow BIcMQ)                                       | 483 (9.3)      |   6.44 | 566 (10.9)     |   7.59 |
| Hypotension (BIcMQ, subset of vol. depl.)                             | 430 (8.3)      |   5.69 | 499 (9.6)      |   6.64 |
| Serious                                                               | 77 (1.5)       |   0.97 | 101 (1.9)      |   1.27 |
| Leading to discontinuation                                            | 15 (0.3)       |   0.19 | 25 (0.5)       |   0.31 |
| Symptomatic hypotension (investigator-defined) 2, 3                   | 262/5166 (5.1) |   3.4  | 309/5171 (6.0) |   4.02 |
| Confirmed hypoglycaemic events 4                                      | 108 (2.1)      |   1.38 | 101 (1.9)      |   1.28 |
| In patients with T1DM 2                                               | 1/5 (20.0)     |  18.81 | 2/5 (40.0)     |  24.29 |
| In patients with T2DM 2                                               | 89/2574 (3.5)  |   2.33 | 82/2565 (3.2)  |   2.15 |
| In patients with pre-diabetes 2                                       | 12/1708 (0.7)  |   0.46 | 10/1729 (0.6)  |   0.38 |
| In patients without diabetes or pre-diabetes 2                        | 6/912 (0.7)    |   0.43 | 7/904 (0.8)    |   0.5  |
| Bone fracture (BIcMQ)                                                 | 171 (3.3)      |   2.2  | 182 (3.5)      |   2.32 |
| Serious                                                               | 82 (1.6)       |   1.04 | 91 (1.7)       |   1.15 |
| Leading to discontinuation                                            | 3 (0.1)        |   0.04 | 6 (0.1)        |   0.07 |
| Up to trial completion                                                | 196 (3.8)      |   2.2  | 212 (4.1)      |   2.38 |
| Urinary tract malignancy up to trial completion                       | 22 (0.4)       |   0.24 | 28 (0.5)       |   0.31 |
| (BIcMQ) Patients with ≥6 months of exposure only 2                    | 14/4302 (0.3)  |   0.23 | 18/4343 (0.4)  |   0.29 |

SMQ, standardised MedDRA query; BIcMQ, Boehringer Ingelheim customised MedDRA query

1 Data collected only in 1245.110 and 1245.121

2 Patients with events/patients in subgroup (%)

3 Data collected only in 1245.110, 1245.121, 1245.167, 1245.168

4 Hypoglycaemic AEs with a plasma glucose value of ≤70 mg/dL or where assistance was required

Source data: [SCS appendix 2, c35146126, Tables 2.1.1.10, 2.2.1.5, 2.2.1.6, 2.2.2.4, 2.2.2.5, 2.2.2.6, 2.2.4.3, 2.2.5.5, 2.2.5.6, 2.2.7.5, 2.2.7.6, 2.2.9.1,

2.2.9.7, 2.2.9.8, 2.2.10.14, 2.2.11.5, 2.2.11.6, 2.2.11.7, 2.2.12.2, 2.2.12.3]

## Decreased renal function

The frequencies of patients with acute renal failure (narrow SMQ) were similar in the empagliflozin group and  in  the  placebo  group;  see  Table  28.  The  most  frequently  reported  PT  within  the  SMQ  was  renal impairment. Of note, the PT acute kidney injury was reported for a lower proportion of patients in the empagliflozin group than in the placebo group.

<div style=\"page-break-after: always\"></div>

The frequency of patients with SAEs of acute renal failure was also lower in the empagliflozin group than in the placebo group. Adverse events leading to discontinuation of study medication were reported with similar frequencies in the empagliflozin group and in the placebo group.

Table 28. Patients with acute renal failure (SMQ) in SAF-HF1 - TS

| MedDRA PT                               | Placebo N (%)   | Rate/100 yrs   | Empa 10 mg N (%)   | Rate/100 yrs   | pt-   |
|-----------------------------------------|-----------------|----------------|--------------------|----------------|-------|
| Number of patients                      | 5202 (100.0)    |                | 5206 (100.0)       |                |       |
| Acute renal failure (narrow SMQ)        | 587 (11.3)      | 7.82           | 547 (10.5)         | 7.27           |       |
| Renal impairment                        | 312 (6.0)       | 4.05           | 320 (6.1)          | 4.15           |       |
| Acute kidney injury                     | 166 (3.2)       | 2.11           | 118 (2.3)          | 1.49           |       |
| Renal failure                           | 141 (2.7)       | 1.80           | 131 (2.5)          | 1.66           |       |
| Azotaemia                               | 4 (0.1)         | 0.05           | 0                  | 0              |       |
| Nephropathy toxic                       | 3 (0.1)         | 0.04           | 0                  | 0              |       |
| Oliguria                                | 3 (0.1)         | 0.04           | 2 (<0.1)           | 0.02           |       |
| Anuria                                  | 1 (<0.1)        | 0.01           | 0                  | 0              |       |
| Prerenal failure                        | 1 (<0.1)        | 0.01           | 1 (<0.1)           | 0.01           |       |
| Serious                                 | 262 (5.0)       | 3.36           | 184 (3.5)          | 2.33           |       |
| Leading to discont. of study medication | 61 (1.2)        | 0.77           | 54 (1.0)           | 0.68           |       |

Source data: [SCS appendix 2, c35146126, Tables 2.2.1.4 to 6]

Subgroup analyses were performed by age, sex, race, and baseline eGFR, diabetes status, and use of certain medications (i.e. ACE-inhibitors/ARB/ARNi, diuretics, loop/high-ceiling diuretics).

Investigator-defined decreased renal function (reported as AESI) was reported for 2.7% of patients (133 of 4894) in the empagliflozin group and 4.0% of patients (197 of 4888) in the placebo group.

In the analysis of safety laboratory parameters, the frequencies of patients with serum creatinine ≥2x the baseline value and above the normal range were 1.7% in the empagliflozin group and 2.1% in the placebo group.

## Hepatic injury

The frequency of patients with hepatic injury (narrow SMQs) was lower in the empagliflozin group than in the placebo group (Table 29). The most frequent PTs were liver injury, hepatic function abnormal, and hepatic steatosis. All other PTs were reported for ≤0.2% of pat ients in either treatment group.

Similar frequencies between groups or lower frequencies in the empagliflozin group than in the placebo group were observed for serious hepatic injury, for events leading to discontinuation of study medication, and  for  all  hepatic  injury  events  when  considering  a  longer  period  of  up  to  30 days  after  treatment discontinuation. Patients with diabetes and patients without diabetes showed the same trend as the overall population.

Table 29. Patients with hepatic injury (SMQ; frequency ≥0.2% in at least one treatment group at the PT level) in SAF-HF1 - TS

| MedDRA PT          | Placebo      |          | Empa 10 mg   | pt-yrs   |
|--------------------|--------------|----------|--------------|----------|
|                    | N (%)        | Rate/100 | N (%)        | Rate/100 |
|                    |              | pt-yrs   |              |          |
| Number of patients | 5202 (100.0) |          | 5206 (100.0) |          |

<div style=\"page-break-after: always\"></div>

| Hepatic injury (narrow SMQs)                                               | 248 (4.8)      |   3.20 | 197 (3.8)      |   2.51 |
|----------------------------------------------------------------------------|----------------|--------|----------------|--------|
| Liver injury                                                               | 28 (0.5)       |   0.35 | 19 (0.4)       |   0.24 |
| Hepatic function abnormal                                                  | 26 (0.5)       |   0.33 | 24 (0.5)       |   0.3  |
| Hepatic steatosis                                                          | 24 (0.5)       |   0.3  | 17 (0.3)       |   0.21 |
| Liver disorder                                                             | 11 (0.2)       |   0.14 | 7 (0.1)        |   0.09 |
| Hepatomegaly                                                               | 9 (0.2)        |   0.11 | 6 (0.1)        |   0.07 |
| Hepatic cirrhosis                                                          | 7 (0.1)        |   0.09 | 8 (0.2)        |   0.1  |
| Hyperbilirubinaemia                                                        | 6 (0.1)        |   0.08 | 9 (0.2)        |   0.11 |
| Congestive hepatopathy                                                     | 4 (0.1)        |   0.05 | 9 (0.2)        |   0.11 |
| Hepatic injury (narrow SMQs), serious                                      | 60 (1.2)       |   0.76 | 46 (0.9)       |   0.58 |
| Hepatic injury (narrow SMQs) leading to discont. of study medication       | 12 (0.2)       |   0.15 | 10 (0.2)       |   0.12 |
| Hepatic injury (narrow SMQs) up to 30 days after treatment discontinuation | 256 (4.9)      |   3.2  | 205 (3.9)      |   2.53 |
| With diabetes                                                              | 137/2579 (5.3) |   3.61 | 113/2570 (4.4) |   2.95 |
| Without diabetes                                                           | 111/2620 (4.2) |   2.81 | 84/2633 (3.2)  |   2.1  |

For subgroups, patients in subgroup with events/all patients in subgroup (%) are shown.

Source data: [SCS appendix 2, c35146126, Tables 2.2.2.3 to 7]

The frequencies of patients with elevated liver enzyme values were balanced between treatment groups ( Table 30. ).

Table 30. Patients with elevated liver enzyme values, up to 30 days after treatment discontinuation in SAF-HF1 - TS

| Elevated liver enzymes criteria   | Placebo N (%)   | Empa 10 mg N (%)   |
|-----------------------------------|-----------------|--------------------|
| Number of patients                | 5202 (100.0)    | 5206 (100.0)       |
| ALT and/or AST ≥3x ULN            | 89 (1.7)        | 74 (1.4)           |
| ≥5x ULN                           | 34 (0.7)        | 30 (0.6)           |
| ≥10x ULN                          | 13 (0.2)        | 5 (0.1)            |
| ≥20x ULN                          | 2 (<0.1)        | 2 (<0.1)           |
| With total bilirubin ≥2x ULN 1    | 5 (0.1)         | 4 (0.1)            |
| Alkaline phosphatase <2x ULN 2    | 2 (<0.1)        | 4 (0.1)            |
| Alkaline phosphatase ≥2x ULN 2    | 3 (0.1)         | 0                  |

1 Total bilirubin elevation within 30 days after ALT and/or AST elevation

2 Maximum alkaline phosphatase value within 30 days after ALT and/or AST elevation

Source data: [SCS appendix 2, c35146126, Table 2.3.1.2]

Hepatic events (occurring up to 30 days after treatment discontinuation) were adjudicated; adjudication results  with  patient  details  are  summarised  in  the  CTRs.  No  hepatic  events  that  met  the  criteria  for adjudication were reported in trials 1245.168 and 1245.148.

## Ketoacidosis

For a comprehensive analysis, ketoacidosis was investigated using both broad and narrow BIcMQs. Based on  the  broad  BIcMQ,  events  suggestive  of  ketoacidosis  were  reported  for  63 patients  (1.2%)  in  the empagliflozin group and for 77 patients (1.5%) in the placebo group; see Table 31. . Metabolic acidosis was  the  most  frequent  PT  of  the  broad  BIcMQ;  there  was  no  relevant  increase  in  frequency  with empagliflozin treatment.

<div style=\"page-break-after: always\"></div>

All  events  in  the  broad  BIcMQ  were  adjudicated  (except  for  the  PTs  'abnormal  blood  bicarbonate'  and 'decreased blood bicarbonate' in trial 1245.110, which were added to the broad BIcMQ as part of a MedDRA update while the trial was ongoing). One patient in each group had an event which was adjudicated as certain ketoacidosis by the independent CEC (both patients had T2DM at baseline). The event was of mild severity  in  the  patient  treated  with  empagliflozin  and  of  moderate  severity  in  the  patient  treated  with placebo.

The narrow BIcMQ ketoacidosis included 4 patients (0.1%) in the empagliflozin group and 6 patients (0.1%) in the placebo group. Subgroups (by diabetes status and sex) and ketoacidosis leading to discontinuation of study medication were analysed based on the narrow BIcMQ ( Table 31. )

Table 31. Patients with ketoacidosis (BIcMQ; frequency ≥0.1% in at least one treatment group at the PT level) in SAF-HF1 - TS

| MedDRA PT                           | Placebo N (%)   | Rate/100 yrs   | Empa 10 mg N (%)   | Rate/100 pt- yrs   |
|-------------------------------------|-----------------|----------------|--------------------|--------------------|
| Number of patients                  | 5202 (100.0)    |                | 5206 (100.0)       |                    |
| Ketoacidosis (broad BIcMQ)          | 77 (1.5)        | 0.97           | 63 (1.2)           | 0.79               |
| Metabolic acidosis                  | 23 (0.4)        | 0.29           | 24 (0.5)           | 0.30               |
| Diabetic metabolic decompensation   | 25 (0.5)        | 0.31           | 13 (0.2)           | 0.16               |
| Blood bicarbonate decreased         | 19 (0.4)        | 0.24           | 18 (0.3)           | 0.23               |
| Ketoacidosis                        | 3 (0.1)         | 0.04           | 1 (<0.1)           | 0.01               |
| Ketosis                             | 3 (0.1)         | 0.04           | 0                  | 0                  |
| Diabetic ketoacidosis               | 2 (<0.1)        | 0.03           | 3 (0.1)            | 0.04               |
| Ketoacidosis (broad BIcMQ), serious | 47 (0.9)        | 0.59           | 29 (0.6)           | 0.36               |
| Ketoacidosis (narrow BIcMQ)         | 6 (0.1)         | 0.08           | 4 (0.1)            | 0.05               |
| With T2DM                           | 5/2574 (0.2)    | 0.13           | 4/2565 (0.2)       | 0.10               |
| With pre-diabetes                   | 1/1708 (0.1)    | 0.04           | 0/1729             | 0                  |

For subgroups, patients in subgroup with events/all patients in subgroup (%) are shown. There were no patients with events in the 'T1DM' and 'Without diabetes or pre-diabetes' categories.

Source data: [SCS appendix 2, c35146126, Tables 2.2.3.4 to 6, 2.2.3.9]

## AEs leading to lower limb amputation (LLA)

These events were only analysed for trials with a duration of longer than 12 weeks (i.e. 1245.110 and 1245.121). The frequencies of patients with investigator-defined AEs leading to LLA up to trial completion were similar in the empagliflozin group (29 patients, 0.6%) and in the placebo group (33 patients, 0.7%); see Table 27. . Amputations were mostly minor (e.g. toe[s]) rather than major (empagliflozin: 8 patients [0.2%], placebo: 7 patients [0.1%]; e.g. above the knee). Most common reasons for the first LLA were untreatable/necrotising infection and ischaemic reasons.

Investigator-defined AEs leading to LLA (reported as AESIs during the on-treatment period) were reported for 21 patients (0.4%) in the empagliflozin group and 23 patients (0.5%) in the placebo group.

Subgroups  were  analysed  by  baseline  eGFR,  diabetes  status,  presence  of  a  previous  amputation,  and history of peripheral arterial occlusive disease. The results were consistent with the main analysis of AEs leading to LLA.

<div style=\"page-break-after: always\"></div>

## Urinary tract infection

The frequency of patients with urinary tract infection (narrow sub BIcMQ) was higher in the empagliflozin group than in the placebo group ( Table 32. ). The most frequently reported PT was urinary tract infection, which was mainly driving the difference between groups. Other PTs were reported with similar and/or low (≤0.2%) frequencies in both treatment groups.

A similar trend as for urinary tract infection (narrow BIcMQ) was observed for the frequencies of patients with complicated urinary tract infections and patients with urinary tract infections leading to treatment discontinuation ( Table 32. ).

Table 32. Patients with urinary tract infection (BIcMQ; frequency ≥0.1% in at least one treatment group at the PT level) in SAF-HF1 - TS

| MedDRA PT                               | Placebo N (%)   | Rate/100 pt-yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|-----------------------------------------|-----------------|-------------------|--------------------|-------------------|
| Number of patients                      | 5202 (100.0)    |                   | 5206 (100.0)       |                   |
| Urinary tract infection (narrow BIcMQ)  | 335 (6.4)       | 4.37              | 402 (7.7)          | 5.27              |
| Urinary tract infection                 | 259 (5.0)       | 3.35              | 314 (6.0)          | 4.07              |
| Cystitis                                | 61 (1.2)        | 0.77              | 51 (1.0)           | 0.64              |
| Urosepsis                               | 12 (0.2)        | 0.15              | 17 (0.3)           | 0.21              |
| Escherichia urinary tract               | 4 (0.1)         | 0.05              | 8 (0.2)            | 0.10              |
| Urethritis                              | 4 (0.1)         | 0.05              | 8 (0.2)            | 0.10              |
| Pyelonephritis                          | 3 (0.1)         | 0.04              | 7 (0.1)            | 0.09              |
| Pyelonephritis acute                    | 5 (0.1)         | 0.06              | 7 (0.1)            | 0.09              |
| Urinary tract infection bacterial       | 3 (0.1)         | 0.04              | 7 (0.1)            | 0.09              |
| Asymptomatic bacteriuria                | 6 (0.1)         | 0.08              | 5 (0.1)            | 0.06              |
| Complicated                             | 62 (1.2)        | 0.78              | 78 (1.5)           | 0.98              |
| Leading to discont. of study medication | 21 (0.4)        | 0.26              | 34 (0.7)           | 0.42              |

Source data: [SCS appendix 2, c35146126, Tables 2.2.5.4 to 6]

Subgroup analyses were performed by age, sex, race, and baseline eGFR, diabetes status, and history of chronic or recurrent urinary tract infection. The results of the subgroup analyses were generally similar to the main analyses of urinary tract infections.

Investigator-defined urinary tract infections (including urosepsis and acute pyelonephritis) were reported for 403 patients (7.7%) in the empagliflozin group and 338 patients (6.5%) in the placebo group. Urinary tract  infections  were  predominantly  infections  of  the  lower  urinary  tract  (bladder  and  below)  or asymptomatic bacteriuria. Most patients in both treatment groups had a single episode rather than multiple episodes of urinary tract infection.

The trend observed in the analysis, including the PT urosepsis and pyelonephritis based on the narrow sub BIcMQ (empagliflozin: 30 patients [0.6%], placebo: 21 patients [0.4%]; Table 33. ) was similar to what was observed for urinary tract infection (narrow BIcMQ; presented above). Subgroup analyses by sex and diabetes status were performed for the PT urosepsis and pyelonephritis (narrow sub BIcMQ). The results showed an imbalance in female patients with urosepsis or pyelonephritis, with a higher frequency in the empagliflozin group than in the placebo group, and that events occurred in both patients with diabetes and patients without diabetes ( Table 33. ).

Table 33. Patients with acute pyelonephritis or urosepsis in SAF-HF1 - TS

| MedDRA PT   | Placebo   | Empa 10 mg   |
|-------------|-----------|--------------|

<div style=\"page-break-after: always\"></div>

|                                                     | N (%)         | Rate/100 yrs   | pt-   | N (%)         | Rate/100 yrs   | pt-   |
|-----------------------------------------------------|---------------|----------------|-------|---------------|----------------|-------|
| Number of patients                                  | 5202 (100.0)  |                |       | 5206 (100.0)  |                |       |
| Urosepsis (PT) or pyelonephritis (narrow sub BIcMQ) | 21 (0.4)      | 0.26           |       | 30 (0.6)      | 0.38           |       |
| Urosepsis                                           | 12 (0.2)      | 0.15           |       | 17 (0.3)      | 0.21           |       |
| Pyelonephritis                                      | 3 (0.1)       | 0.04           |       | 7 (0.1)       | 0.09           |       |
| Pyelonephritis acute                                | 5 (0.1)       | 0.06           |       | 7 (0.1)       | 0.09           |       |
| Pyelitis                                            | 2 (<0.1)      | 0.03           |       | 0             | 0              |       |
| Kidney infection                                    | 0             | 0              |       | 2 (<0.1)      | 0.02           |       |
| Male                                                | 15/3287 (0.5) | 0.31           |       | 10/3311 (0.3) | 0.20           |       |
| Female                                              | 6/1915 (0.3)  | 0.20           |       | 20/1895 (1.1) | 0.65           |       |
| With diabetes                                       | 13/2579 (0.5) | 0.33           |       | 15/2570 (0.6) | 0.38           |       |
| Without diabetes                                    | 8/2620 (0.3)  | 0.20           |       | 15/2633 (0.6) | 0.37           |       |

For subgroups, patients in subgroup with events/all patients in subgroup (%) are shown.

Source data: [SCS appendix 2, c35146126, Tables 2.2.6.1 to 3]

Events of investigator-defined sepsis with source urinary tract infection or non-urinary tract infection were collected only in trials 1245.110, 1245.121, and 1245.148. Sepsis with an origin other than urinary tract infections (investigator-defined) was reported for 76 patients (1.6%) in the empagliflozin group and for 56 patients (1.1%) in the placebo group. The two EMPEROR trials contributed differently to the analysis of the pooled safety data (see below). No events were reported in trial 1245.148.

In trial 1245.121, sepsis with an origin other than urinary tract infections (investigator-defined, including those with missing origin) was reported for 28 patients (1.5%) in the empagliflozin group and for 14 patients (0.8%) in the placebo group. The difference in frequency could not be attributed to specific PTs. All cases were medically reviewed, and no clear pattern regarding the source of non-urinary tract infection sepsis could be observed. In trial 1245.110, the frequencies of patients with sepsis with an origin other than urinary  tract  infections  (investigator-defined)  were  balanced  between  treatment  groups  (empagliflozin: 48 patients [1.6%], placebo: 43 patients [1.4%]).

## Genital infection

Genital infections (based on narrow BIcMQ) were reported for more patients in the empagliflozin group than in the placebo group (Table 34. ). The most frequent PTs in the empagliflozin group were vulvovaginal mycotic  and  vulvovaginal  candidiasis.  Genital  infections  leading  to  treatment  discontinuation  were infrequent, although they showed the same trend. No difference between treatment groups was observed in the frequencies of patients with complicated genital infections (Table 34. ).

Table 34. Patients with genital infection (BIcMQ; frequency ≥0.2% in at least one treatment grou p at the PT level) in SAF-HF1 - TS

| MedDRA PT                        | Placebo N (%)   | Rate/100 pt-yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|----------------------------------|-----------------|-------------------|--------------------|-------------------|
| Number of patients               | 5202 (100.0)    |                   | 5206 (100.0)       |                   |
| Genital infection (narrow BIcMQ) | 35 (0.7)        | 0.44              | 101 (1.9)          | 1.28              |
| Vulvovaginal mycotic             | 4 (0.1)         | 0.05              | 15 (0.3)           | 0.19              |

<div style=\"page-break-after: always\"></div>

| Vulvovaginal candidiasis                | 7 (0.1)   |   0.09 | 14 (0.3)   |   0.18 |
|-----------------------------------------|-----------|--------|------------|--------|
| Genital infection fungal                | 0         |   0    | 11 (0.2)   |   0.14 |
| Fungal balanitis                        | 0         |   0    | 10 (0.2)   |   0.13 |
| Balanoposthitis                         | 0         |   0    | 9 (0.2)    |   0.11 |
| Complicated                             | 14 (0.3)  |   0.18 | 14 (0.3)   |   0.18 |
| Leading to discont. of study medication | 2 (<0.1)  |   0.03 | 15 (0.3)   |   0.19 |

Source data: [SCS appendix 2, c35146126, Tables 2.2.7.4 to 6]

Subgroup analyses were performed by age, sex, race, and baseline eGFR, diabetes status, and history of chronic or recurrent genital infection. The results of the subgroup analyses were consistent with the main analysis, showing higher frequencies in the empagliflozin group than in the placebo group ( Table 35. ).

Table 35. Patients with genital infection (BIcMQ) in subgroups in SAF-HF1 (by sex and diabetes status) TS

| Subgroup         | Placebo n/N (%)   |   Rate/100 pt-yrs | Empa 10 mg n/N (%)   |   Rate/100 pt-yrs |
|------------------|-------------------|-------------------|----------------------|-------------------|
| All patients     | 35/5202 (0.7)     |              0.44 | 101/5206 (1.9)       |              1.28 |
| Male             | 15/3287 (0.5)     |              0.31 | 53/3311 (1.6)        |              1.09 |
| Female           | 20/1915 (1.0)     |              0.66 | 48/1895 (2.5)        |              1.59 |
| With diabetes    | 19/2579 (0.7)     |              0.49 | 57/2570 (2.2)        |              1.48 |
| Without diabetes | 16/2620 (0.6)     |              0.4  | 44/2633 (1.7)        |              1.09 |

N, all patients in subgroup; n, patients in subgroup with analysed AE category

Source data: [SCS appendix 2, c35146126, Tables 2.2.7.4, 2.2.7.8, 2.2.7.11]

Investigator-defined genital infections were reported for 115 patients (2.2%) in the empagliflozin group and 32 patients (0.6%) in the placebo group. Most patients with genital infections had a single episode rather than multiple episodes.

## Volume depletion and hypotension

The frequency of patients with volume depletion (narrow BIcMQ), including hypotension (BIcMQ, subset of volume depletion), was higher in the empagliflozin group than in the placebo group ( Table 36. ). The most frequently reported PT was hypotension, which was also analysed separately as BIcMQ. Hypotension based on the BIcMQ was reported for 499 patients (9.6%) in the empagliflozin group and for 430 patients (8.3%) in the placebo group. In the BIcMQ analysis, there was no other PT which predominantly accounted for the difference in frequencies. The same trend as in the analysis of all events was observed in the analysis of volume depletion (narrow BIcMQ) or hypotension (BIcMQ) leading to treatment discontinuation (which were infrequent) and in the analysis of serious volume depletion (narrow BIcMQ) or serious hypotension (BIcMQ; Table 36. ).

Table 36. Patients with volume depletion (narrow BIcMQ) and hypotension (BIcMQ) in SAF-HF1 (frequency ≥0.2% in at least one treatment group at the PT level) - TS

| MedDRA PT                                     | Placebo      | Placebo         | Empa 10 mg   | Empa 10 mg       |
|-----------------------------------------------|--------------|-----------------|--------------|------------------|
|                                               | N (%)        | Rate/100 pt-yrs | N (%)        | Rate/100 pt- yrs |
| Number of patients                            | 5202 (100.0) | 5202 (100.0)    | 5206 (100.0) | 5206 (100.0)     |
| Volume depletion (narrow BIcMQ)               | 483 (9.3)    | 6.44            | 566 (10.9)   | 7.59             |
| Dehydration                                   | 71 (1.4)     | 0.90            | 87 (1.7)     | 1.10             |
| Hypovolaemia                                  | 8 (0.2)      | 0.10            | 6 (0.1)      | 0.07             |
| Hypotension (BIcMQ, subset of vol. depletion) | 430 (8.3)    | 5.69            | 499 (9.6)    | 6.64             |

<div style=\"page-break-after: always\"></div>

| Hypotension                                                                              | 313 (6.0)   |   4.09 | 372 (7.1)   |   4.87 |
|------------------------------------------------------------------------------------------|-------------|--------|-------------|--------|
| Orthostatic hypotension                                                                  | 32 (0.6)    |   0.4  | 37 (0.7)    |   0.46 |
| Circulatory collapse                                                                     | 10 (0.2)    |   0.13 | 3 (0.1)     |   0.04 |
| Syncope                                                                                  | 81 (1.6)    |   1.03 | 98 (1.9)    |   1.24 |
| Presyncope                                                                               | 13 (0.2)    |   0.16 | 22 (0.4)    |   0.28 |
| Volume depletion (narrow BIcMQ), serious                                                 | 91 (1.7)    |   1.15 | 113 (2.2)   |   1.43 |
| Hypotension (BIcMQ), serious                                                             | 77 (1.5)    |   0.97 | 101 (1.9)   |   1.27 |
| Volume depletion (narrow BIcMQ) leading to                                               | 17 (0.3)    |   0.21 | 30 (0.6)    |   0.37 |
| discont. of study medication Hypotension (BIcMQ) leading to discont. of study medication | 15 (0.3)    |   0.19 | 25 (0.5)    |   0.31 |

Source data: [SCS appendix 2, c35146126, Tables 2.2.8.2 to 4, 2.2.9.6 to 8]

Subgroup analyses for hypotension (BIcMQ) were performed by age, sex, race, baseline eGFR, diabetes status, blood pressure, and use of certain medications. The results of the subgroup analyses were consistent with the main analysis of hypotension.

The results of the subgroup analyses for volume depletion (narrow BIcMQ; by age, sex, race, baseline eGFR, diabetes status, blood pressure, and use of certain medications) were consistent with the results of the main analysis of volume depletion and with those for hypotension.

The analysis of clinically relevant investigator-defined symptomatic hypotension events ( Table 37. ) showed the same trend as the analysis of hypotension (BIcMQ) presented above.

Table 37. Patients with investigator-defined symptomatic hypotension events in SAF-HF1 - TS

|                                                | Placebo N (%)   | Rate/100 pt-yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|------------------------------------------------|-----------------|-------------------|--------------------|-------------------|
| Number of patients                             | 5166 (100.0)    |                   | 5171 (100.0)       |                   |
| Patients with investigator-defined symptomatic | 262 (5.1)       | 3.40              | 309 (6.0)          | 4.02              |
| hypotension events                             |                 |                   |                    |                   |
| Serious events                                 | 43 (0.8)        | 0.54              | 49 (0.9)           | 0.62              |
| Leading to discontinuation                     | 12 (0.2)        | 0.15              | 17 (0.3)           | 0.21              |

Investigator-defined symptomatic hypotension events were only collected for 1245.110, 1245.121, 1245.167, and 1245.168

Source data: [SCS appendix 2, c35146126, Tables 2.2.9.1, 2.2.9.3, 2.2.9.4]

In  cases  of  symptomatic  hypotension  episodes,  the  intensity  of  both  diuretic  and  non-diuretic  antihypertensive therapy was more often reduced in the empagliflozin group than in the placebo group ( Table 38. ).

Table 38. Investigator-defined symptomatic hypotension episodes in SAF-HF1 - TS

|                                                             | Placebo    | Empa 10 mg   |
|-------------------------------------------------------------|------------|--------------|
| Number of patients, N                                       | 5166       | 5171         |
| Number of episodes (episodes per 100 patient years at risk) | 300 (3.77) | 364 (4.55)   |
| Intensity of diuretic therapy reduced                       | 104 (1.31) | 158 (1.98)   |
| Intensity of non-diuretic anti-hypertensive therapy reduced | 170 (2.14) | 221 (2.76)   |

<div style=\"page-break-after: always\"></div>

Investigator-defined symptomatic hypotension events were only collected for 1245.110, 1245.121, 1245.167, and 1245.168 Source data: [SCS appendix 2, c35146126, Table 2.2.9.5]

## Hypoglycaemia

The frequencies of patients with confirmed hypoglycaemic events were balanced between treatment groups ( Table 27. ). No imbalance in confirmed hypoglycaemic events was observed in the subgroup analysis by diabetes status. The remaining subgroup analyses (i.e. by age, sex, race, and baseline eGFR) also showed no relevant difference between treatment groups.

Consistent results were obtained for the SMQ-based analysis: 124 patients (2.4%) in the empagliflozin group and 134 patients (2.6%) in the placebo group had hypoglycaemic events based on the narrow SMQ.

Investigator-defined  hypoglycaemic events were reported for 122 patients (2.3%) in the empagliflozin group and 132 patients (2.5%) in the placebo group. Of those patients, similar proportions in both groups had  hypoglycaemic  events  that  required  assistance  (empagliflozin:  30 patients  [0.6%],  placebo:  28 patients [0.5%]). Most patients had 1 or 2 confirmed hypoglycaemic episodes rather than ≥3 episodes). The  severity  of  hypoglycaemic  AEs  (investigator-defined)  was  summarised  by  diabetes  status.  The proportions of patients with severe hypoglycaemic events that required assistance were similar between treatment groups, and the events occurred predominantly in patients with T2DM (empagliflozin: 28 patients [1.1%], placebo: 26 patients [1.0%]) rather than in patients with pre-diabetes (empagliflozin: 1 patient [0.1%], placebo: 2 patients [0.1%]) or in patients without (pre-) diabetes (empagliflozin: 1 patient [0.1%], placebo: none).

Symptomatic hypoglycaemic episodes with a blood glucose level &lt;54 mg/dL and no assistance required were less frequently reported in the empagliflozin group (32 episodes, 0.40 episodes/100 pt-yrs) than in the  placebo  group  (128  episodes,  1.61 episodes/100  pt-yrs).  For  other  categories  of  symptomatic  or asymptomatic  hypoglycaemic  episodes,  there  was  no  marked  imbalance  in  the  frequencies  between treatment groups.

## Bone fracture

The frequencies of patients with bone fracture (BIcMQ) were similar between treatment groups ( Table 39. ).  No  relevant  difference  between  treatment  groups  was  observed  for  bone  fractures  leading  to discontinuation, or reported as SAEs, or when including the events up to trial completion ( Table 27. ). There were no relevant differences between treatment groups in subgroup analyses by age, sex, race, baseline eGFR, and diabetes status.

Investigator-defined bone fractures were reported for 179 patients (3.4%) in the empagliflozin group and for 171 patients (3.3%) in the placebo group. Bone fractures were more frequently classified as traumatic rather than as non-traumatic ( Table 39. ).

Table 39. Patients with investigator-defined bone fracture in SAF-HF1 - TS

|                                                  | Placebo N (%)   | Rate/100 yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|--------------------------------------------------|-----------------|----------------|--------------------|-------------------|
| Number of patients                               | 5202 (100.0)    |                | 5206 (100.0)       |                   |
| Patients with investigator-defined bone fracture | 171 (3.3)       | 2.19           | 179 (3.4)          | 2.28              |
| Traumatic                                        | 155 (3.0)       | 1.99           | 156 (3.0)          | 1.98              |
| Non-traumatic                                    | 15 (0.3)        | 0.19           | 26 (0.5)           | 0.33              |

<div style=\"page-break-after: always\"></div>

## Urinary tract malignancy

The frequencies of patients with urinary tract malignancies (broad sub BIcMQs) were similar between the empagliflozin group (18 patients, 0.4%) and the placebo group (14 patients, 0.3%; Table 27. ) in patients with a cumulative exposure of ≥6 months when events up to trial completion were considered. Consistent results were obtained for the overall population regardless of exposure (empagliflozin: 28 patients [0.5%], placebo: 22 patients [0.4%]; analysis also considered events up to trial completion; Table 27. ).

## Constipation

In SAF-HF1, the PT constipation was reported for more patients in the empagliflozin group (153 patients, 2.9%) than in the placebo group (107 patients, 2.1%). Few patients had serious events or events leading to treatment discontinuation ( Table 40. ). The trend was generally observed in both EMPEROR trials and across all subgroups, including by diabetes status.

Table 40. Patients with the PT constipation in SAF-HF1 and in trials 1245.110 and 1245.121 - TS

|                            | SAF-HF1         | SAF-HF1         | SAF-HF1      | SAF-HF1         | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   |
|----------------------------|-----------------|-----------------|--------------|-----------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                            | Placebo         | Placebo         | Empa 10 mg   | Empa 10 mg      | Placebo                              | Placebo                              | Empa 10 mg                           | Empa 10 mg                           | Placebo                            | Placebo                            | Empa 10 mg                         | Empa 10 mg                         |
|                            | N (%)           | Rate/100 pt-yrs | N (%)        | Rate/100 pt-yrs | N (%)                                | Rate/100 pt-yrs                      | N (%)                                | Rate/100 pt-yrs                      | N (%)                              | Rate/100 pt-yrs                    | N (%)                              | Rate/100 pt-yrs                    |
| Number patients            | of 5202 (100.0) |                 | 5206 (100.0) |                 | 2989 (100.0)                         |                                      | 2996 (100.0)                         |                                      | 1863 (100.0)                       |                                    | 1863 (100.0)                       |                                    |
| PT constipation            | 107 (2.1)       | 1.36            | 153 (2.9)    | 1.94            | 76 (2.5)                             | 1.37                                 | 93 (3.1)                             | 1.67                                 | 27 (1.4)                           | 1.21                               | 57 (3.1)                           | 2.56                               |
| Investigator defined drug- | 7 (0.1)         | 0.09            | 13 (0.2)     | 0.16            | 6 (0.2)                              | 0.11                                 | 8 (0.3)                              | 0.14                                 | 1 (0.1)                            | 0.04                               | 5 (0.3)                            | 0.22                               |
| Leading treatment discont. | to 1 (<0.1)0.01 |                 | 2 (<0.1)     | 0.02            | 1 (<0.1)                             | 0.02                                 | 0                                    |                                      | 0                                  |                                    | 2 (0.1)                            | 0.09                               |
| Serious                    | 2 (<0.1)0.03    |                 | 4 (0.1)      | 0.05            | 1 (<0.1)                             | 0.02                                 | 1 (<0.1)0.02                         |                                      | 1 (0.1)                            | 0.04                               | 3 (0.2)                            | 0.13                               |

Source data: [SCS appendix 2, c35146126, Tables 2.1.1.2, 5 to 7; CTR 1245.110, c31803238, Tables 15.3.1.1: 2, 5 to 7; CTR 1245.121, c28576542, Tables 15.3.1.1: 2, 5 to 7]

## Unexpected AEs

## Fall

Previously,  in  trial  1245.121  (EMPEROR-Reduced),  the  PT  fall  was  reported  for  more  patients  in  the empagliflozin group than in the placebo group. However, this imbalance was not observed in trial 1245.110 (EMPEROR-Preserved). When all 5 trials in patients with HF were pooled in SAF-HF1, the EMPEROR trials contributed almost all events of fall, and no obvious imbalance in fall was observed (Table 41. ).

<div style=\"page-break-after: always\"></div>

Table 41. Patients with the PT fall in SAFHF1 and in trials 1245.110 and 1245.121 - TS

|                      | SAF-HF1         | SAF-HF1          | SAF-HF1      | SAF-HF1          | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   |
|----------------------|-----------------|------------------|--------------|------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                      | Placebo         | Placebo          | Empa 10 mg   | Empa 10 mg       | Placebo                              | Placebo                              | Empa 10 mg                           | Empa 10 mg                           | Placebo                            | Placebo                            | Empa 10 mg                         | Empa 10 mg                         |
|                      | N (%)           | Rate/10 0 pt-yrs | N (%)        | Rate/10 0 pt-yrs | N (%)                                | Rate/10 0 pt-yrs                     | N (%)                                | Rate/10 0 pt-yrs                     | N (%)                              | Rate/10 0 pt-yrs                   | N (%)                              | Rate/10 0 pt-yrs                   |
| Number patients      | of 5202 (100.0) |                  | 5206 (100.0) |                  | 2989 (100.0)                         |                                      | 2996 (100.0)                         |                                      | 1863 (100.0)                       |                                    | 1863 (100.0)                       |                                    |
| PT fall              | 249 (4.8)       | 3.24             | 261 (5.0)    | 3.37             | 219 (7.3)                            | 4.08                                 | 213 (7.1)                            | 3.92                                 | 27 (1.4)                           | 1.21                               | 43 (2.3)                           | 1.92                               |
| Investigator defined | 4 (0.1)         | 0.05             | 3 (0.1)      | 0.04             | 3 (0.1)                              | 0.05                                 | 3 (0.1)                              | 0.05                                 | 1 (0.1)                            | 0.04                               | 0                                  |                                    |
| Leading              | to 3 (0.1)      | 0.04             | 3 (0.1)      | 0.04             | 2 (0.1)                              | 0.04                                 | 1 (<0.1)0.02                         | 1 (<0.1)0.02                         | 1 (0.1)                            | 0.04                               | 2 (0.1)                            | 0.09                               |
| Serious              | 35 (0.7)        | 0.44             | 47 (0.9)     | 0.59             | 30 (1.0)                             | 0.54                                 | 31 (1.0)                             | 0.55                                 | 4 (0.2)                            | 0.18                               | 15 (0.8)                           | 0.66                               |

Source data: [SCS appendix 2, c35146126, Tables 2.1.1.2, 5 to 7; CTR 1245.110, c31803238, Tables 15.3.1.1: 2, 5 to 7; CTR 1245.121, c28576542, Tables 15.3.1.1: 2, 5 to 7]

Considering the late divergence in falls between treatment groups (after about 8 months in trial 1245.121), the  lack  of  a  plausible  pathophysiological  cause  related  to  empagliflozin's  mode  of  action  (e.g.  via hypotension,  volume  depletion,  hypoglycaemia),  and  the  lack  of  consistency  between  the  clinical  trial results (of trials 1245.121 and 1245.25), the small numerical imbalance in the PT fall observed in trial 1245.121 was likely due to random variation associated with a large number of comparisons between treatment groups in the safety analyses.

No obvious pattern in the PT fall was observed in the subgroup analyses of the EMPEROR trials. Numerically more patients in the empagliflozin group than in the placebo group experienced fall in the Asian subgroup in both trials, while in the White and Black/African American subgroups of trial 1245.110, the trend was opposite with fewer patients in the empagliflozin group than in the placebo group ( Table 42. ).

Table 42. Subgroup analysis by race for the PT fall in trials 1245.110 and 1245.121 - TS

|                        | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   |
|------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                        | Placebo                              | Placebo                              | Empa 10 mg                           | Empa 10 mg                           | Placebo                            | Placebo                            | Empa 10 mg                         | Empa 10 mg                         |
|                        | n/N (%)                              | Rate/10 0 pt-yrs                     | n/N (%)                              | Rate/100 pt-yrs                      | n/N (%)                            | Rate/10 0 pt-yrs                   | n/N (%)                            | Rate/10 0 pt-yrs                   |
| All                    | 219/2989 (7.3)                       | 4.08                                 | 213/2996 (7.1)                       | 3.92                                 | 27/1863 (1.4)                      | 1.21                               | 43/1863 (2.3)                      | 1.92                               |
| White                  | 173/2254 (7.7)                       | 4.31                                 | 162/2285 (7.1)                       | 3.92                                 | 24/1301 (1.8)                      | 1.56                               | 33/1325 (2.5)                      | 2.11                               |
| Black/African American | 10/125 (8.0)                         | 4.85                                 | 7/133 (5.3)                          | 3.01                                 | 1/134 (0.7)                        | 0.64                               | 4/123 (3.3)                        | 2.71                               |
| Asian                  | 26/411 (6.3)                         | 3.31                                 | 39/413 (9.4)                         | 5.06                                 | 1/334 (0.3)                        | 0.23                               | 6/337 (1.8)                        | 1.36                               |
| Other including race   | mixed 10/198 (5.1)                   | 2.79                                 |                                      | 5/164 (3.0)                          | 1.69 0/63                          |                                    | 0 /51                              |                                    |

<div style=\"page-break-after: always\"></div>

Source data: [CTR 1245.110, c31803238, Tables 15.3.1.2.2: 5, 15.3.1.1: 2; CTR 1245.121, c28576542, Tables 15.3.1.2.2: 5, 15.3.1.1: 2]

In Asian patients, no event led to treatment discontinuation and serious events were infrequent ( Table 43. ).

Table 43. Asian patients with the PT fall in trials 1245.110 and 1245.121 - TS

|                          | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.110 (EMPEROR-Preserved)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   | Trial 1245.121 (EMPEROR-Reduced)   |
|--------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                          | Placebo                              | Placebo                              | Empa 10 mg                           | Empa 10 mg                           | Placebo                            | Placebo                            | Empa 10 mg                         | Empa 10 mg                         |
|                          | N (%)                                | Rate/ 100 pt-yrs                     | N (%)                                | Rate/10 0 pt-yrs                     | N (%)                              | Rate/1 00 pt- yrs                  | N (%)                              | Rate/1 00 pt- yrs                  |
| Number of Asian patients | 411 (100.0)                          |                                      | 413 (100.0)                          |                                      | 334 (100.0)                        |                                    | 337 (100.0)                        |                                    |
| PT fall                  | 26 (6.3)                             | 3.31                                 | 39 (9.4)                             | 5.06                                 | 1 (0.3)                            | 0.23                               | 6 (1.8)                            | 1.36                               |
| discontinuation          |                                      |                                      |                                      |                                      |                                    |                                    |                                    |                                    |
| Serious                  | 4 (1.0)                              | 0.50                                 | 8 (1.9)                              | 1.00                                 | 0                                  |                                    | 1 (0.3)                            | 0.23                               |

Source data: [CTR 1245.110, c31803238, Tables 15.3.1.2.2: 5, 15.3.1.2.3: 5, 15.3.1.2.4: 5; CTR 1245.121, c28576542, Tables 15.3.1.2.2: 5, 15.3.1.2.3: 5, 15.3.1.2.4: 5]

In addition, each event of fall in the Asian patients of trial 1245.110 was extensively medically reviewed for the origin of the fall. The incidence of fall started to diverge between treatment groups after about 1 year.  No  plausible  pathophysiological  cause  related  to  empagliflozin's  mode  of  action  (e.g.  via hypotension, volume depletion, hypoglycaemia) could be identified. The imbalance appeared to be mainly due to accidental falls, i.e. reported by the investigator as 'accidental fall' or 'mechanical fall' which implied an external force (e.g. environmental) or due to other causes (e.g. 'slipped', 'stumbled', etc.).

In conclusion, considering the late divergence in falls between treatment groups, the lack of a plausible pathophysiological cause related to empagliflozin's mode of action, and the lack of consistency in other subgroups (including other races), the small numerical imbalance in the PT fall observed in Asian patients was likely due to random variation associated with a large number of comparisons between treatment groups and among subgroups in the safety analyses.

## Serious adverse event/deaths/other significant events

The overall frequency of patients with SAEs was lower in the empagliflozin group than in the placebo group. Serious adverse events were most commonly reported in the SOC cardiac disorders. On the PT level, cardiac failure,  pneumonia,  acute  kidney  injury,  atrial  fibrillation,  and  cardiac  failure  congestive  were  most common. All other SAEs by PT were reported for &lt;2.0% of patients in either group ( Table 44. ).

In addition, all-cause and HF-related hospitalisations and all-cause mortality were analysed as efficacy endpoints in the two EMPEROR trials. In both trials, the risks of heart failure hospitalisations, recurrent heart failure hospitalisations, and investigator-defined CV hospitalisations were reduced with empagliflozin treatment compared with placebo. Also, in both trials, the cause of each death was adjudicated by the CEC, and the incidences of all-cause mortality were similar between treatment groups.

Table 44. Patients with SAEs in SAFHF1 (frequency ≥1.0% in at least one treatment group at the PT level) - TS

| MedDRA SOC   | Placebo   | Empa 10 mg   |
|--------------|-----------|--------------|

<div style=\"page-break-after: always\"></div>

| MedDRA PT                                            | N (%)        | Rate/100 pt-yrs   | N (%)        | Rate/100 pt-yrs   |
|------------------------------------------------------|--------------|-------------------|--------------|-------------------|
| Number of patients                                   | 5202 (100.0) |                   | 5206 (100.0) |                   |
| Total with SAEs                                      | 2502 (48.1)  | 44.39             | 2250 (43.2)  | 37.35             |
| Cardiac disorders                                    | 1552 (29.8)  | 23.67             | 1259 (24.2)  | 18.14             |
| Cardiac failure                                      | 1064 (20.5)  | 15.18             | 792 (15.2)   | 10.74             |
| Atrial fibrillation                                  | 127 (2.4)    | 1.62              | 118 (2.3)    | 1.50              |
| Cardiac failure congestive                           | 110 (2.1)    | 1.40              | 83 (1.6)     | 1.05              |
| Ventricular tachycardia                              | 60 (1.2)     | 0.76              | 77 (1.5)     | 0.97              |
| Acute myocardial infarction                          | 66 (1.3)     | 0.83              | 75 (1.4)     | 0.94              |
| Cardiac failure chronic                              | 62 (1.2)     | 0.78              | 43 (0.8)     | 0.54              |
| Cardiac failure acute                                | 58 (1.1)     | 0.73              | 32 (0.6)     | 0.40              |
| Myocardial infarction                                | 44 (0.8)     | 0.55              | 53 (1.0)     | 0.67              |
| Infections and infestations                          | 501 (9.6)    | 6.59              | 475 (9.1)    | 6.17              |
| Pneumonia                                            | 182 (3.5)    | 2.32              | 155 (3.0)    | 1.96              |
| COVID-19                                             | 50 (1.0)     | 0.63              | 50 (1.0)     | 0.63              |
| Urinary tract infection                              | 40 (0.8)     | 0.50              | 50 (1.0)     | 0.63              |
| Nervous system disorders                             | 264 (5.1)    | 3.40              | 299 (5.7)    | 3.83              |
| Ischaemic stroke                                     | 55 (1.1)     | 0.69              | 61 (1.2)     | 0.77              |
| Renal and urinary disorders                          | 315 (6.1)    | 4.06              | 241 (4.6)    | 3.07              |
| Acute kidney injury                                  | 166 (3.2)    | 2.11              | 118 (2.3)    | 1.49              |
| Renal impairment                                     | 69 (1.3)     | 0.87              | 55 (1.1)     | 0.69              |
| Respiratory, thoracic and mediastinal disorders      | 220 (4.2)    | 2.82              | 160 (3.1)    | 2.03              |
| Chronic obstructive pulmonary disease                | 50 (1.0)     | 0.63              | 34 (0.7)     | 0.43              |
| General disorders and administration site conditions | 175 (3.4)    | 2.22              | 172 (3.3)    | 2.16              |
| Death 1                                              | 65 (1.2)     | 0.82              | 76 (1.5)     | 0.95              |

1  Deaths not attributed to another PT by the investigator. The frequencies of patients with fatal AEs were balanced between treatment groups (see Error! Reference source not found. )

Source data: [SCS appendix 2, c35146126, Table 2.1.1.7]

## Laboratory findings

A summary of patients with elevated serum creatinine in SAF-HF1 is provided above (Decreased renal function). Renal function parameters were also analysed as efficacy endpoints in the long-term outcome trials.  A  summary of patients with elevated liver enzymes in SAF-HF1 is also provided above (Hepatic injury).

Safety  laboratory  analyses  at  trial  level  are  presented  in  CTRs.  In  trials  1245.110  and  1245.121, haemoglobin and haematocrit values increased on treatment and then partially returned to baseline after treatment discontinuation in the empagliflozin group, with small decreases observed in the placebo group. There was a decrease in uric acid (urate) values in the empagliflozin group compared with the placebo group. After  treatment  discontinuation,  uric  acid  values  returned towards  baseline  in  the  empagliflozin group. There were no relevant alterations in the other safety laboratory parameters. In the 12-week trials, the trends were consistent with those observed in 1245.110 and 1245.121.

## Vital sign, physical findings and other observation related to safety

No meaningful changes in blood pressure (systolic or diastolic) or in heart/pulse rate were observed with empagliflozin treatment compared with placebo in any of the HF trials. There were no relevant differences

<div style=\"page-break-after: always\"></div>

in new ECG findings after baseline between empagliflozin and placebo. No pregnancy was reported other than a spontaneous abortion as an AE in trial 1245.121.

## Safety in special populations

Subgroup analyses of AEs were carried out by demographic and baseline characteristics (age, sex, race, geographic  region,  ethnicity,  diabetes  status  at  baseline,  baseline  eGFR,  baseline  blood  pressure,  and baseline use of ACE-inhibitor/ARB/ARNi, diuretics, or loop/high-ceiling diuretics).

In  SAF-HF1,  the  AE  profile  in  subgroups  was  generally  consistent  with  that  of  the  overall  population, including the subgroups by diabetes status and by eGFR categories at baseline (including patients with an eGFR of &lt;30 mL/min/1.73 m 2 ). No relevant difference in the AE profile was observed between patients with HFrEF and patients with HFpEF.

## Age

Adverse events by age categories were generally consistent with the overall AE profile of the pooled safety data ( Table 45. ).

Table 45. AEs by age in SAF-HF1 - TS

| Category of AEs                         | Placebo N (%)   | Rate/100 pt- yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|-----------------------------------------|-----------------|--------------------|--------------------|-------------------|
| Age <50 years                           | 244 (100.0)     |                    | 198 (100.0)        |                   |
| Any AE                                  | 188 (77.0)      | 158.71             | 147 (74.2)         | 140.93            |
| Leading to discont. of study medication | 28 (11.5)       | 8.52               | 25 (12.6)          | 8.94              |
| SAEs                                    | 101 (41.4)      | 43.04              | 72 (36.4)          | 32.78             |
| Acute renal failure (SMQ)               | 18 (7.4)        | 5.71               | 15 (7.6)           | 5.53              |
| Urinary tract infection (BIcMQ)         | 12 (4.9)        | 3.75               | 6 (3.0)            | 2.21              |
| Genital infection (BIcMQ)               | 6 (2.5)         | 1.84               | 5 (2.5)            | 1.82              |
| Volume depletion (BIcMQ)                | 22 (9.0)        | 7.14               | 17 (8.6)           | 6.38              |
| Hypotension (BIcMQ)                     | 20 (8.2)        | 6.48               | 15 (7.6)           | 5.60              |
| Confirmed hypoglycaemic events 1        | 5 (2.0)         | 1.55               | 0                  | 0                 |
| Bone fracture (BIcMQ)                   | 3 (1.2)         | 0.91               | 1 (0.5)            | 0.36              |
| Age 50 to <65 years                     | 1178 (100.0)    |                    | 1154 (100.0)       |                   |
| Any AE                                  | 917 (77.8)      | 149.31             | 869 (75.3)         | 124.81            |
| Leading to discont. of study medication | 185 (15.7)      | 10.66              | 160 (13.9)         | 9.44              |
| SAEs                                    | 530 (45.0)      | 41.84              | 445 (38.6)         | 34.26             |
| Acute renal failure (SMQ)               | 133 (11.3)      | 8.09               | 104 (9.0)          | 6.45              |
| Urinary tract infection (BIcMQ)         | 49 (4.2)        | 2.90               | 63 (5.5)           | 3.82              |
| Genital infection (BIcMQ)               | 8 (0.7)         | 0.46               | 19 (1.6)           | 1.13              |
| Volume depletion (BIcMQ)                | 85 (7.2)        | 5.13               | 97 (8.4)           | 6.00              |
| Hypotension (BIcMQ)                     | 77 (6.5)        | 4.61               | 95 (8.2)           | 5.87              |
| Confirmed hypoglycaemic events 1        | 29 (2.5)        | 1.69               | 25 (2.2)           | 1.49              |
| Bone fracture (BIcMQ)                   | 22 (1.9)        | 1.28               | 20 (1.7)           | 1.19              |
| Age 65 to <75 years                     | 1852 (100.0)    |                    | 1932 (100.0)       |                   |
| Any AE                                  | 1493 (80.6)     | 144.16             | 1537 (79.6)        | 137.81            |
| Leading to discont. of study medication | 291 (15.7)      | 10.06              | 322 (16.7)         | 10.76             |
| SAEs                                    | 853 (46.1)      | 40.22              | 818 (42.3)         | 35.61             |

<div style=\"page-break-after: always\"></div>

| Acute renal failure (SMQ)        | 211 (11.4)   |   7.73 | 209 (10.8)   |   7.35 |
|----------------------------------|--------------|--------|--------------|--------|
| Urinary tract infection (BIcMQ)  | 117 (6.3)    |   4.18 | 133 (6.9)    |   4.6  |
| Genital infection (BIcMQ)        | 10 (0.5)     |   0.34 | 32 (1.7)     |   1.07 |
| Volume depletion (BIcMQ)         | 147 (7.9)    |   5.3  | 203 (10.5)   |   7.23 |
| Hypotension (BIcMQ)              | 135 (7.3)    |   4.85 | 178 (9.2)    |   6.3  |
| Confirmed hypoglycaemic events 1 | 32 (1.7)     |   1.11 | 38 (2.0)     |   1.28 |
| Bone fracture (BIcMQ)            | 49 (2.6)     |   1.71 | 69 (3.6)     |   2.35 |

Continued on the next page

<div style=\"page-break-after: always\"></div>

AEs by age in SAF-HF1 - TS

| Category of AEs                         | Placebo N (%)   | Rate/100 pt-yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|-----------------------------------------|-----------------|-------------------|--------------------|-------------------|
| Age 75 to <85 years                     | 1653 (100.0)    |                   | 1675 (100.0)       |                   |
| Any AE                                  | 1406 (85.1)     | 180.04            | 1398 (83.5)        | 157.45            |
| Leading to discont. of study medication | 326 (19.7)      | 12.72             | 345 (20.6)         | 13.26             |
| SAEs                                    | 870 (52.6)      | 49.94             | 777 (46.4)         | 40.13             |
| Acute renal failure (SMQ)               | 188 (11.4)      | 7.70              | 188 (11.2)         | 7.72              |
| Urinary tract infection (BIcMQ)         | 117 (7.1)       | 4.70              | 166 (9.9)          | 6.73              |
| Genital infection (BIcMQ)               | 11 (0.7)        | 0.43              | 43 (2.6)           | 1.67              |
| Volume depletion (BIcMQ)                | 196 (11.9)      | 8.19              | 212 (12.7)         | 8.73              |
| Hypotension (BIcMQ)                     | 172 (10.4)      | 7.12              | 178 (10.6)         | 7.25              |
| Confirmed hypoglycaemic events 1        | 39 (2.4)        | 1.54              | 35 (2.1)           | 1.35              |
| Bone fracture (BIcMQ)                   | 79 (4.8)        | 3.17              | 74 (4.4)           | 2.88              |
| Age ≥85 years                           | 275 (100.0)     |                   | 247 (100.0)        |                   |
| Any AE                                  | 230 (83.6)      | 172.59            | 213 (86.2)         | 195.01            |
| Leading to discont. of study medication | 69 (25.1)       | 17.55             | 60 (24.3)          | 15.82             |
| SAEs                                    | 148 (53.8)      | 54.44             | 138 (55.9)         | 50.74             |
| Acute renal failure (SMQ)               | 37 (13.5)       | 9.94              | 31 (12.6)          | 8.65              |
| Urinary tract infection (BIcMQ)         | 40 (14.5)       | 10.98             | 34 (13.8)          | 9.63              |
| Genital infection (BIcMQ)               | 0               | 0                 | 2 (0.8)            | 0.52              |
| Volume depletion (BIcMQ)                | 33 (12.0)       | 8.99              | 37 (15.0)          | 10.89             |
| Hypotension (BIcMQ)                     | 26 (9.5)        | 6.96              | 33 (13.4)          | 9.56              |
| Confirmed hypoglycaemic events 1        | 3 (1.1)         | 0.77              | 3 (1.2)            | 0.80              |
| Bone fracture (BIcMQ)                   | 18 (6.5)        | 4.74              | 18 (7.3)           | 4.91              |

1 Hypoglycaemic AEs with a plasma glucose value of ≤70 mg/dL or where assistance was required

Source data: [SCS appendix 2, c35146126, Tables 2.1.2.2.1, 2.1.2.3.1, 2.1.2.4.1, 2.2.20.1]

## Diabetes status at baseline

Adverse events by diabetes status at baseline were generally consistent with the overall AE profile of the pooled safety data ( Table 46. ).

Table 46. AEs by baseline diabetes status in SAF-HF1 - TS

| Category of AEs                               | Placebo N (%)   | Rate/100 pt- yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|-----------------------------------------------|-----------------|--------------------|--------------------|-------------------|
| With diabetes                                 | 2579 (100.0)    |                    | 2570 (100.0)       |                   |
| Any AE                                        | 2121 (82.2)     | 167.66             | 2086 (81.2)        | 151.31            |
| Leading to discont. of study medication       | 475 (18.4)      | 12.21              | 477 (18.6)         | 12.26             |
| SAEs                                          | 1287 (49.9)     | 47.71              | 1158 (45.1)        | 39.84             |
| Acute renal failure (SMQ)                     | 324 (12.6)      | 8.83               | 332 (12.9)         | 9.16              |
| Hepatic injury (SMQ)                          | 137 (5.3)       | 3.61               | 113 (4.4)          | 2.95              |
| Ketoacidosis (narrow BIcMQ)                   | 5 (0.2)         | 0.13               | 4 (0.2)            | 0.10              |
| AEs leading to LLA 1 (up to trial completion) | 30/2397 (1.3)   | 0.68               | 27/2392 (1.1)      | 0.61              |
| Urinary tract infection (BIcMQ)               | 184 (7.1)       | 4.91               | 208 (8.1)          | 5.59              |
| Genital infection (BIcMQ)                     | 19 (0.7)        | 0.49               | 57 (2.2)           | 1.48              |

<div style=\"page-break-after: always\"></div>

| Volume depletion (BIcMQ)                      | 226 (8.8)    | 6.11   | 271 (10.5)   | 7.36   |
|-----------------------------------------------|--------------|--------|--------------|--------|
| Hypotension (BIcMQ)                           | 198 (7.7)    | 5.31   | 235 (9.1)    | 6.35   |
| Confirmed hypoglycaemic events 2              | 90 (3.5)     | 2.36   | 84 (3.3)     | 2.20   |
| Bone fracture (BIcMQ)                         | 81 (3.1)     | 2.11   | 89 (3.5)     | 2.32   |
| Without diabetes                              | 2620 (100.0) |        | 2633 (100.0) |        |
| Any AE                                        | 2112 (80.6)  | 149.08 | 2077 (78.9)  | 135.41 |
| Leading to discont. of study medication       | 424 (16.2)   | 10.55  | 435 (16.5)   | 10.73  |
| SAEs                                          | 1215 (46.4)  | 41.35  | 1092 (41.5)  | 35.04  |
| Acute renal failure (SMQ)                     | 263 (10.0)   | 6.86   | 215 (8.2)    | 5.52   |
| Hepatic injury (SMQ)                          | 111 (4.2)    | 2.81   | 84 (3.2)     | 2.10   |
| Ketoacidosis (narrow BIcMQ)                   | 1 (<0.1)     | 0.02   | 0            | 0      |
| AEs leading to LLA 1 (up to trial completion) | 3/2455 (0.1) | 0.07   | 2/2467 (0.1) | 0.04   |
| Urinary tract infection (BIcMQ)               | 151 (5.8)    | 3.86   | 194 (7.4)    | 4.96   |
| Genital infection (BIcMQ)                     | 16 (0.6)     | 0.40   | 44 (1.7)     | 1.09   |
| Volume depletion (BIcMQ)                      | 257 (9.8)    | 6.76   | 294 (11.2)   | 7.79   |
| Hypotension (BIcMQ)                           | 232 (8.9)    | 6.07   | 263 (10.0)   | 6.90   |
| Confirmed hypoglycaemic events 2              | 18 (0.7)     | 0.45   | 17 (0.6)     | 0.42   |
| Bone fracture (BIcMQ)                         | 90 (3.4)     | 2.28   | 93 (3.5)     | 2.32   |

1 Data collected only in 1245.110 and 1245.121, shown as patients with events/patients in group (%)

2 Hypoglycaemic AEs with a plasma glucose value of ≤70 mg/dL or where assistance was required

## Baseline eGFR

The adverse event profile in each eGFR category was generally consistent with the overall AE profile of the pooled safety data ( Table 47. ).

Table 47. AEs by baseline eGFR in SAF-HF1 - TS

| Category of AEs                               | Placebo      | Placebo         | Empa 10 mg   | Rate/100   |
|-----------------------------------------------|--------------|-----------------|--------------|------------|
|                                               | N (%)        | Rate/100 pt-yrs | N (%)        | pt-yrs     |
| eGFR ≥90 mL/min/1.73m 2                       | 481 (100.0)  |                 | 482 (100.0)  |            |
| Any AE                                        | 360 (74.8)   | 129.13          | 346 (71.8)   | 107.08     |
| Leading to discont. of study medication       | 51 (10.6)    | 6.90            | 62 (12.9)    | 8.32       |
| SAEs                                          | 188 (39.1)   | 32.99           | 163 (33.8)   | 27.36      |
| Acute renal failure (SMQ)                     | 25 (5.2)     | 3.46            | 20 (4.1)     | 2.71       |
| AEs leading to LLA 1 (up to trial completion) | 3/457 (0.7)  | 0.36            | 2/460 (0.4)  | 0.24       |
| Urinary tract infection (BIcMQ)               | 26 (5.4)     | 3.66            | 25 (5.2)     | 3.47       |
| Genital infection (BIcMQ)                     | 5 (1.0)      | 0.68            | 7 (1.5)      | 0.95       |
| Volume depletion (BIcMQ)                      | 30 (6.2)     | 4.20            | 35 (7.3)     | 4.89       |
| Hypotension (BIcMQ)                           | 27 (5.6)     | 3.77            | 35 (7.3)     | 4.89       |
| Confirmed hypoglycaemic events 2              | 9 (1.9)      | 1.23            | 5 (1.0)      | 0.67       |
| Bone fracture (BIcMQ)                         | 10 (2.1)     | 1.36            | 12 (2.5)     | 1.63       |
| eGFR 60 to <90 mL/min/1.73m 2                 | 2139 (100.0) |                 | 2141 (100.0) |            |
| Any AE                                        | 1693 (79.1)  | 138.32          | 1661 (77.6)  | 126.79     |
| Leading to discont. of study medication       | 313 (14.6)   | 9.30            | 317 (14.8)   | 9.43       |
| SAEs                                          | 945 (44.2)   | 37.84           | 817 (38.2)   | 30.87      |
| Acute renal failure (SMQ)                     | 170 (7.9)    | 5.24            | 150 (7.0)    | 4.62       |
| AEs leading to LLA 1 (up to trial completion) | 9/2006 (0.4) | 0.24            | 9/2002 (0.4) | 0.24       |
| Urinary tract infection (BIcMQ)               | 106 (5.0)    | 3.22            | 145 (6.8)    | 4.47       |

<div style=\"page-break-after: always\"></div>

| Genital infection (BIcMQ)                     | 14 (0.7)      | 0.42   | 49 (2.3)     | 1.47   |
|-----------------------------------------------|---------------|--------|--------------|--------|
| Volume depletion (BIcMQ)                      | 175 (8.2)     | 5.44   | 185 (8.6)    | 5.83   |
| Hypotension (BIcMQ)                           | 157 (7.3)     | 4.85   | 166 (7.8)    | 5.20   |
| Confirmed hypoglycaemic events 2              | 38 (1.8)      | 1.14   | 24 (1.1)     | 0.72   |
| Bone fracture (BIcMQ)                         | 56 (2.6)      | 1.69   | 67 (3.1)     | 2.03   |
| eGFR 45 to <60 mL/min/1.73m 2                 | 1326 (100.0)  |        | 1322 (100.0) |        |
| Any AE                                        | 1091 (82.3)   | 159.68 | 1073 (81.2)  | 150.84 |
| Leading to discont. of study medication       | 232 (17.5)    | 11.31  | 237 (17.9)   | 11.69  |
| SAEs                                          | 655 (49.4)    | 45.06  | 609 (46.1)   | 40.26  |
| Acute renal failure (SMQ)                     | 152 (11.5)    | 7.84   | 139 (10.5)   | 7.26   |
| AEs leading to LLA 1 (up to trial completion) | 11/1238 (0.9) | 0.48   | 8/1224 (0.7) | 0.35   |
| Urinary tract infection (BIcMQ)               | 81 (6.1)      | 4.10   | 110 (8.3)    | 5.70   |
| Genital infection (BIcMQ)                     | 9 (0.7)       | 0.44   | 23 (1.7)     | 1.14   |
| Volume depletion (BIcMQ)                      | 121 (9.1)     | 6.22   | 182 (13.8)   | 9.70   |
| Hypotension (BIcMQ)                           | 109 (8.2)     | 5.57   | 161 (12.2)   | 8.52   |
| Confirmed hypoglycaemic events 2              | 23 (1.7)      | 1.14   | 27 (2.0)     | 1.34   |
| Bone fracture (BIcMQ)                         | 48 (3.6)      | 2.39   | 47 (3.6)     | 2.36   |

Continued on the next page

<div style=\"page-break-after: always\"></div>

AEs by baseline eGFR in SAF-HF1 - TS

| Category of AEs                               | Placebo N (%)   | Rate/100 yrs   | Empa 10 mg N (%)   | Rate/100 yrs   | pt-   |
|-----------------------------------------------|-----------------|----------------|--------------------|----------------|-------|
| eGFR 30 to <45 mL/min/1.73m 2                 | 980 (100.0)     |                | 977 (100.0)        |                |       |
| Any AE                                        | 848 (86.5)      | 211.84         | 826 (84.5)         | 175.16         |       |
| Leading to discont. of study medication       | 210 (21.4)      | 14.78          | 212 (21.7)         | 14.74          |       |
| SAEs                                          | 543 (55.4)      | 60.15          | 487 (49.8)         | 48.11          |       |
| Acute renal failure (SMQ)                     | 171 (17.4)      | 13.23          | 175 (17.9)         | 13.57          |       |
| AEs leading to LLA 1 (up to trial completion) | 8/898 (0.9)     | 0.48           | 6/909 (0.7)        | 0.36           |       |
| Urinary tract infection (BIcMQ)               | 93 (9.5)        | 6.84           | 91 (9.3)           | 6.58           |       |
| Genital infection (BIcMQ)                     | 6 (0.6)         | 0.42           | 19 (1.9)           | 1.32           |       |
| Volume depletion (BIcMQ)                      | 122 (12.4)      | 9.33           | 117 (12.0)         | 8.64           |       |
| Hypotension (BIcMQ)                           | 108 (11.0)      | 8.18           | 101 (10.3)         | 7.37           |       |
| Confirmed hypoglycaemic events 2              | 22 (2.2)        | 1.55           | 24 (2.5)           | 1.68           |       |
| Bone fracture (BIcMQ)                         | 47 (4.8)        | 3.37           | 46 (4.7)           | 3.24           |       |
| eGFR <30 mL/min/1.73m 2                       | 273 (100.0)     |                | 283 (100.0)        |                |       |
| Any AE                                        | 240 (87.9)      | 253.80         | 258 (91.2)         | 269.67         |       |
| Leading to discont. of study medication       | 92 (33.7)       | 27.61          | 84 (29.7)          | 22.37          |       |
| SAEs                                          | 170 (62.3)      | 81.29          | 174 (61.5)         | 68.14          |       |
| Acute renal failure (SMQ)                     | 69 (25.3)       | 23.03          | 63 (22.3)          | 18.94          |       |
| AEs leading to LLA 1 (up to trial completion) | 2/250 (0.8)     | 0.49           | 4/263 (1.5)        | 0.87           |       |
| Urinary tract infection (BIcMQ)               | 29 (10.6)       | 9.00           | 31 (11.0)          | 8.78           |       |
| Genital infection (BIcMQ)                     | 1 (0.4)         | 0.30           | 3 (1.1)            | 0.80           |       |
| Volume depletion (BIcMQ)                      | 35 (12.8)       | 11.09          | 47 (16.6)          | 13.94          |       |
| Hypotension (BIcMQ)                           | 29 (10.6)       | 9.01           | 36 (12.7)          | 10.48          |       |
| Confirmed hypoglycaemic events 2              | 16 (5.9)        | 4.94           | 21 (7.4)           | 5.77           |       |
| Bone fracture (BIcMQ)                         | 10 (3.7)        | 3.03           | 10 (3.5)           | 2.67           |       |

Patients with missing information are shown in the source tables; this includes 1 patient in the empagliflozin group and 3 patients in the placebo group.

1 Data collected only in 1245.110 and 1245.121, shown as patients with events/patients in group (%)

2 Hypoglycaemic AEs with a plasma glucose value of ≤70 mg/dL or where assistance was required

Source data: [SCS, c35218777, Section 5.1.6]

## Use in pregnancy and lactation

The use of empagliflozin during pregnancy and lactation was not specifically studied in the HF trials. See the currently approved product information of empagliflozin for more information.

A spontaneous abortion was reported as an AE in trial 1245.121. No pregnancies were reported in trials 1245.168, 1245.167, 1245.148, or 1245.110.

## Safety related to drug-drug interactions and other interactions

Drug  interactions  were  not  specifically  studied  in  the  HF  trials.  See  the  currently  approved  product information of empagliflozin for more information. For subgroup analyses by certain medications (i.e. ACEinhibitors/ARB/ARNi, diuretics, loop/high-ceiling diuretics) at baseline, see below.

<div style=\"page-break-after: always\"></div>

## Baseline use of certain medications

Only acute renal failure (SMQ), volume depletion (BIcMQ), and hypotension (BIcMQ, subset of volume depletion) were included in subgroup analyses. Adverse events by baseline use of certain medications (i.e. ACE-inhibitors/ARB/ARNi, diuretics, loop/high-ceiling diuretics) showed trends similar to those observed for the overall population ( Table 48. ).

Table 48. AEs by baseline use of certain medications in SAF-HF1 - TS

| Category of AEs                        | Placebo N (%)   | Rate/100 pt-yrs   | Empa 10 mg N (%)   | Rate/100 pt-yrs   |
|----------------------------------------|-----------------|-------------------|--------------------|-------------------|
| Without ACE-inhibitor, ARB or ARNi     | 856 (100.0)     |                   | 851 (100.0)        |                   |
| Acute renal failure (SMQ)              | 97 (11.3)       | 7.81              | 87 (10.2)          | 6.72              |
| Volume depletion (BIcMQ)               | 83 (9.7)        | 6.79              | 90 (10.6)          | 7.04              |
| Hypotension (BIcMQ)                    | 75 (8.8)        | 6.09              | 80 (9.4)           | 6.20              |
| With ACE-inhibitor, ARB or ARNi        | 4346 (100.0)    |                   | 4355 (100.0)       |                   |
| Acute renal failure (SMQ)              | 490 (11.3)      | 7.83              | 460 (10.6)         | 7.39              |
| Volume depletion (BIcMQ)               | 400 (9.2)       | 6.37              | 476 (10.9)         | 7.70              |
| Hypotension (BIcMQ)                    | 355 (8.2)       | 5.62              | 419 (9.6)          | 6.73              |
| Without ARNi                           | 4684 (100.0)    |                   | 4732 (100.0)       |                   |
| Acute renal failure (SMQ)              | 530 (11.3)      | 7.61              | 509 (10.8)         | 7.23              |
| Volume depletion (BIcMQ)               | 432 (9.2)       | 6.20              | 503 (10.6)         | 7.19              |
| Hypotension (BIcMQ)                    | 380 (8.1)       | 5.41              | 445 (9.4)          | 6.32              |
| With ARNi                              | 518 (100.0)     |                   | 474 (100.0)        |                   |
| Acute renal failure (SMQ)              | 57 (11.0)       | 10.61             | 38 (8.0)           | 7.86              |
| Volume depletion (BIcMQ)               | 51 (9.8)        | 9.64              | 63 (13.3)          | 13.52             |
| Hypotension (BIcMQ)                    | 50 (9.7)        | 9.42              | 54 (11.4)          | 11.45             |
| Without diuretics                      | 510 (100.0)     |                   | 579 (100.0)        |                   |
| Acute renal failure (SMQ)              | 45 (8.8)        | 5.51              | 37 (6.4)           | 4.03              |
| Volume depletion (BIcMQ)               | 30 (5.9)        | 3.69              | 40 (6.9)           | 4.37              |
| Hypotension (BIcMQ)                    | 27 (5.3)        | 3.30              | 34 (5.9)           | 3.70              |
| With diuretics                         | 4692 (100.0)    |                   | 4627 (100.0)       |                   |
| Acute renal failure (SMQ)              | 542 (11.6)      | 8.11              | 510 (11.0)         | 7.72              |
| Volume depletion (BIcMQ)               | 453 (9.7)       | 6.77              | 526 (11.4)         | 8.04              |
| Hypotension (BIcMQ)                    | 403 (8.6)       | 5.98              | 465 (10.0)         | 7.05              |
| Without loop or high-ceiling diuretics | 1333 (100.0)    |                   | 1342 (100.0)       |                   |
| Acute renal failure (SMQ)              | 104 (7.8)       | 4.88              | 101 (7.5)          | 4.70              |
| Volume depletion (BIcMQ)               | 106 (8.0)       | 5.04              | 114 (8.5)          | 5.38              |
| Hypotension (BIcMQ)                    | 92 (6.9)        | 4.34              | 103 (7.7)          | 4.85              |
| With loop or high-ceiling diuretics    | 3869 (100.0)    |                   | 3864 (100.0)       |                   |
| Acute renal failure (SMQ)              | 483 (12.5)      | 8.99              | 446 (11.5)         | 8.30              |
| Volume depletion (BIcMQ)               | 377 (9.7)       | 6.99              | 452 (11.7)         | 8.46              |
| Hypotension (BIcMQ)                    | 338 (8.7)       | 6.22              | 396 (10.2)         | 7.35              |

Source data: [SCS appendix 2, c35146126, Tables 2.2.1.12 to 15, 2.2.8.11 to 14, 2.2.9.15 to 18]

## Discontinuation due to adverse events

The frequencies of patients with AEs leading to discontinuation of study medication were similar between treatment  groups.  The  most  commonly  reported  (≥0.2%  in  at  least  one  group)  of  these  events  are

<div style=\"page-break-after: always\"></div>

summarised in Table 49. On the PT level, the most frequently reported AEs leading to discontinuation were cardiac failure and death.

Table 49. Patients with AEs leading to discontinuation of study medication in SAFHF1 (frequency ≥0.2% in at least one treatment group at the PT level) - TS

| MedDRA SOC MedDRA PT                            | Placebo N (%)   | Rate/100 pt- yrs   | Empa 10 mg N (%)   | Rate/100 pt- yrs   |
|-------------------------------------------------|-----------------|--------------------|--------------------|--------------------|
| Number of patients                              | 5202 (100.0)    |                    | 5206 (100.0)       |                    |
| Total with AEs leading to discontinuation       | 899 (17.3)      | 11.36              | 912 (17.5)         | 11.47              |
| Cardiac disorders                               | 261 (5.0)       | 3.28               | 224 (4.3)          | 2.80               |
| Cardiac failure                                 | 135 (2.6)       | 1.70               | 110 (2.1)          | 1.38               |
| Myocardial infarction                           | 21 (0.4)        | 0.26               | 16 (0.3)           | 0.20               |
| Acute myocardial infarction                     | 17 (0.3)        | 0.21               | 19 (0.4)           | 0.24               |
| Cardiac arrest                                  | 13 (0.2)        | 0.16               | 17 (0.3)           | 0.21               |
| Cardiac failure congestive                      | 16 (0.3)        | 0.20               | 11 (0.2)           | 0.14               |
| Cardiac failure acute                           | 14 (0.3)        | 0.18               | 8 (0.2)            | 0.10               |
| Cardiogenic shock                               | 8 (0.2)         | 0.10               | 6 (0.1)            | 0.07               |
| Infections and infestations                     | 109 (2.1)       | 1.37               | 136 (2.6)          | 1.70               |
| Urinary tract infection                         | 13 (0.2)        | 0.16               | 24 (0.5)           | 0.30               |
| Pneumonia                                       | 23 (0.4)        | 0.29               | 19 (0.4)           | 0.24               |
| COVID-19                                        | 18 (0.3)        | 0.23               | 12 (0.2)           | 0.15               |
| COVID-19 pneumonia                              | 5 (0.1)         | 0.06               | 12 (0.2)           | 0.15               |
| Sepsis                                          | 8 (0.2)         | 0.10               | 9 (0.2)            | 0.11               |
| Septic shock                                    | 7 (0.1)         | 0.09               | 8 (0.2)            | 0.10               |
| General disorders and administration conditions | 118 (2.3)       | 1.48               | 123 (2.4)          | 1.54               |
| Death 1                                         | 57 (1.1)        | 0.72               | 69 (1.3)           | 0.86               |
| Sudden cardiac death                            | 19 (0.4)        | 0.24               | 12 (0.2)           | 0.15               |
| Sudden death                                    | 11 (0.2)        | 0.14               | 14 (0.3)           | 0.17               |
| Cardiac death                                   | 10 (0.2)        | 0.13               | 8 (0.2)            | 0.10               |
| Renal and urinary disorders                     | 90 (1.7)        | 1.13               | 83 (1.6)           | 1.04               |
| Renal impairment                                | 25 (0.5)        | 0.31               | 30 (0.6)           | 0.37               |
| Acute kidney injury                             | 19 (0.4)        | 0.24               | 16 (0.3)           | 0.20               |
| Renal failure                                   | 17 (0.3)        | 0.21               | 8 (0.2)            | 0.10               |
| Chronic kidney disease                          | 16 (0.3)        | 0.20               | 15 (0.3)           | 0.19               |
| Nervous system disorders                        | 77 (1.5)        | 0.97               | 82 (1.6)           | 1.02               |
| Ischaemic stroke                                | 20 (0.4)        | 0.25               | 18 (0.3)           | 0.22               |
| Dizziness                                       | 14 (0.3)        | 0.18               | 7 (0.1)            | 0.09               |
| Cerebrovascular accident                        | 12 (0.2)        | 0.15               | 13 (0.2)           | 0.16               |
| Gastrointestinal disorders                      | 47 (0.9)        | 0.59               | 50 (1.0)           | 0.63               |
| Dyspepsia                                       | 9 (0.2)         | 0.11               | 2 (<0.1)           | 0.02               |
| Vascular disorders                              | 33 (0.6)        | 0.41               | 35 (0.7)           | 0.44               |
| Hypotension                                     | 12 (0.2)        | 0.15               | 17 (0.3)           | 0.21               |

1 Deaths not attributed to another PT by the investigator. The frequencies of patients with fatal AEs were balanced between treatment groups.

Source data: [SCS appendix 2, c35146126, Table 2.1.1.6]

## Post marketing experience

See the periodic benefit-risk evaluation report (PBRER) for post-marketing data in patients with T2DM.

<div style=\"page-break-after: always\"></div>

On 17 Jun 2021, empagliflozin was approved in the EU for use in patients with HFrEF (with or without T2DM). There has been no substantial post-marketing experience in these patients.

## 2.5.1. Discussion on clinical safety

In  SAF-HF1,  10408  patients  were  treated,  and  28.2%  of  patients  prematurely  discontinued  study medication (including patients who died). More than 70% of patients had an exposure for at least 52 weeks. The exposure is considered acceptable to perform a safety evaluation.

The number of AEs and severe AEs were similar for empagliflozin compared to placebo, but the number of cardiac events were lower for empagliflozin vs. placebo. A similar number of total AEs could therefore result from a larger number of other AEs. Based on the most frequently reported AEs, this number of events is also  similar  for  empagliflozin  compared  to  placebo,  except  for  hypotension  (empagliflozin  372  (7.1%) placebo  313  (6.0%))  and  urinary  tract  infections  (empagliflozin  314  (6.0%)  placebo  259  (5.0%)). Hypotension is a known side-effect for SGLT2i treatment and can be related to other symptoms, such as syncope and fall, discussed below. Urinary tract infections and genital infections are also known side effects of SGLT2i treatment.

The safety analyses in SAF-HF1 were also performed focused on AESIs and specific AEs. The numbers of events with acute renal failure (empagliflozin 547 (10.5%), placebo 587 (11.3%)), keto-acidosis (broad BIcMQ: empagliflozin 63 (1.2%), placebo 77 (1.5%); narrow BIcMQ: empagliflozin 4 (0.1%), placebo 6 (0.1%))  and  hepatic  injury  (empagliflozin  197  (3.8%),  placebo  248  (4.8%))  were  not  larger  for empagliflozin compared to placebo. The number of AEs leading to LLA was also similar between placebo and empagliflozin treatment (empagliflozin 29 (0.6%), placebo 33 (0.7%)), both for patients with and without diabetes. The numbers of bone fractures (empagliflozin 179 (3.4%), placebo 171 (3.3%)) and confirmed hypoglycaemic events (empagliflozin 101 (1.9%), placebo 108 (2.1%)) were also similar for empagliflozin vs. placebo, except for hypoglycaemic events in T1DM, but this consisted of a very small number of  events  and  therefore  not  contributing  to  the  evaluation  (empagliflozin  2/5  (40%),  placebo 1/5(20%)).

As expected from previous safety evaluation and reported ADRs, urinary tract infections (empagliflozin 402 (7.7%), placebo 335 (6.4%)) and genital infections (empagliflozin 101 (1.9%), placebo 35 (0.7%)) were more common in the empagliflozin group than in the placebo group. The number of complicated urinary tract  infections,  urosepsis  or  pyelonephritis,  was  also  more  in  the  empagliflozin  group  vs  placebo.  The treatment difference was most pronounced in female patients for urosepsis or pyelonephritis (empagliflozin 20/1895 (1.1%), placebo 6/1915 (0.3%)) and for patients without diabetes (empagliflozin 15/2633 (0.6%), placebo 8/2620 (0.3%)). It is known that female subjects are more susceptible for urinary tract infection, and  this  may  partly  explain  the  increased  incidence  in  female  subjects  with  empagliflozin  treatment. Patients without diabetes normally do not have glucosuria, but this is altered by SGLT2i treatment and could therefore increase the risk of urinary tract infection. The number of complicated genital infections was similar between empagliflozin and placebo (empagliflozin 14 (0.3%), placebo 14 (0.3%)). Urinary tract infections, including urosepsis and pyelonephritis, and genital infections are included in Section 4.8 of the SmPC. The current observations are in line with the described ARD in the SmPC.

Volume depletion was also more frequent with empagliflozin treatment (empagliflozin 566 (10.9%), placebo 483 (9.3%)), including the number of symptomatic hypotension and syncope. Serious volume depletion events  were  also  more  frequent  with  empagliflozin  treatment  (empagliflozin  113  (2.2%),  placebo  91 (1.7%)).  During  treatment  with  empagliflozin,  the  intensity  of  diuretic  therapy  or  non-diuretic  antihypertensive therapy was more frequently reduced. Volume depletion, including hypotension, is described in Section 4.4 and 4.8 of the SmPC. The current observations are in line with de described ARD in the SmPC.

<div style=\"page-break-after: always\"></div>

In the EMPEROR Reduced trial, falls were reported for more patients in the empagliflozin vs the placebo group. In the current SAF-HF1, the treatment difference in the number of reported falls is less pronounced (empagliflozin 261 (5.0%), placebo 249 (4.8%)). In the EMPEROR preserved trial, the number of falls is similar for the empagliflozin group vs placebo (empagliflozin 213 (7.1%), placebo 219 (7.3%)), but falls were reported much more frequent in the EMPEROR preserved trial compared to the EMPEROR-reduced (empagliflozin 43 (2.3%), placebo 27 (1.4%)). This is probably due to a difference in the study population (e.g. difference in percentage of female subjects). The difference between treatments in reported falls in the SF-HF1 and EMPEROR-preserved is considered small. The number of falls was also more frequent in the  Asian  subgroup  with  empagliflozin  vs  placebo.  This  was  present  in  both  the  EMPEROR-reduced (empagliflozin 6/337 (1.8%), placebo 1/334 (0.3%)) and EMPEROR-preserved trial (empagliflozin 39/413 (9.4%), placebo 26/411 (6.3%)). The Applicant describes that each event of fall in the Asian patients of EMPEROR-preserved trial was extensively medically reviewed for the origin of the fall and that this did not lead  to  plausible  pathophysiological  causes  and  was  not  related  to  empagliflozin's  mode  of  action (hypotension, volume depletion, hypoglycaemia), but mainly due to accidental falls.

Constipation is consistently more frequently reported in the empagliflozin group compared to placebo group and is included in Section 4.8 of the SmPC.

In the SAF-HF1, the number of serious adverse events was not larger for empagliflozin compared to placebo (empagliflozin 2250 (43.1%), placebo 2502 (48.1%)).The reported number of myocardial infarctions and ischaemic stroke was slightly more for empagliflozin vs placebo (myocardial infarction: empagliflozin 53 (1.0%), placebo 44 (0.8%); ischaemic stroke: empagliflozin 61 (1.2%), placebo 55 (1.1%)). However, the differences between treatments are considered very small. This finding may be related to chance and this will not be pursued further.

The Applicant performed subgroup analyses to evaluate safety in special populations. As expected, the total number of AEs are reported more frequently in the older age groups, but similar for empagliflozin compared to placebo treatment. Volume depletion and genital infection are in general more frequent in the empagliflozin group, but the difference in frequency empagliflozin vs. placebo appears more pronounced in elderly patients (&gt;75years). Elderly patients appear, therefore, more vulnerable for these side effects. The increased risk for volume depletion in elderly patients is described in Section 4.4 of the SmPC. For genital infections (Age 50-&lt;65 empagliflozin 19 (1.6%), placebo 8 (0.7%); age 65-&lt;75: empagliflozin 32 (1.7%), placebo 10 (0.5%); age 75-&lt;85 empagliflozin 43 (2.6%), placebo 11 (0.7%)), the increased risk in elderly is considered only mildly elevated and is not deemed necessary to be included in section 4.8.

As  expected,  the  number  of  AEs  is  more  in  the  lower  eGFR  subgroups  compared  to  the  higher  eGFR subgroups,  as  the  low  eGFR  subgroups  represent  a  more  vulnerable  patient  population.  The  effect  of empagliflozin treatment on volume depletion appears larger in the eGFR subgroup 45-&lt;60 compared to the higher eGFR subgroups (eGFR 60 - &lt;90: empagliflozin 185 (8.6%), placebo 175 (8.2%); eGFR 45-&lt;60: empagliflozin 182 (13.8%), placebo 121 (9.1%)). However, in the eGFR subgroup 30 -&lt;45 (empagliflozin 117  (12.0%),  placebo  122  (12.4%)),  there  was  no  difference  in  volume  depletion  frequency  between empagliflozin and placebo and the observation for the eGFR subgroup 45 -&lt;60 is therefore not consistently observed.

There  was  no  difference  in  the  number  or  the  type  of  AEs  leading  to  discontinuation  between  the empagliflozin group and the placebo group.

## 2.5.2. Conclusions on clinical safety

The safety profile of empagliflozin in patients with HF, with or without diabetes, appears in general similar to the safety profile in patients with HFrEF and/or T2DM. No new large safety issues have been identified.

<div style=\"page-break-after: always\"></div>

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version with this application (RMP v16, date of final sign off: 04 Aug 2021). The main proposed RMP changes were the following:

## *Part I. Product overview

This part is proposed to be updated in order to include information on the proposed extension of indication to add the treatment of patients with Heart Failure with preserved ejection fraction.

## *Part II. Safety specification .

The following modules have been updated:

MODULE SI Epidemiology of the indications and target populations

The MAH has updated all data of epidemiology concerning the new proposed indication.

## MODULE SIII clinical trial exposure

The MAH has updated this section including data from clinical trials in patients with HFpEF (trials 1245.110, 1245.148 and 1245.167).

Four safety analysis sets were described as used for clinical trial exposure calculation:

SIII.Table 1

Overview of safety analysis sets

| SAF          | Description                                                                                                                    | Trials included                                                                                                                                                                                                                              |
|--------------|--------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SAF-HF4      | Randomised, placebo-controlled clinical trials in patients with HFpEF                                                          | 1245.110, 1245.148(HFpEF arm),1245.167                                                                                                                                                                                                       |
| SAF-HF5      | Randomised, placebo-controlled clinical trials in patients with HFrEF                                                          | 1245.121, 1245.168                                                                                                                                                                                                                           |
| SAF-43 2     | Randomised, double-blind, placebo- controlled trials in patients with T2DM                                                     | 1245.4, 1245.9, 1245.10, 1245.15, 1245.19, 1245.20, 1245.23 (Met only and Met+SU), 1245.25, 1245.29, 1245.33, 1245.35, 1245.36, 1245.38, 1245.48, 1245.49, 1245.107, 1275.9, 1275.19, 1276.10                                                |
| SAF- POOL2 2 | Randomised, placebo-controlled clinical trials across indications HFpEF, HFrEF and T2DM (comprisingSAF-H4, SAF-HF5 and SAF-43) | 1245.4, 1245.9, 1245.10, 1245.15, 1245.19, 1245.20, 1245.23 (Met only, Met+SU), 1245.25, 1245.29, 1245.33, 1245.35, 1245.36, 1245.38, 1245.48, 1245.49, 1245.107, 1245.110, 1245.121, 1245.148, 1245.167, 1245.168, 1275.9, 1275.19, 1276.10 |

1  Data from trial 1245.148 was not available at the time of database lock for the HFrEF submission; the trial is therefore not included in the pooling.

2  The data of extension trial 1245.31 are contained in the core trials 1245.19, 1245.20, and 1245.23.

Data source: data on file, SAF-43 Table 31.3.1.1; SAF-HF5(HFrEF), Tables 1.1 and 1.2; and SAF-HF4(HFpEF), Tables 1.1 and 1.2

## MODULE SIV Populations not studied in clinical trials

<div style=\"page-break-after: always\"></div>

Exposure of special populations included or not in clinical trial development programs has been updated.

## MODULE SV Post-authorisation experience

This module has been updated with the most recent data on post-authorisation exposure up to April 2021.

## MODULE SVII Identified and potential risk

No new safety concerns have been identified by the MAA following new data from clinical trials in patients with HFpEF.

The MAH has updated the characterisation of the identified and potential risks, with risk analyses from HFpEF trials (1245.110, 1245.148-HFpEFarm and 1245.168).

## *Part VI Summary of the risk management plan

This part has been updated to include information on the proposed indication.

No new safety concern has been identified.

Regarding the pharmacovigilance plan, no new additional pharmacovigilance activities have been proposed, which is endorsed.

No new additional risk minimisation measures have been added either, which is also considered acceptable.

Overall, the changes of the RMP are acceptable.

## 2.6.1. Overall conclusion on the RMP

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 16.0, date of final sign off: 04 Aug 2021, is acceptable.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated. Particularly, a new warning with regard to Infiltrative disease or Takotsubo cardiomyopathy has been added to the product information. The Package Leaflet has been updated accordingly.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Chronic  heart  failure  is  a  progressive  syndrome  characterised  by  the  inability  of  the  heart  to  provide adequate blood supply to meet the metabolic demand of different tissues, or the heart can only provide adequate  blood  supply  at  the  expense  of  elevated  left  ventricular  filling  pressure.  Symptoms  include dyspnoea (shortness of breath), oedema (build-up of fluid in the body tissues), persistent coughing and wheezing (due to build-up of fluid in the lungs), tiredness or fatigue, reduced appetite or nausea, confusion, disorientation, and increased heart rate.

Worldwide, heart failure has a prevalence of 1% to 2% and affects over 64 million people as of 2017. In the US alone the prevalence is 6.2 million, and this number has been projected to grow to over 8 million by 2030. HF is associated with premature mortality and frequent hospitalisations. HF contributes to 1 in 9 deaths, and the estimated 5-year survival is about 50% at the time of diagnosis. HF is the leading cause of hospitalisation in patients above 65 years of age.

Patients with HF are categorised according to measurements of left ventricular ejection fraction (LVEF); patients with LVEF ≤40% are considered to have HFrEF, and those with LVEF &gt;50% are considered to have HFpEF. LVEF of &gt;40% to &lt;50% is considered as HFpEF in many clinical trials and registries, although more recently, the term HF with 'mid-range' EF (HFmEF) was introduced to categorise this group separately. The relative prevalence of HFpEF among HF patients is approximately 50% and appears to be increasing. HFrEF and HFpEF differ in several aspects, including underlying aetiologies, demographics, co-morbidities, and responses to treatment. Patients with HFpEF tend to be older, more often women, and more likely to have a history of hypertension and atrial fibrillation than patients with HFrEF. Although HFpEF and HFrEF have similarly profound impacts on patient quality of life and prognosis, historically, therapies shown to improve prognosis in patients with HFrEF do not seem to be effective in patients with HFpEF.

## 3.1.2. Available therapies and unmet medical need

HFrEF can be treated with drugs that act to attenuate the overactivation of endogenous neurohormonal systems. The therapeutic options for patients with HFpEF are limited.

Recommendations for the treatment of HFrEF include the use of angiotensin-converting enzyme inhibitors (ACEi),  angiotensin  receptor  blockers  (ARB),  angiotensin  receptor-neprilysin  inhibitors  (ARNi),  betablockers, mineralocorticoid receptor antagonists (MRA), and the use of implantable devices like ICD and CRT, all of which have been shown to reduce mortality in patients with HFrEF.

For patients with HFpEF, no therapy has been proven to be superior to control based on the pre-specified primary endpoint in any prior pivotal clinical outcome study in patients with HFpEF. According to the current guidelines, the management of HFpEF involves control of congestive symptoms, usually with diuretics, and the treatment of co-morbidities. A lack of therapeutic options that can reduce the risk of mortality and hospitalisation in these patients represents an unmet medical need.

## Empagliflozin

Empagliflozin (Jardiance) is an orally administered, potent and selective inhibitor of the human sodiumglucose cotransporter-2 (SGLT 2) developed by Boehringer Ingelheim (BI). By inhibition of SGLT 2 in the

<div style=\"page-break-after: always\"></div>

kidneys, empagliflozin reduces the reabsorption of glucose by the kidneys leading to increased urinary glucose excretion and, in consequence, to a lowering of blood glucose. Empagliflozin is approved for the treatment of T2DM worldwide as an adjunct therapy to diet and exercise to improve glycaemic control in adults with type 2 diabetes. In the United States and several other countries, it is also approved to reduce the risk of CV death in patients with T2DM and established CV disease. On 17 Jun 2021 empagliflozin was approved in the EU for the treatment of heart failure with reduced ejection fraction based on the EMPERORReduced study (1245.121) results.

Empagliflozin exerts its effect by preventing sodium and glucose reabsorption. While natriuresis will be compensated within days of drug administration through changes in tubulo-glomerular feedback, glucosuria will last for as long as the medication is used. This leads to long-lasting hemodynamic changes associated with modest osmotic diuresis, blood pressure-lowering effect, improvement in arterial stiffness, reduction in  oxidative  stress,  and  decrease  in  rate  pressure  product,  an  indirect  measure  of  myocardial  oxygen demands,  with  no  increase  in  HR  and  no  effect  on  sympathetic  nerve  activity.  The  non-glycosuric physiological  and  hemodynamic  adaptations  under  empagliflozin  may,  therefore,  provide  benefits  for patients with HF with or without diabetes.

## 3.1.3. Main clinical studies

Based on the results of trial 1245.25 (EMPA-REG OUTCOME) in patients with T2DM and established CV disease,  BI  initiated  a  phase  III  program  for  empagliflozin  10  mg  once  daily  in  chronic  heart  failure regardless of diabetes status, including two pivotal CV outcome trials ('EMPEROR') in patients with HFrEF and HFpEF.

Based on the results of the pivotal trial 1245.110, BI sought an extension of indication, i.e. for the treatment of symptomatic chronic heart failure.

## EMPEROR-preserved - trial 1245.110

Trial 1245.110 was carried out at 622 clinical sites in 23 countries in Europe, Latin America, North America, Asia, and others (South Africa, Australia, India). In total, 5988 patients were randomised to double-blind empagliflozin 10 mg (2997 patients) or placebo (2991 patients) once-daily treatment. Randomisation was stratified by region, diabetes history, LVEF, and eGFR (CKD-EPI)cr at screening. Patients were to be treated with randomised study medication in addition to standard of care (in accordance with local/international guidelines) until the required number of patients with adjudicated primary endpoint events was expected to be reached. The median exposure to study medication was about 23 months. After the last intake of study medication, patients were to be followed up for 30 days.

The aim of the EMPEROR-preserved trial is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with HFpEF. The primary endpoint was the time to the first event of adjudicated CV death or adjudicated HHF. The two key secondary endpoints (confirmatory) were; the occurrence of adjudicated HHF (first and recurrent) and eGFR (CKD-EPI)cr slope of change from baseline.

Patients in this trial represented a population with chronic heart failure with preserved ejection fraction (LVEF: 33.1% of patients had &lt;50%, 34.4% had 50 to &lt;60%, and 32.5% had ≥ 60%; mean 54.3%, SD 8.8) with a NYHA class of II (81.5%), III (18.1%), or IV (0.3%, 18 patients). The average age was 71.9 years (SD 9.4); 44.7% were women, 75.9% White, 13.8% Asian, and 4.3% Black/African American. About half of patients (48.9%) had T2DM; 10 patients (0.2%) had T1DM. Half of the patients (49.9%) had an eGFR of &lt;60 mL/min/1.73 m2 (of whom 309 patients, 5.2%, had an eGFR of &lt;30) at baseline. At study baseline,  patients  were  treated  with  drugs  for  symptoms  and  co-morbidities;  80.7%  of  patients  were

<div style=\"page-break-after: always\"></div>

treated with ACE inhibitors/ARBs/ARNi, 86.3% with beta-blockers, 86.2% with diuretics (37.5% MRAs) and 70.8% with lipid-lowering drugs. Demographics and baseline characteristics were balanced between the treatment groups.

## 3.2. Favourable effects

## Cardiovascular endpoints

CV death or HHF (primary endpoint) occurred in a lower proportion of patients in the empagliflozin group than in the placebo group (empagliflozin 415/2997, 13.8%; placebo 511/2991, 17.1%), and the risk of CV death  or  HHF  was  reduced  with  empagliflozin  treatment  compared  with  placebo  (HR  empagliflozin  vs placebo 0.79, 95% CI 0.69 to 0.90). Adjudicated HHF (first or recurrent, key secondary endpoint) occurred in fewer patients in the empagliflozin group than in the placebo group (HR 0.73, 95% CI 0.61 to 0.88). Fewer patients were reported with CV death with empagliflozin versus placebo, but this difference was not statistically significant (HR 0.91, 95% CI 0.76 to 1.09).

## Renal endpoints

An initial dip in eGFR was observed with empagliflozin treatment, followed by a slower decrease in eGFR over time. The change of eGFR slope from baseline (key secondary endpoint) showed a slower decline in eGFR in the empagliflozin group, with an estimated difference in slope of 1.363 mL/min/1.73 m 2  per year vs placebo (99.9% CI 0.861 to 1.865). The results for the composite renal endpoint (i.e. chronic dialysis, renal  transplant,  or  sustained  reduction  in  eGFR;  secondary/exploratory  endpoint)  are  similar  for empagliflozin vs. placebo (empagliflozin 108/2997 (3.6%), placebo 112/2991 (3.7%), HR 0.95 95% CI 0.73  to  1.24).  The  proportion  of  patients  progressing  to  macroalbuminuria  (secondary/exploratory endpoint) was less with empagliflozin vs. placebo (HR 0.82, 95% CI 0.68, to 0.98).

## Mortality

All-cause mortality was similar in both treatment groups (HR 1.00, 95% CI 0.87 to 1.15). The number of CV  death  are  described  above.  The  number  of  non-CV  death  was  larger  with  empagliflozin,  but  this difference was not statistically significant (empagliflozin 203/2997, placebo 183/2991, HR 1.13, 95% CI 0.92 to 1.38).

## Patient reported outcomes

The change from baseline in KCCQ clinical summary score was a secondary/exploratory endpoint. The mean treatment difference in change was 1.32, 95% CI 0.45 to 2.19. The proportion of patients achieving a clinically  relevant  change  (i.e.  5  points)  was  larger  in  the  empagliflozin  group  compared  to  placebo (empagliflozin 1126 patients, 41.7%; placebo 1034 patients, 38.7%).

## Elderly patients

In elderly patients, i.e. age ≥ 70 years, the point estimate of treat ment effect was larger compared to patients &lt; 70 for the primary endpoint (age ≥70 years HR 0.75, 95% CI 0.64-0.95, age &lt;70 years HR 0.88, 95% CI 0.701.11) and key secondary endpoint (HHF) (age ≥70 years HR 0.65, 95% CI 0.52-0.82, age &lt;70 years HR 0.92, 95%CI 0.67-1.26).

<div style=\"page-break-after: always\"></div>

In addition, the applicant discussed efficacy results and the safety data of both EMPEROR trials in patients aged ≥85 years. The number of patients aged ≥85 years that were included is 483 patients. The data do not  suggest  that  patients  a ged  ≥85  years  benefit  less  form  treatment  of  the  indication  of  chronic symptomatic heart failure. The efficacy in general appears similar. The safety profile also appears similar across the age groups. The applicant therefore concluded that 'limited therapeutic experience' in the elderly population is no longer suitable and amended sections 4.2 and 4.4 in the SmPC and the Package Leaflet to remove the warning. The amendments proposed by the MAH are considered acceptable.

## 3.3. Uncertainties and limitations about favourable effects

## Effects independent of LVEF

Although  HFpEF  has  been  defined  from  a  LVEF  &gt;40%,  the  range  between  40  and  50%  is  currently considered HFmEF, and this group of patients may differ in the aetiology and treatment response compared to  patients  with  LVEF  &gt;50%/HFpEF.  Retrospective  analyses  have  suggested  that  the  benefits  of neurohormonal antagonists in patients with HFrEF extend to those with a mildly reduced ejection fraction (Dewan P et al. Eur J Heart Fail 2020). This may affect the interpretation of the overall efficacy results. Stratified randomisation was performed for LVEF subgroups (i.e. LVEF &lt;50%, LVEF 50-&lt;60% and LVEF ≥60%),  and  the  number  of  patients  was  equally  distributed  between  the  LVEF  subgroups.  Subgr oup analyses for LVEF were performed for the primary and key secondary endpoints. Although the p value for interaction was not significant (p=0.2098) for the primary endpoint (CV death or HHF), the effect was more pronounced in patients with LVEF &lt;50% comp ared to ≥60%, but was still significant for the group LVEF 50&lt;60% and remained positive for LVEF≥60% (LVEF &lt;50% HR 0.71, 95%CI 0.57 -0.88; LVEF 50-&lt;60%, HR 0.80, 95%CI 0.640.99; LVEF &gt;60%, HR 0.87, 95%CI 0.69 -1.10). As the effect of empagliflozin on the primary endpoint was beneficial for all LVEF subgroups, the indication for the treatment of heart failure in patients with HFpEF is acceptable. As the indication for the treatment of heart failure is for all types of heart failure, the wording ' for the treatment of symptomatic chronic heart failure.' is considered acceptable.

It could, however, be suggested that there is a modification of the treatment effect in subjects with higher LVEF for the key secondary endpoint, i.e. adjudicated HHF (first and recurrent), where the point estimate for the subgroup LVEF ≥60% is HR 1.06 (95%CI 0.76 -1.46) and p for interaction 0.0077. This could indicate that patients with LVEF ≥60% benefit less from treatment with empagliflozin. The lower HR in the subgroup ≥70%, however , contradicts this suggestion, although the number of subjects was small in this subgroup. The analyses on the contribution of HHF events by number of events experienced per patient showed that only a small number of patients contributed to the high number of recurrent HHF in the empagliflozin group, which may contribute to the imbalance in the analysis of the first and recurrent HHF in this subgroup. This may be related to chance.

## Renal endpoints

The change of eGFR (CKD-EPI)cr slope from baseline was a key secondary endpoint and showed a slower decline in eGFR in the empagliflozin group, with an estimated difference in slope of 1.363 mL/min/1.73 m2 per year. This endpoint has the limitation that a long treatment period, i.e. more than 2 years, is considered needed to confirm a beneficial effect. The effect on the renal composite endpoint is preferred for evaluation of renal effects. The effect of empagliflozin on the eGFR slope is not supported or confirmed by the observed effects on the composite renal endpoint (i.e. chronic dialysis, renal transplant, or sustained reduction in eGFR), as the results are similar for empagliflozin vs. placebo (empagliflozin 108/2997 (3.6%), placebo 112/2991 (3.7%), HR 0.95 95%CI 0.73, 1.24). However, the finding in the eGFR slope was supported by other additional pre-specified analyses, i.e. eGFR change from pre-treatment (baseline) to post-treatment

<div style=\"page-break-after: always\"></div>

(follow-up;  FU)  analysed  with  ANCOVA,  'true  slope'  (annualised  change  from  pre-treatment  to  posttreatment  weighted  by  time  of  FU  squared)  and  progression  to  or  reversal  from  macro-albuminuria. Although all exploratory, these findings indicate a consistent finding and this appears clinical relevant.

## Mortality

All-cause mortality was similar in both treatment groups (HR 1.00, 95%CI 0.87 - 1.15). The number of non-CV  death  was  larger  with  empagliflozin,  but  this  difference  was  not  statistically significant (empagliflozin 203/2997, placebo 183/2991, HR 1.13, 95%CI 0.92 - 1.38). The Applicant provided an extensive evaluation of the causes of non-CV death and could not show a specific increase in a cause of death during empagliflozin treatment. A beneficial effect on all-cause mortality with empagliflozin treatment in patients with HFpEF could not be demonstrated.

## Patient reported outcomes

A larger difference in change from baseline in KCCQ clinical summary was observed in the empagliflozin vs. placebo group. Although statistically significant, the treatment difference appears modest, and the clinical relevance is questionable. The proportion of patients achieving a clinically relevant change (i.e. 5 points) was not defined as a secondary endpoint and resulted in a larger proportion of patients with clinically relevant change, but the difference in percentages is small. The treatment effects are considered small.

## Combined treatment

Although effectiveness of treatment with ACEi/ARB, MRA's and/or ARNI's have not been demonstrated in patients with HFpEF, the majority of the patients used these treatments during the trial, i.e. ACEi/ARB's, 82.6%, MRA's 46.0%, ARNI's 4.4%. Empagliflozin was, therefore, evaluated on top of these medication, but these medications are not registered for the treatment of HFpEF. The Applicant described the baseline use of these agents in the trial population in Section 5.1 of the SmPC. The subgroup analysis for baseline use of ACEi/ARB/ARNI's and/or MRA's resulted in a similar risk reduction with empagliflozin vs. placebo for the primary and key secondary endpoints for patients using these agents compared to patients not using these agents at baseline. As the efficacy of empagliflozin appears consistent with vs without the use of these agents, it is considered acceptable that the indication for the treatment of HFpEF is independent of the baseline use of these agents.

## 3.4. Unfavourable effects

In SAF-HF1, 10408 patients were treated and 28.2% of patients prematurely discontinued study medication (including patients who died). More than 70% of patients had an exposure for at least 52 weeks. The exposure is considered acceptable to perform a safety evaluation.

## Adverse events

The  number  of  AEs  and  severe  AEs  were  similar  for  empagliflozin  compared  to  placebo  (any  AE; empagliflozin 81.4%, placebo 80.0%, severe AE; empagliflozin 26.5%, placebo 24.3%). Based on the most frequently reported AEs, this number of events is also similar for empagliflozin compared to placebo, except for hypotension (empagliflozin 372 (7.1%) placebo 313 (6.0%)) and urinary tract infections (empagliflozin 314 (6.0%) placebo 259 (5.0%)).

<div style=\"page-break-after: always\"></div>

## Deaths, serious adverse events and adverse events leading to treatment discontinuation

In the SAF-HF1, the number of serious adverse events was not larger for empagliflozin compared to placebo (empagliflozin 43.1%, placebo 48.1%). The frequencies of patients with AEs leading to discontinuation of study medication were similar between treatment groups (empagliflozin 17.5%, placebo 17.3%). There was not a difference between the type of AEs leading to discontinuation between the empagliflozin group and the placebo group. Number of deaths/mortality did not differ between the treatment groups.

## Adverse events of special interest

## Urinary tract infections

Urinary  tract  infections  (empagliflozin  402  patients  (7.7%),  placebo  335  patients  (6.4%))  were  more common in the empagliflozin group than in the placebo group. The number of complicated urinary tract infections, urosepsis or pyelonephritis, was also more in the empagliflozin group vs placebo. The treatment difference was most pronounced in female patients for urosepsis or pyelonephritis (empagliflozin 20/1895 (1.1%),  placebo  6/1915  (0.3%))  and  for  patients  without  diabetes  (empagliflozin  15  patients  (0.6%), placebo 8 patients (0.3%)).

## Genital infections

Genital infections (empagliflozin 101 patients (1.9%), placebo 35 patients (0.7%)) were more common in the empagliflozin group than in the placebo group. The number of complicated genital infections was similar between empagliflozin and placebo (empagliflozin 14 patients (0.3%), placebo 14 patients (0.3%)). Genital infections with empagliflozin treatment were reported slightly more frequently in elderly patients (Age 50&lt;65 empagliflozin 19 (1.6%), placebo 8 (0.7%); age 65-&lt;75: empagliflozin 32 (1.7%), placebo 10 (0.5%); age 75-&lt;85 empagliflozin 43 (2.6%), placebo 11 (0.7%)).

## Volume depletion

Volume  depletion  was  also  more  frequent  with  empagliflozin  treatment  (empagliflozin  566  patients (10.9%), placebo 483 patients (9.3%)), including the number of symptomatic hypotension and syncope. Serious volume depletion events were also more frequent with empagliflozin treatment (empagliflozin 113 patients (2.2%), placebo 91 patients (1.7%)). During treatment with empagliflozin, the intensity of diuretic therapy or non-diuretic anti-hypertensive therapy was more frequently reduced.

## Keto-acidosis

Based on the broad BIcMQ, events suggestive of ketoacidosis were reported for 63 patients (1.2%) in the empagliflozin  group  and  for  77 patients  (1.5%)  in  the  placebo  group.  The  narrow  BIcMQ  ketoacidosis included 4 patients (0.1%) in the empagliflozin group and 6 patients (0.1%) in the placebo group.

## Lower limb amputation

The number of AEs leading to LLA was similar between placebo and empagliflozin treatment (empagliflozin 29 (0.6%), placebo 33 (0.7%)), both for patients with and without diabetes.

<div style=\"page-break-after: always\"></div>

## Decreased renal function

The numbers of events with acute renal failure (empagliflozin 547 patients (10.5%), placebo 587 patients (11.3%)) were not larger in the empagliflozin group compared to placebo.

## Hepatic injury

The frequency of patients with hepatic injury was  not higher in the empagliflozin group (197 patients (3.8%)) than in the placebo group (248 patients (4.8%)). The most frequent PTs were liver injury, hepatic function abnormal, and hepatic steatosis.

## Hypoglycaemia

The numbers of confirmed hypoglycaemic events (empagliflozin 101 patients (1.9%), placebo 108 patients (2.1%)) were similar for empagliflozin vs. placebo, except for hypoglycaemic events in T1DM (empagliflozin 2/5 (40%), placebo 1/5(20%)).

## Constipation

Constipation was reported for more patients in the empagliflozin group (153 patients (2.9%)) than in the placebo  group  (107  patients  (2.1%)).  The  number  of  serious  events  or  events  leading  to  treatment discontinuation was low in both treatment groups.

## Laboratory findings

In trials 1245.110 and 1245.121, haemoglobin and haematocrit values increased on treatment and then partially  returned  to  baseline  after  treatment  discontinuation  in  the  empagliflozin  group,  with  small decreases  observed  in  the  placebo  group.  There  was  a  decrease  in  uric  acid  (urate)  values  in  the empagliflozin group compared with the placebo group. After treatment discontinuation, uric acid values returned towards baseline in the empagliflozin group.

## Vital signs

No meaningful changes in blood pressure (systolic or diastolic) or in heart/pulse rate were observed with empagliflozin treatment compared with placebo in any of the HF trials. There were no relevant differences in new ECG findings after baseline between empagliflozin and placebo.

## 3.5. Uncertainties and limitations about unfavourable effects

The safety profile of empagliflozin in patients with HF, with or without diabetes, appears in general similar to  the  safety  profile  in  patients  with  T2DM.  However,  uncertainties  remain  about  several  unfavourable effects:

## Urinary tract infection

Urinary tract infections were more common in the empagliflozin group than in the placebo group and the difference was most pronounced in female patients for urosepsis or pyelonephritis. It is known that female subjects are more susceptible for urinary tract infection, and this may partly explain the increased incidence in  female  subjects  with  empagliflozin  treatment.  Urinary  tract  infections,  including  urosepsis  and

<div style=\"page-break-after: always\"></div>

pyelonephritis,  are  included  in  Section  4.8  of  the  SmPC.  The  current  observations  are  in  line  with  the described ADRs in the SmPC.

## Hypoglycaemia

The numbers of confirmed hypoglycaemic events were similar for empagliflozin vs. placebo, except for hypoglycaemic events in T1DM. But the latter consisted of a very small number of events (empagliflozin 2/5 (40%), placebo 1/5(20%)) and does therefore not contribute to the evaluation for increased risk.

## Elderly patients

As expected, the total AEs are reported more frequently in the older age groups, but similar for empagliflozin compared to placebo treatment. Volume depletion and genital infection are in general more frequent in the empagliflozin  group,  but  the  difference  in  frequency  vs.  placebo  appears  more  pronounced  in  elderly patients  (&gt;75years).  Elderly  patients  appear,  therefore,  more  vulnerable  for  these  side  effects.  The increased risk for volume depletion in elderly patients is described in Section 4.4 of the SmPC. The increased risk for genital infections is not described in the SmPC, but this risk is considered only mildly elevated in elderly patients and is not deemed necessary to be included in section 4.8.

## 3.6. Effects Table

Table 50. Effects Table for Jardiance for the treatment of HFpEF

| Effect                  | Short description Unit                                      |                                 | Empagliflozin (10mg)     | Control (placebo)        | Uncertainties (Unc) / Strength of evidence (SoE)                                                                                                                                                                       | Trial                                  |
|-------------------------|-------------------------------------------------------------|---------------------------------|--------------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| Favourable Effects      | Favourable Effects                                          | Favourable Effects              | Favourable Effects       | Favourable Effects       | Favourable Effects                                                                                                                                                                                                     | Favourable Effects                     |
| CV death or HHF         | Composite primary endpoint                                  | N (%)                           | 415/2997 (13.8)          | 511/2991 (17.1)          | SoE : HR 0.79, 95%CI 0.69 to 0.90, p<0.0001 Unc: seems mainly driven by HHF                                                                                                                                            | EMPEROR- preserved, (trial 1245.110)   |
| First and recurrent HHF | adjudicated HHF event (key secondary endpoint)              | N (%)                           | 259 (8.6%)               | 352 (11.8%)              | SoE: HR 0.79, 95%CI 0.69 to 0.90, p=0.0009 Unc: beneficial effect not demonstrated in all subgroups LVEF <50%: HR 0.57, 95%CI 0.42-0.79 LVEF 50-<60% : HR 0.66, 95%CI 0.48- 0.91) LVEF ≥60%: HR 1.06, 95%CI 0.76 -1.46 | EMPEROR- preserved                     |
| Mortality               | all-cause mortality                                         | N (%)                           | 422 (14.1%)              | 427/2991 (14.3%)         | SoE: HR 1.00, 95%CI 0.87 to 1.15 Unc: CV death similar for empagliflozin and placebo (HR 0.91, 95%CI 0.76 to 1.09) number of non-CV death higher for empagliflozin                                                     | EMPEROR- preserved                     |
| eGFR slope              | eGFR slope of change from baseline (key secondary endpoint) | Slope [/year] estimate (95% CI) | - 1.253 (-1.465, -1.041) | - 2.616 (-2.827, -2.405) | SoE: Difference vs placebo: 1.363, 99%CI 0.861 to 1.865, p<0.0001 Unc: not supported by combined renal endpoint                                                                                                        | EMPEROR- preserved                     |
| Unfavourable Effects    | Unfavourable Effects                                        | Unfavourable Effects            | Unfavourable Effects     | Unfavourable Effects     | Unfavourable Effects                                                                                                                                                                                                   | Unfavourable Effects                   |
| AEs                     |                                                             | %                               | 80.0                     | 81.4                     |                                                                                                                                                                                                                        | SAF-HF1, (trial 1245.110 and 1245.121) |

<div style=\"page-break-after: always\"></div>

| Effect                   | Short description Unit   | Short description Unit   | Empagliflozin (10mg)   | Control (placebo)   | Uncertainties (Unc) / Strength of evidence (SoE)                                                           | Trial   |
|--------------------------|--------------------------|--------------------------|------------------------|---------------------|------------------------------------------------------------------------------------------------------------|---------|
| SAEs                     |                          | %                        | 43.2                   | 48.1                | Mainly driven by cardiac events                                                                            | SAF-HF1 |
| Volume depletion         | (including hypotension)  | N (%)                    | 566 (10.9)             | 483 (9.3)           | Serious volume depletion events more frequent with empagliflozin. Volume more frequent in elderly patients | SAF-HF1 |
| Genital infections       |                          | N (%)                    | 101 (1.9)              | 35 (0.7)            | Seemingly effect of treatment more outspoken for elderly patients                                          | SAF-HF1 |
| Urinary tract infections |                          | N (%)                    | 402 (7.7)              | 335 (6.4)           | Difference was most pronounced in female patients for urosepsis or pyelonephritis                          | SAF-HF1 |

Abbreviations : AE, adverse events; CI, confidence interval; CV, cardio vascular; GFR, glomerular filtration rate; HR, hazard ratio; N, number; SAE, serious adverse events

Notes : Favourable effect based on EMPEROR preserved (Trial 1245.110), unfavourable effects based on SAF-HF1

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

HF is a progressive syndrome with a high global prevalence. A treatment-induced decrease in HF-related complications such as HHF and CV death is therefore important. Especially for patients with HFpEF, the registered  treatment  options  are  limited.  The  finding  in  the  EMPEROR-preserved  trial  of  decreased occurrence of HHF or CV death with empagliflozin treatment (HR 0.79, 95%CI 0.69 to 0.90) is considered an important benefit. During the trial period, the number of patients who would need to have been treated with empagliflozin to prevent one primary event (NNT) was 31 (95%CI 20 to 69). Although this effect seems mainly due to the decrease in HHF and to a lesser extent to the decrease in CV death, it is still regarded as clinically relevant, especially as the normal progression of HF is still associated with a high frequency of rehospitalizations. Importantly, there was, however, no benefit on all-cause mortality. The number of non-CV death was larger with empagliflozin, but this difference was not statistically significant. The Applicant provided an extensive evaluation of the causes of non-CV death and could not show a specific increase in a cause of death during empagliflozin treatment.

This current application is an indication for the treatment of chronic heart failure independent of LVEF. For the primary endpoint a positive effect of empagliflozin treatment was observed overall and in all the predefined LVEF subgroups. The p for interaction was not significant. However, for the secondary endpoint (first and recurrent HHF) the HR point estimate and the level of precision for the subgroup LVEF ≥60% is 1.06 (95%CI 0.76-1.46, p for interaction p=0.00 77). This finding in subjects with LVEF ≥60% could indicate a decrease in efficacy in the higher LVEF subgroups for this endpoint. The lower HR in the subgroup ≥70%, however, contradicts this suggestions, although the number of subjects was small in this subgroup. The analyses on the contribution of HHF events by number of events experienced per patient showed that only a small number of patients contributed to the high number of recurrent HHF in the empagliflozin group, which may contribute to the imbalance in the analysis of the first and recurrent HHF in this subgroup. This may be related to chance. Based on these findings it is not considered supported that there is a decrease in efficacy in patients with higher LVEF.

The finding of a slower eGFR slope decline with empagliflozin treatment (estimated difference in slope of 1.733 mL/min/1.73 m2 per year vs placebo (99.9% CI 0.669, 2.796; p&lt;0.0001)), could be regarded as not convincing. Although this endpoint was a key secondary endpoint, the slope analysis modelling is better suited in providing descriptive information on renal outcomes than providing definitive statistical and clinical evidence of a renal effect as it is used now. The data on the eGFR slope were not supported by a beneficial effect on the preferred renal composite (secondary/exploratory) outcome endpoint (i.e. chronic dialysis,

<div style=\"page-break-after: always\"></div>

renal transplant, or sustained reduction in eGFR) (HR 0.95 95%CI 0.73 to 1.24). The results are also not fully in line with earlier observations in patients with HFrEF or T2DM. However, the finding in the eGFR slope  was  supported  by  other  additional  pre-specified  analyses,  i.e.  eGFR  change  from  pre-treatment (baseline) to post-treatment (follow-up; FU) analysed with ANCOVA, 'true slope' (annualised change from pre-treatment to post-treatment weighted by time of FU squared) and progression to or reversal from macro-albuminuria. Although all exploratory, these findings indicate a consistent finding and this appears clinical relevant.

In  the  EMPEROR-preserved  trial,  the  KCCQ  'clinical  summary  score'  was  used  to  measure  as  a secondary/exploratory  endpoint  of  a  patient-reported  outcome.  Although  statistically  significant,  the treatment difference appears modest, and the clinical relevance is questionable. The Applicant also provided the proportion of patients achieving a clinically relevant change (i.e. 5 points), but again the difference in percentages is small. The potential beneficial  effects  of  empagliflozin  on  HF-related  symptoms  are  not established robustly and are, therefore, of questionable importance.

Treatment  with  empagliflozin  in  patients  with  HFpEF  generally  revealed  no  new  large  safety  findings compared with the known safety profile of empagliflozin in patients with HFrEF and/or T2DM. The numbers of reported AEs and SAEs were equally distributed between the treatment groups. As expected, genital infections,  urinary  tract  infections  and  volume  depletion  were  more  reported  during  empagliflozin treatment, but these are known side-effects and included in the SmPC. They have previously not affected the benefit-risk balance to a negative ratio for the indication for the treatment of HFrEF and/or T2DM.

## 3.7.2. Balance of benefits and risks

The MAH agreed to amend the initially applied indication i.e.

The final agreed indication is:

## Heart failure

Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

The reduced incidence of HHF or CV death is an important benefit and significantly contributes to a positive B/R ratio. It is important to point out that this finding is mainly driven by an effect on HHF, as no relevant reduction in CV death was observed.

A beneficial effect on the primary endpoint was observed across all LVEF subgroups and the indication for the treatment of heart failure in patients with HFpEF is acceptable. As the indication for the treatment of heart failure is for all types of heart failure, the wording ' for the treatment of symptomatic chronic heart failure.' is considered acceptable.

Results on the key secondary endpoint, i.e. first and recurrent HHF, could indicate that there a decrease in effect in patients with higher LVEF (≥60%). Additional analyses, i.e. f urther subgroup analyses based on LVEF and analyses on the contribution of HHF events by number of events experienced per patient, suggest that this finding is related to chance.

Treatment  with  empagliflozin  in  patients  with  HFpEF  generally  revealed  no  new  large  safety  findings compared with the known safety profile of empagliflozin in patients with HFrEF and/or T2DM.

## 3.8. Conclusions

The overall B/R of Jardiance in the treatment of symptomatic chronic heart failure is positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to add the treatment of treatment of symptomatic chronic heart failure based on the results from the clinical study 1245.110 EMPEROR-preserved.

As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC and sections 1, 2 and 4 of the PIL are updated accordingly.

Further, the MAH applied for an additional year of market protection. The updated RMP v 16.0 has also been submitted.

In addition, the statement 'sodium free' was re-located from section 2 of the SmPC to section 4.4. to comply with EMA'S QRD guidance and minor linguistic changes to the national translations are included in this submission.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Additional market protection

Furthermore, the CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies (see appendix 1).